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Abstract 
B cells are increasingly recognised to play an important role in the ongoing control of chronic viral 
infections, yet their contribution to the persistence of HBV is poorly understood. The development 
of antibodies against HBV envelope protein (HBsAg) is considered the hallmark of resolution of 
acute infection; accordingly, seroconversion against HBsAg represents a key therapeutic goal for 
functional cure of chronic HBV (CHB). The production of inadequate anti-HBsAg (anti-HBs) 
antibodies to neutralise large quantities of circulating HBsAg in chronic infection suggests there may be 
defects in the B cell response upon HBV infection. To investigate constraints on their antiviral 
potential, global and antigen-specific B cells were characterised directly ex vivo from the blood and liver 
of patients with CHB. HBsAg-specific B cells persisted in the blood and liver in patients with CHB at 
similar frequencies to patients with acute-resolving infection and healthy HBV-vaccinated controls. 
However, differentiation of HBsAg-specific B cells from patients with CHB demonstrated decreased 
antibody production, consistent with undetectable anti-HBs antibodies in vivo. HBsAg-specific and 
global B cell compartments had an accumulation of CD27-CD21low/- atypical memory B cells 
(atMBCs), characterised by high expression of inhibitory receptors, including PD-1. These atMBCs 
demonstrated altered signalling, homing, differentiation into antibody-producing cells, survival and 
antiviral cytokine production, that could be partially rescued by PD-1 blockade. PD-1hi atMBCs were 
further expanded in healthy and HBV-infected livers compared to the periphery, implicating the 
combination of this tolerogenic niche and HBV infection in driving PD-1hi atMBCs and impairing 
B cell immunity. Finally, the identification of endogenous antigen-specific B cells demonstrates 
previously unappreciated potential for these cells in natural control of HBV that may be enhanced 
through immunotherapeutic targeting. Work presented in this thesis has start to identify targets for 
reconstitution of their antiviral efficacy.  
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Impact Statement 
Recent studies have highlighted the increasing burden of disease attributable to hepatitis B virus 
infection. In chronic HBV infection (CHB), the immune response fails to control the virus and 
instead triggers tissue damage, culminating in an estimated ~700 000 deaths a year worldwide. 
Current treatment approaches fail to induce off-treatment viral control, highlighting a pressing need 
to develop new and improved therapeutic strategies. The success of immunotherapy for the 
treatment of cancer, highlighted by the recent Nobel Prize awarded for the discovery of immune 
checkpoints, shows significant promise in the development of new treatment regimens for the 
control of chronic viral infections, that are well-tolerated by patients and able to maintain long-term 
viral control.  
CHB is characterised by exhausted adaptive immunity in association with an absence of detectable 
protective antibodies against the HBV envelope protein (HBsAg). While much progress has been 
made in identifying targets underpinning T cell exhaustion in the setting of persistent antigenic 
stimulation, detailed characterisation of anti-HBV-specific B cell responses is lacking. Through 
analysing the frequency, function and phenotype of global and HBsAg-specific B cells, we show 
that HBsAg-specific B cells can persist in the blood and liver of patients with CHB. However, both 
global and antigen-specific B cell compartments are enriched for B cells with a dysfunctional, 
atypical memory phenotype, characterised by increased expression of co-inhibitory molecules, 
including PD-1. In characterising these cells, this study has begun to identify targets for the 
immunotherapeutic boosting of B cell immunity, which may have important implications for the 
design of therapeutic vaccines and other approaches aiming to induce co-ordinated immune 
responses.  
In particular, blockade of checkpoint molecules, such as PD-1, represents a key immunotherapeutic 
approach envisaged to restore exhausted adaptive immune responses and rescue control of viral 
infection; as such, anti-PD-1 therapy, in combination with therapeutic vaccination, is now 
undergoing testing in patients with CHB. In order to maximise efficacy and minimise off-target 
effects, it is important to understand how PD-1-targeted therapy affects all aspects of the immune 
response. In this respect, we show that PD-1 blockade can modestly increase pro-inflammatory 
cytokine production by B cells, but may potentiate the accumulation of dysfunctional B cell subsets. 
This recognition that humoral responses may be affected by PD-1 targeted therapy may therefore 
have important implications for the application of checkpoint blockade in patients with CHB.  
Finally, the concept of persistent antigen stimulation perturbing memory B cell responses has been 
gathering impetus over recent years, with many papers now demonstrating hypo-responsiveness of 
memory B cells in settings of chronic infection, autoimmunity and ageing. Natural infection with 
HBV provides an ideal setting to compare the effects of persistent and resolving infection with 
vaccine-induced immunity on B cell subsets. This study is also one of the first to describe antigen-
specific memory B cells in a non-lymphoid organ, at the site of viral infection. Thus, these data may 
have broader impmlications for understanding the role of B cells within non-lymphoid tissues.   
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Chapter 1 Introduction 
 
1.1 The immunological revolution 
The realisation that the human body is innately programmed to fight any entity it detects as foreign 
and dangerous came only as recently as 1989. Although many eminent scientists, including Edward 
Jenner, had alluded to the ability of the body to recognise non-self, the first description of the ability 
of the immune system to detect when something is likely to be a threat was conveyed in a seminal 
paper published by Charles Janeway (Janeway, 1989). Since then, many important discoveries have 
been made that piece together the intricacies of the human body to fight invading pathogens. Not 
only have these revolutionised the way that we view the human body, these important findings have 
ignited transformative approaches for medicine in the 21st century.  
It is now apparent that layer upon layer of immune checks and balances regulate interactions 
between a diverse range of immune cell types. Together, these cells mastermind co-ordinated 
responses that fight infection and minimise destruction caused. Where these responses go wrong, 
chronic infection and tissue damage can ensue. 
Already we have found ways to employ the immune system to create innovative new drugs, 
referred to as immunotherapies, that have shown significant promise in the treatment of cancer, 
arthritis and diabetes. The current excitement surrounding the power of body’s own defence system 
has been recently exemplified by the success of popular science books such as ‘The Beautiful Cure’, 
by Dan Davies at the University of Manchester (Davis, 2018). Moreover, immunologists central to 
the characterisation of the immune response and the development of ground breaking 
immunotherapies were recently honoured at the highest level, with Professor John P. Allison and 
Professor Tasuku Honjo awarded the 2018 Nobel Prize in Physiology or Medicine for their 
discovery of cancer therapy by checkpoint blockade, and Sir Gregory P. Winter awarded the 2018 
Nobel Prize in Chemistry for his work on phage display of peptides and antibodies. These 
examples, highlighting the importance of immunology in modern medicine, demonstrate the power 
and potential of immunological research, and advocate for the continued study of the multifaceted 
immune response following infection. 
  
 
 
24 
1.2 Overview of HBV 
1.2.1 The global health burden of HBV  
Intensive efforts over the last 20 years have succeeded in reducing mortality from communicable 
disease with the notable exception of viral hepatitis. Whilst deaths arising from the WHO’s top 
three priorities – HIV-AIDs, malaria and tuberculosis - have consistently fallen, mortality and 
morbidity attributable to viral hepatitis have continued to rise, with the annual death rate 
attributable hepatitis B virus (HBV) or hepatitis C virus (HCV) infection increasing by 
approximately 60% over the last 20 years (Stanaway et al., 2016). Both viruses are able to establish 
persistent infection that can evolve to liver cirrhosis and hepatocellular carcinoma; as it stands, an 
estimated 240 million people are chronically infected with HBV, with HBV-related complications 
resulting in approximately 780,000 deaths a year worldwide (Stanaway et al., 2016). A significant 
proportion of HBV infection is concentrated in highly endemic areas, predominantly sub-Saharan 
Africa and Asia, where up to 20% of the population is infected (Liaw and Chu, 2009) 
HBV transmission can occur via a number of different routes: sexual, parenteral (for example 
through illicit drug use or via blood transfusion products) or perinatal (from HBV-infected mothers 
to neonates). Transmission in highly endemic areas is largely perinatal (vertical transmission, 
common in East Asia) or occurs very early during childhood via horizontal transmission, for 
example via saliva and open wounds. Horizontal transmission most commonly occurs in 
households with a persistent carrier and is most readily detected in Sub-Saharan Africa (Gray Davis 
et al., 1989). In contrast, infection in low prevalence areas tends to be acquired during adulthood. 
In high-income countries, HBV prevalence is heavily influenced by global migration; for instance, 
the prevalence of HBV-infection in London - where this thesis was written - has been estimated at 
~2.02 per 100,000 of the population, nearly twice as high as the rest of England and reflective of 
the multicultural demographic of the capital. [Data collected from Public Health England; 
www.gov.uk/government/publications/hepatitis-b-epidemiology-in-london-2012]. 
As with most communicable diseases, effective prevention strategies are key to reducing the burden 
from disease. Current available prophylactic vaccines are highly effective and protect ~94-98% of 
individuals from infection. Where vaccination strategies capture at-risk populations early in life, 
prevalence of HBsAg can be reduced to zero, resulting in concomitant decreases in HBV-related 
disease (Chen, 2009). However, the application of large-scale vaccination strategies can be difficult 
and often fails in the absence of effective public health education and deliverance. This is further 
complicated by the necessity of three doses required for adequate protection, which means that 
coverage and compliance can be low. Moreover, vaccine efficacy varies markedly between different 
populations, with approximately 5-10% of individuals failing to mount an effective antibody 
response following vaccination. These differences are thought to be a consequence of genetic 
predisposition and immune status (Walayat et al., 2015) and has resulted in the development of 
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more immunogenic hepatitis B vaccines that target protective regions of HBV and require fewer 
doses (discussed in more detail in section 1.6.1).  
Hence, whilst effective vaccines are available, there remains a clear necessity for drugs to treat 
HBV-infected individuals and reduce carriage of the virus. Whilst new therapies for HCV have 
delivered striking results, with more than 90% of patients achieving viral clearance following 
treatment with directly acting antivirals (Foster et al., 2015), current treatment strategies for HBV, 
namely pegylated-interferon-alpha (Peg-IFNα) and nucleoside analogues (NUCs), rarely achieve 
functional cure (defined as sustained loss of viraemia and HBV-surface antigen (HBsAg) following 
termination of therapy). Since NUCs target HBV at the level of DNA synthesis only, they are 
unable to eradicate the episomal form of HBV and thus necessitate long-term therapy. Importantly, 
this persistence of episomal and integrated DNA provides an ongoing source of secreted HBsAg 
and thus represents a key target for new therapeutic strategies. Numerous studies are now 
investigating the potential for NUC-therapy withdrawal, with the aim to identify patient groups that 
are able to maintain viral suppression following NUC discontinuation (Berg et al., 2017; 
Hadziyannis et al., 2012; Rivino et al. 2018). 
Alongside additional problems associated with cost, compliance, toxicity and global access, there is 
a pressing need to develop new strategies that are better tolerated by patients and provide ongoing 
immune surveillance, as is observed in resolved HBV. The recent successes of immunotherapies for 
treatment of cancer raises the prospect of immunotherapeutic approaches for the treatment of 
chronic HBV, supported by the rationale that the immune response is able to maintain long-term 
viral control in the majority of patients who are acutely infected with HBV (Maini and Pallett, 
2018). Thus, restoration of defective cellular and humoral antiviral immunity is likely to be 
indispensable for off-treatment virus control. These strategies should also aim to induce 
neutralising antibody responses that can prevent the spread of infection from hepatocytes and 
thereby prevent reactivation of HBV replication (discussed in more detail in section 1.6.1). 
 
1.2.2 HBV life cycle 
HBV is a non-cytopathic, partially double-stranded DNA virus of the Hepadnaviridae family and can 
be categorised into ten distinct genotypes (A-J) based on divergence in the viral sequence. These 
strains differ in their geographical distribution and may correlate with disease progression and 
treatment response (Lin and Kao, 2015). As a hepatotropic virus, HBV can efficiently infect a large 
proportion of hepatocytes and establish persistent infection in the liver (Protzer et al., 2012; Seeger 
and Mason, 2015). Pathology arises due to a failure of the immune response to control the 
infection, instead triggering tissue damage leading to liver cirrhosis and cancer.  
HBV is one of the smallest DNA viruses with a genome of approximately 3200 nucleotides that 
encodes seven viral proteins in four overlapping reading frames (Figure 1.1). The infectious HBV 
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virion (Dane particle) has a spherical, double-shelled structure consisting of a lipid envelope 
containing the envelope protein, HBsAg. This surrounds an inner nucelocapsid composed of 
hepatitis B core antigen (HBcAg) complexed with virally encoded polymerase and the viral DNA 
genome. HBV virions initiate interactions with hepatocytes through interactions with cell surface 
glycoproteins referred to as heparan sulphate proteoglycans (HSPGs) (Schulze et al., 2007). These 
proteins act as a low affinity receptor for HBV and localise virions to the liver to enhance viral 
binding and entry (Leistner et al., 2008). Following initial attachment to HSPGs, HBV virions bind 
to sodium taurocholate co-transporting peptide (NTCP) through specific interactions between 
NTCP and the HBV large surface protein (HBsAg) (Ni et al., 2014; Yan et al., 2012). NTCP is 
expressed exclusively by hepatocytes and is responsible for the transport of conjugated bile salts; 
thus, the ubiquitous expression of NTCP by hepatocytes is postulated to underpin the tropism of 
HBV for the liver.  
 
Figure 1-1 Schematic depicting the HBV genome 
HBV is a partially double-stranded DNA virus. The innermost circles (black) represent the full length minus strand (-) 
and the incomplete plus strand (+) of the genome. The seven HBV viral proteins (discussed in 1.2.2) are shown by the 
outermost coloured lines: large, middle and small HBV surface proteins, polymerase protein, X protein and core and pre-
core proteins. Adapted from (Rehermann and Nascimbeni, 2005). 
 
Following viral entry, virions undergo a process of uncoating, whereby partially double stranded 
circular DNA (rcDNA) is delivered into the cytoplasm of the hepatocyte (Figure 1.2). HBV 
nucleocapsids translocate to the nucleus, where the relaxed circular DNA is transformed into 
covalently closed circular DNA (cccDNA). cccDNA provides a template for the transcription of 
viral mRNAs, driven by a host polymerase II enzyme (Pol-II). Viral RNAs are then transported to 
the cytoplasm where they are translated to produce HBV surface, pre-core/core, polymerase and X 
proteins, as follows (Beck and Nassal, 2007; Dandri and Locarnini, 2012; Grimm et al., 2011; Liang, 
2009; Rehermann and Nascimbeni, 2005; Tu and Urban, 2018): 
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1. Core: Gives rise to distinct proteins, depending on whether translation is initiated from the 
core or pre-core regions 
a. Pre-core protein: transported to the endoplasmic reticulum and excreted as secretory 
HBeAg 
b. Core protein: forms the nucleocapsid protein (HBcAg) required for capsid assembly  
2. Envelope proteins: consisting of three different sizes, small (S), middle (M) and large (L) 
3. HBx protein: activates HBV promoter activity and required for the initiation of infection 
4. Polymerase: reverse transcriptase required for DNA synthesis 
Resultant proteins are assembled to form nucleocapsids, into which a strand of pregenomic RNA is 
encapsidated within the polymerase protein and reverse transcribed to minus-strand DNA. This 
minus-strand DNA is then used to synthesize plus-strand DNA. Resulting capsids either bud into 
the endoplasmic reticulum, where they are enveloped with L, M and S surface antigens and released 
as complete virions, or transported back to the nucleus, where they are converted to cccDNA and 
maintain the pool of templates (Beck and Nassal, 2007; Dandri and Locarnini, 2012; Grimm et al., 
2011; Rehermann and Nascimbeni, 2005; Tong and Revill, 2016; Tu and Urban, 2018; Urban et al., 
2014; Verrier et al., 2016). As a replicative intermediate, cccDNA is central to the persistence of 
HBV, proving an ongoing template for the transcription of viral proteins. In this way, persistence 
of cccDNA presents a major target in the development of future treatment regimens aiming to 
achieve complete virus eradication.  
The replication of HBV via reverse transcription of an RNA intermediate distinguishes HBV from 
all other known mammalian DNA viruses. Reverse transcription is inherently error-prone and as 
such, incorporates errors and mutations to the genomic sequence. This process results in the 
emergence of highly heterogeneous viral populations, referred to as quasispecies. Such variation 
within populations presents a reservoir for viral selection under pressure from antiviral treatment 
and the immune response (Aragri et al., 2016; Cao et al., 2014).  
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Figure 1-2 Schematic of the HBV replication cycle 
Schematic depicting the life cycle of HBV following entry into the hepatocyte via NTCP. Full details of the viral life cycle 
are outlined in 1.2.2. [Abbreviations used: cccDNA = covalently closed circular DNA; rcDNA = relaxed, partially double 
stranded DNA; NTCP = sodium taurocholate co-transporting polypeptide; HSPG = heparan sulphate proteoglycans] 
 
1.2.2.1 Hepatitis B surface antigen (HBsAg) 
In addition to the secretion of whole virions, large amounts of spherical and filamentous HBsAg 
particles are also secreted, where they outnumber virions by a factor of 104-106 (Rehermann and 
Nascimbeni, 2005). HBsAg was the first identified component of HBV, discovered by Baruch 
Blumberg in 1965; initially named ‘Australia Antigen’, HBsAg was identified in the serum of 
haemophiliac patients and reacted against proteins present in the serum of an Aboriginal Australian 
(Blumberg, 1977; Blumberg and Alter, 1965). HBsAg was later demonstrated to be an envelope 
protein consisting of several subtypes that differ in their geographical distribution. These subtypes 
share a common a-determinant region, but differ according to mutually exclusive expression of d or 
y, and w and r antigenic determinants (Peterson, 1987). Why HBV has evolutionary maintained its 
ability to produce large quantity of sub-viral, non-infectious particles is still not clear. Possible 
explanations include the proposition of sub-viral particles as a decoy to divert anti-HBs antibodies 
away from infectious viral particles, or the direct ability of HBsAg to suppress humoral or cellular 
immunity. 
Over the years, research into HBsAg has culminated in the development of an effective 
preventative vaccine. Early incarnations involved highly purified preparations isolated from the 
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plasma of low level carriers, which conferred high levels of protection (>92%) when tested on 
high-risk groups (Coutinho et al., 1983; Szmuness et al., 1980). Following this finding, a 
recombinant HBsAg vaccine was made and produced using yeast cell culture, and was licensed for 
use in humans in 1986 (McAleer et al., 1984). Recombinant HBsAg vaccines are now a standard 
component of routine vaccination schedules worldwide, and were recently incorporated into the 
vaccination schedule for the UK. Universal vaccination strategies have had significant success in 
reducing the prevalence of HBV and HBV-associated hepatocellular carcinoma (Chien et al., 2006); 
however, vaccine implementation still varies widely, reflecting the global incidence of disease 
(Trépo et al., 2014).  
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1.3 Natural history of HBV infection 
Infection with HBV results in divergent clinical outcomes (Figure 1.3). Two major determinants of 
the outcome of HBV infection are the age and immune competence of the individual at the time of 
infection. In adult-acquired HBV, >95% of cases result in clearance of HBsAg, termed acute-
resolving infection. Comparatively, perinatal infection in neonates and infection in young children, 
more commonly results in an initial subclinical phase and high rates of chronic infection. 
Numerically, this equates to viral persistence in 1.5% of infected adults, 20-30% of those infected 
as young children and up to 90% of perinatally infected individuals (Liaw and Chu, 2009). 
 
 
Figure 1-3 Natural history of HBV infection 
A. Schematic depicting the immune response in acute infection with HBV through horizontal transmission, characterised 
by sequential peaks of HBV DNA and serum ALT. Clinical recovery, characterised by detection of anti-HBs and HBV-
specific T cells is shown. B. Chronically evolving HBV resulting from vertical transmission, characterised by several 
phases of variable length (for details, see main section 1.3.2.1). [Clinical phases of disease correspond to those described 
in 3.3.2.1 as follows: ‘Immunotolerant’ = HBeAg+ infection; ‘Immunoactive phase’ = HBeAg+ hepatitis; ‘Low replicative 
phase’ = HBeAg- infection; ‘High replicative phase’ = HBeAg- hepatitis. Adapted from (Rehermann and Nascimbeni, 
2005)]  
Acute-resolving infection Chronic HBVBA
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1.3.1 Acute-resolving infection 
HBV infection acquired in adulthood is typified by an initial quiescent phase, whereby infection can 
remain subclinical for a number of weeks (Figure 1.3). Following this period, HBV replication 
enters an exponential phase, during which levels of HBV DNA rapidly rise and peak prior to the 
onset of clinical symptoms and the induction of an adaptive T cell-mediated response. This 
symptomatic phase of disease classically corresponds with an increase in serum alanine 
transaminase (ALT) levels; an enzyme that is released from dying hepatocytes and thus used as a 
readout for liver inflammation and damage. HBV-specific antibodies associated with viral control 
are detected following clearance of the virus and a reduction in ALT. The presence of antibodies 
against HBsAg (anti-HBs), together with HBV-specific memory T-cells, provides long-term viral 
control and protection against reinfection and reactivation of HBV.  
Due to limitations in obtaining samples from patients at the earliest pre-symptomatic stages of 
HBV infection, the majority of our understanding of the immune response in acute-resolving HBV 
has utilised models of HBV infection in chimpanzee and murine models, and the closely related 
woodchuck hepatitis virus infection. As HBV does not demonstrate natural tropism for murine 
hepatocytes, numerous models have been designed based on the introduction of human 
hepatocytes, including the production of chimeric mice bearing human hepatocytes and transgenic 
mice that express NTCP or HBV viral proteins. However, these are not without problems: for 
instance, chimeric mouse often display profound immunodeficiency, and transgenic mice often fail 
to effectively recapitulate the entire viral life cycle (Guo et al., 2018; Iannacone and Guidotti, 2015). 
Nonetheless, animal models have revealed important insights into the innate and adaptive immune 
responses involved in HBV viral clearance. In stark contrast to most other acute viral infections, 
including HCV, early responses to HBV are characterised by a notable lack of innate immunity. 
Type I interferons are generally produced by infected cells and trigger the transcription of 
interferon stimulated genes (ISGs) that in turn control intracellular antiviral pathways that help to 
limit infectivity, for instance by reducing viral replication and spread (Wieland and Chisari, 2005). 
This was first demonstrated in an experimental model of HBV infection in chimpanzees; genomic 
analysis in HBV-infected chimpanzees identified a lack of upregulated Type I ISGs following viral 
infection and early expansion (Wieland et al., 2004). Building on this finding, temporal analysis of 
patients with acute HBV infection demonstrated delayed and impaired production of pro-
inflammatory cytokines, including type I interferons, within the first 30 days of infection, in 
comparison to acute hepatitis A, HIV and HCV infection (Dunn et al., 2009; Stacey et al., 2009). In 
avoiding the induction of ISGs, HBV is said to behave like a ‘stealth virus’, whereby it can spread 
throughout the liver without alerting the innate immune response. How the virus achieves this is 
remains a subject of much debate; it is not yet understood whether the virus ‘hides’ from the innate 
response, by sequestering cccDNA or RNA/DNA intermediates to the cell nucleus or cytoplasmic 
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core particles, or is instead able to actively repress its induction (Durantel and Zoulim, 2009; Maini 
and Gehring, 2016; Tan et al., 2015; Tang et al., 2018; Wieland and Chisari, 2005). Likely, HBV 
evasion of innate immune responses is a combination of both limited sensing and active 
suppression (Maini and Gehring, 2016). Recent evidence using livers from patients with CHB 
demonstrated an absence of ISGs in hepatocytes infected with HBV, yet ISGs were sufficiently 
induced following pattern-recognition receptor (PRR) engagement using TLR-3 ligands or Sendai 
virus stimulation (Suslov et al., 2018). HBx protein and HBV-induced miRNA have also been 
implicated in the inhibition of intracellular machinery, including signalling mediated by cytosolic 
sensory molecules, such as retinoic acid-induced gene-I (RIG-I) (Hou et al., 2016; Sato et al., 2015; 
Tan et al., 2015). HBV is able to abort cell-intrinsic immunity in hepatocytes through actively 
suppressing TLR-3 and RIG-I pathways, resulting in weak and transient production of Type I 
interferons and antiviral cytokines, including IL-6 (Luangsay et al., 2015). These data suggest that an 
inability to activate PRR’s, either through evasion or active suppression, may be one mechanism by 
which HBV evades the innate immune response. 
Due to the poor induction of innate intracellular immunity, adaptive immune responses during 
acute-resolving infection are essential for viral clearance, and are efficiently and timely induced 
following HBV replication; however, in contrast to most other acute infections, viral clearance can 
take several months to establish. The exponential phase of HBV replication is accompanied by 
robust production of TNFa and IFNg, that clear the majority of the viral burden whilst avoiding 
the induction of liver damage, as indicated by raised levels of ALT (Figure 1.3). As such, the 
majority of HBV clearance is deemed to be non-cytolytic and mediated by the direct antiviral 
effects of TNFa and IFNg. Production of these cytokines has been associated mainly with an 
efficient HBV-specific T cell response, as demonstrated in transgenic mice and chimpanzees 
(Guidotti et al., 1996, 1999).  
Accordingly, patients who spontaneously recover from HBV demonstrate robust induction of 
strong and multi-epitope specific CD4 and CD8 T cell responses. HBV-specific CD8 T cells 
accumulate in the blood and liver during HBV infection (Maini et al., 1999; Thimme et al., 2003). 
Depletion of CD8 T cells at the peak of viraemia delays viral clearance until CD8 T cells return, 
providing direct evidence for the principal role of CD8 T cells in resolution of infection (Thimme 
et al., 2003). However, in addition to secreting antiviral cytokines that suppress HBV gene 
expression and replication, HBV-specific CD8 T cells also contribute to viral clearance through the 
lysis of infected hepatocytes (Thimme et al., 2003) and recruitment of inflammatory cells to the 
liver microenvironment (Kakimi et al., 2001). Thus, despite their crucial role in viral clearance, the 
cytotoxic ability of CD8 T cells to kill infected hepatocytes, and their role in driving liver 
inflammation, are thought to be key factors underlying liver damage in HBV infection. As such, 
their peak abundance often coincides with the peak of liver damage (Fisicaro et al., 2009; Guidotti 
et al., 1999; Webster et al., 2000).  
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Functional CD4 T cell responses are likewise essential to the co-ordination of adaptive antiviral 
immune responses. CD4 T cells regulate the efficacy of CD8 T cell responses, and thus their 
frequency and function positively correlate with HBV clearance (Chisari and Ferrari, 1995; Guidotti 
et al., 2015a). Accordingly, patients with resolved HBV demonstrate robust and multi-specific CD4 
T cell responses, whilst CD4 T cells in CHB characteristically have a narrow repertoire of responses 
and much weaker proliferative capacity (Ferrari et al., 1990, 1991). The central role of CD4 T cells 
in influencing the outcome of infection is supported by the in vivo clinical observation that HIV-
infected patients with low CD4 T cell counts have an increased risk of developing chronic HBV 
infection following horizontal transmission (Puoti et al., 2006). Moreover, whilst depletion of CD4 
T cells at the peak of viraemia does not affect HBV resolution, depletion prior to HBV infection 
results in qualitative and quantitative impairments in HBV-specific CD8 T cell responses, resulting 
in HBV persistence (Asabe et al., 2009; Thimme et al., 2003). These data point to an indirect role 
for CD4 T cells in early virus control, likely through the priming of CD8 T cell responses via the 
secretion of cytokines such as IL-2 (Zhang et al., 2009) and through the activation/licensing of 
professional antigen-presenting cells, which in turn activate CD8 T cells (Schoenberger et al., 1998). 
In addition, CD4 T cells also have a crucial role in the initiation of neutralising antibody responses.  
Natural killer (NK) cells may also contribute to viral clearance (Yang et al., 2010). TNFa and IFNg 
are secreted by NK cells and natural killer T (NKT) cells at sufficient levels to control HBV 
replication. Stimulation of NK cells in transgenic mice promoted IFNg production by intrahepatic 
NK and NKT cells, resulting in the non-cytopathic inhibition of viral replication (Kimura et al., 
2002). More recently, the administration of TLR-7 agonists in chimpanzee models of HBV induced 
both type I interferon responses and IFNg production by activated NK cells, resulting in clearance 
of HBV-infected cells (Lanford et al., 2013). Importantly, NK cells are enriched in the liver 
compared to the blood (including during HBV infection), where they can account for up to 40% of 
the lymphocyte population and contribute to antiviral immunity (Doherty et al., 1999; Maini and 
Peppa, 2013). Although classical iNKT cells are only present at very low numbers in human livers, 
an analogous population of mucosal-associated invariant T (MAIT) cells are abundant and can 
produce large quantities of IFNg (Garner et al., 2018; Jo et al., 2014; Loh et al., 2016; Tang et al., 
2013; Ussher et al., 2014). 
Although the virus is likely never eradicated completely, resolution of HBV provides an informative 
model for functional cure, demonstrating that viral replication can be controlled by functional T 
cell responses (Penna et al., 1996; Rehermann et al., 1996). How much the humoral response 
contributes to viral control is poorly understood at present; however, it probably has a more 
important role than previously thought (discussed in detail in section 1.6). 
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1.3.2 Failure of immune control and chronic HBV  
Chronic HBV infection (CHB) is characterised by the persistence of HBsAg in the absence of anti-
HBs. Mechanisms underpinning immune dysregulation in CHB have yet to be fully elucidated. 
However, it is clear that the failure of immune control in patients with CHB is multifactorial; viral 
persistence is thought to be a result of: immune exhaustion resulting from high-dose antigen 
stimulation ± direct effects of viral proteins; continued production of stable forms of HBV 
(including cccDNA); and HBV tropism for the tolerogenic environment of the liver. In persistent 
infection, the immune response fails to control the virus and can instead trigger tissue damage, 
leading to cirrhosis and ultimately liver cancer. 
 
1.3.2.1 Clinical manifestations in CHB 
Chronic infection with HBV manifests as several distinct phases of disease, reflective of the 
interaction between HBV replication and the host immune response. The natural course of CHB 
infection is divided into four clinically distinct phases based on a combination of virological, 
serological and biochemical parameters (Table 1.1; Figure 1.3). These have recently been re-named 
according to positive or negative detection of secretory HBeAg, and to whether there is simply 
ongoing infection or evidence of liver disease (i.e. hepatitis). The immune mechanisms that dictate 
these different phases and mediate the transition between them have yet to be fully established. 
 
Table 1-1 Natural history and classification of patients with CHB based on virological, serological and 
biochemical parameters 
Based on European Association for the Study of Liver (EASL) clinical guidelines (European Association for the Study of 
the Liver, 2017). Clinical phases of disease previously referred to as follows: ‘Immunotolerant’ = HBeAg+ infection; 
‘Immunoactive phase’ = HBeAg+ hepatitis; ‘Low replicative phase’ = HBeAg- infection; ‘High replicative phase’ = 
HBeAg- hepatitis. 
 
 HBeAg+ 
Chronic infection 
HBeAg+ 
Chronic hepatitis 
HBeAg- 
Chronic infection 
HBeAg- 
Chronic hepatitis 
HBsAg High High/intermediate Low Intermediate 
HBeAg Positive Positive Negative Negative 
HBV DNA >107 IU/ml  104-107 IU/ml <2000 IU/ml ³2000 IU/ml 
ALT Normal Elevated Normal Elevated  
Liver disease None/minimal Moderate/severe None Moderate/severe 
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HBeAg+ chronic infection is characterised by the co-occurrence of extremely high levels of HBV 
DNA with a normal or minimally raised ALT levels, indicative of a lack of liver 
inflammation/damage. As a result, patients demonstrate minimal or no liver fibrosis, yet high levels 
of HBV DNA integration in hepatocytes suggests that early pro-carcinogenic changes may already 
be underway (Kennedy et al., 2017). HBeAg+ chronic infection is more commonly detected in 
young patients following vertical infection by HBeAg+ mothers, and can persist for 20-30 years, in 
contrast to those who acquire HBV infection in adulthood in whom this period is short or even 
absent.  
The mechanisms associated with the loss of immunotolerance and the transition through to active 
disease phase are still mostly unknown, although previous work from our group has suggested a 
role of arginase-expression myeloid derived suppressor cells in maintenance of the 
immunotolerant/HBeAg+ chronic infection phase (Pallett et al., 2015). HBeAg+ chronic hepatitis is 
characterised by fluctuating levels of HBV DNA and raised ALT levels. Accordingly, HBeAg+ 
chronic hepatitis is associated with progression of liver fibrosis, attributable to immune-mediated 
responses against the virus. HBeAg+ chronic hepatitis is more frequently (and more rapidly) 
initiated in patients infected during adulthood.  
Seroconversion against HBeAg is often accompanied by a non-replicative or inactive phase, termed 
HBeAg- chronic infection. During this phase, patients have undetectable or low levels of HBeAg 
coupled with normalised ALT values. These patients have a low risk of progression to cirrhosis or 
HCC, assuming that they remain within this phase. Approximately 1% of patients within this phase 
spontaneously clear HBsAg and/or produce detectable anti-HBs (Villa et al., 2011). This period of 
inactive disease can be long-lasting; however, HBV reactivation is known to occur in a subset of 
patients, characterised by fluctuating levels of HBV DNA and ALT (referred to as HBeAg+ chronic 
hepatitis). HBV reactivation is associated with recurrent necroinflammatory liver disease and 
fibrosis. The majority of cases of HBV reactivation can be attributed to HBV variants in the 
precore and core promoter regions, that lead to evasion of protective immune responses whilst 
limiting re-expression of HBeAg (Fattovich et al., 2008). 
 
1.3.3 Mechanisms of lymphocyte dysfunction in CHB 
Persistent infections are commonly characterised by weak and mono-specific T cell responses. 
Depletion of virus-specific T cell responses is particularly evident in patients with CHB, who 
demonstrate profoundly decreased levels of ex vivo HBV-specific CD8 T cells compared to those 
with acute infection (Boni et al., 2007; Maini et al., 2000). Accumulating evidence over recent years 
has described mechanisms by which HBV-specific T cells are depleted in persistent infection. Gene 
expression profiling of HBV-specific T cells identified high expression of the pro-apoptotic 
molecule, Bcl-2-interacting mediator (Bim), in cells isolated from patients with chronic infection 
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relative to those in which it resolved (Lopes et al., 2008). Elevated Bim expression was confirmed at 
the protein level and was associated with premature apoptosis of HBV-specific T cells both ex vivo 
and in culture; in opposition, blockade of Bim rescued HBV-specific T cells from premature cell 
death. An increased propensity towards premature cell death, also observed in intrahepatic and 
peripheral HCV-specific T cells (Radziewicz et al., 2008), is postulated to be driven by the nature of 
T cell activation within the tolerogenic liver. This concept is supported by the demonstration that 
antigen presentation by hepatocytes results in T cells prone to premature death through the 
upregulation of Bim (Bowen et al., 2004; Holz et al., 2008). In addition, intrahepatic CD8 T cells 
may be further depleted through interactions with liver-infiltrating and liver-resident NK cells, 
which upregulate the death ligand TNF-related apoptosis-inducing ligand (TRAIL), enabling them 
to kill HBV-specific T cells expressing high levels of the death receptor, TRAIL-R2 (Das et al., 
2008; Peppa et al., 2013; Stegmann et al., 2016). 
Cells that resist depletion are often profoundly dysfunctional. HBV-specific CD8 T cells in patients 
with high levels of viral replication and extensive liver damage show markedly decreased 
proliferative capacity compared to those with low level viral replication and minimal or absent liver 
disease (Maini et al., 2000), in line with similar data showing reduced functional capacity of CD8 T 
cells and deletion of immune-dominant clones in murine models of chronic LCMV infection 
(Wherry et al., 2003). Mechanisms underpinning dysfunction in HBV-specific T cells are outlined 
below and summarised in Figure 1.4.  
 
1.3.3.1 Viral exhaustion of lymphocytes 
CD8 T cells show a gradual decline in effector function following persistent antigen stimulation. 
This state is referred to as ‘exhaustion’ and contributes to impairment of antiviral responses in 
settings of chronic viral infections and cancer; in opposition, this reduction in function also has a 
role in avoiding extensive tissue damage in the context of antigen persistence.  
Exhaustion within T cells typically manifests as hierarchical loss of effector function, altered 
expression of transcription factors and checkpoint molecules, and metabolic dysregulation (Wherry 
et al., 2003). T cell exhaustion can also impair memory responses: exhausted virus-specific T cells 
display a loss of maintenance of memory responsiveness independent of antigen, indicative of 
dependence on cognate antigen for long-term persistence (Shin et al., 2007a). Exhausted virus-
specific T cells were first described in models of chronic LCMV, with functional exhaustion 
ascribed to loss of cytokine production, namely IFNg (Zajac et al., 1998). Analogous defective T 
cells have since been identified in human infections (reviewed in Wherry and Kurachi, 2015), 
including chronic HBV (Boni et al., 2007), where the combination of persistently high viral load 
and tolerogenic environment of the liver are thought to drive exhaustion. In CHB, persisting HBV-
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specific T cells produce less IFNg, have a reduced proliferative capacity and exhibit a phenotype 
associated with exhaustion. 
Central to T cell exhaustion are pathways involved in immune regulation. Activation of 
lymphocytes is carefully regulated, requiring a delicate balance between activation of effector cells 
in response to pathogenic challenge whilst maintaining peripheral tolerance against ‘self’ antigen. 
This is accomplished through immune checkpoints that act as brakes for the cell and repress its 
function: cells must overcome these co-inhibitory signals in order to perform their full effector 
function. Persistent TCR stimulation in the context of chronic infection leads to the upregulation 
of a number of co-inhibitory molecules, including cytotoxic T-lymphocyte associated protein 4 
(CTLA-4), T cell immunoglobulin gene and mucin-3 (Tim-3) and programmed cell death protein 
(PD-1), partially attributable to the upregulation of nuclear factor of activated T cells (NFAT) 
(Martinez et al., 2015). Although viral persistence is required for the induction of lymphocyte 
exhaustion, T cell functionality in CHB does not clearly correlate with quantities of viral protein 
detectable in patient serum (Loggi et al., 2013), with varying levels of T cell restoration achieved 
following NUC-treatment and HBsAg clearance (Boni et al., 2012). Importantly, expression of co-
inhibitory molecules results in suppression of effector function in instances where excess co-
inhibitory signals outweigh co-stimulatory signals (Blackburn et al., 2009).  
The best characterised immune checkpoint within the context of chronic viral infection is PD-1. 
Upon binding to its ligands PD-L1/L2, PD-1 associates with the TCR, in combination with the 
phosphatase, SHP-2. Together, these induce the de-phosphorylation of proximal TCR signalling 
molecules, resulting in the suppression of TCR signalling (Yokosuka et al., 2012). However, more 
recent work has shown that PD-1 also has a more potent role in de-phosphorylation and 
suppression of the T cell co-receptor CD28 (Hui et al., 2017), indicating additional mechanisms by 
which PD-1 restrains T cell activation. In addition, PD-1 ligation has been suggested to upregulate 
expression of the transcription factor BATF, which in turn impairs proliferation and cytokine 
production by T cells (Quigley et al., 2010). These data suggest that development of T cell 
exhaustion is an active process that can be recovered through blockade of co-inhibitory molecules. 
Numerous studies have now identified elevated expression of co-inhibitory molecules on virus-
specific T cells in HBV associated with impaired effector function (Boni et al., 2007; Fisicaro et al., 
2012; Nebbia et al., 2012; Schurich et al., 2011). PD-1 shows the highest level of expression relative 
to other co-inhibitory molecules, identifiable on approximately 80% of HBV-tetramer staining T 
cells and rising to almost 100% of HBV-specific T cells in the liver (Bengsch et al., 2014). This is 
exacerbated by the high levels of PD-1 ligands expressed by hepatocytes and non-parenchymal cells 
in the liver, that increase further in the context of viral infection and impair local effector responses 
(Protzer et al., 2012). 
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To this end, blockade of PD-1 has shown promising results in re-invigorating host immune 
responses in cancer treatment. Blockade of PD-L1 resulted in increased frequencies of HBV-
specific T cells in vitro, but showed significant heterogeneity in responses between individuals tested 
(Bengsch et al., 2014). PD-1 blockade also increased the frequency of IFNg and IL-2 producing 
cells, showing much greater rescue of intrahepatic T cell function, compared to cells isolated from 
the periphery (Fisicaro et al., 2010). The addition of IL-12 in combination with PD-L1 blockade 
significantly enhanced IFNg production by HBV-specific T cells, as did blockade of another 
checkpoint molecule, CTLA-4 (Schurich et al., 2011, 2013).  
Although lymphocyte exhaustion is most commonly discussed in relation to CD8 T cells, growing 
evidence now suggests that additional immune cell populations also display evidence of 
‘exhaustion’. Like CD8 T cells, CD4 T cells also show signs of impaired proliferation and weak 
cytokine production in models of chronic infection, including LCMV (Antoine et al., 2012) and 
chronic HCV (Ulsenheimer et al., 2003). Blockade of PD-1 ligands resulted in release of HCV-
specific T cell proliferation and cytokine production (Raziorrouh et al., 2011). In comparison, 
illustration of exhausted CD4 T cell responses in CHB is limited. HBV-specific CD4 T cells 
demonstrate upregulated expression of inhibitory molecules including PD-1 and TIM-3 (Nebbia et 
al., 2012; Raziorrouh et al., 2014), in line with a supposed exhausted phenotype (Ye et al., 2015). 
However, as yet, the functional consequences of CD4 T cell exhaustion in CHB remain poorly 
understood.  
 
1.3.3.2 Altered metabolism of HBV-specific T cells 
It is increasingly recognised that defects in cellular metabolism contribute to the profound 
functional exhaustion of HBV-specific CD8 T cells. Dynamic metabolic reprogramming is essential 
for lymphocyte effector function and memory formation; upon activation, lymphocytes must 
undergo metabolic reprogramming in order to meet increased demand. Exhausted PD-1hi HBV-
specific T cells demonstrate upregulated expression of the glucose transporter, Glut-1, in line with 
their dependence on glucose to maintain effector cytokine expression. Upon glucose withdrawal, 
HBV-specific T cells were unable to utilise oxidative phosphorylation in contrast to more 
functional CMV-specific T cells from within the same patient, likely due to underlying defects in 
mitochondria (Schurich et al., 2016). This was supported by data demonstrating a link between 
impaired mitochondrial polarisation and function with virus-specific T cell exhaustion; accordingly, 
improvement of mitochondria via targeted antioxidant treatment resulted in the functional 
restoration of HBV-specific T cell responses (Fisicaro et al., 2017). Metabolic pathways, including 
both oxidative phosphorylation and glycolysis, appear to be modulated early in chronic infection, 
which appears to be in part mediated by expression of PD-1 (Bengsch et al., 2016).  
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Figure 1-4 Schematic outlining the features of T cell defects in the context of chronic HBV infection 
Diagram depicting mechanisms associated with T cell dysfunction in CHB, including: i. defective metabolism and 
mitochondrial polarisation; ii. repetitive TCR signalling and upregulation of inhibitory receptor expression; iii. elevated 
expression of the pro-apoptotic mediator Bim. [Adapted from (Maini and Pallett, 2018). Abbreviations used: Glut-1 = 
glucose transporter 1. Trail = tumour necrosis factor-related apoptosis-inducing ligand. TCR=T-cell receptor. 
ROS=reactive oxygen species. MHCI=MHC class I] 
 
1.3.4 A role for failed humoral immunity in viral persistence? 
An additional mechanism that may contribute to failure of immune control in CHB and that has 
been understudied to date, is a defect in the frequency or function of antiviral B cells. B cells are 
responsible for the production of neutralising antibodies that can limit infectivity and promote 
clearance of the virus. Typically, non-cytopathic viruses such as HBV induce delayed low titre 
neutralising antibody responses due to decreased pressure pertaining to the survival of the host and 
a strong reliance on T cell toxicity for viral clearance. However, it is also possible that HBV is able 
to deplete/modify B cell subsets, subvert CD4 T cell responses leading to abnormal B cell 
activation, and/or induce pathological changes in secondary lymphoid organs: all factors that may 
contribute to impaired neutralising responses during non-cytopathic viral infection (Hangartner et 
al., 2006). To understand how B cell responses may contribute to HBV persistence, it is first 
important to consider the role of B cells in antiviral responses. 
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1.4 B cell responses in viral infections 
The ability of the adaptive immune response to respond to a wide range of pathogens is beholden 
in the diversity of the antigen receptor repertoire for T and B cells. B cell antigen-specificity is 
proffered by the expression and production of immunoglobulins. Membrane-bound 
immunoglobulin serves as the receptor for antigen, referred to as the B cell receptor (BCR). As the 
constant region of the immunoglobulin is inserted into the cell membrane, the antibody itself does 
not exert an effector function; instead, the exposed variable regions of the immunoglobulin are 
responsible for recognising and binding antigen, leading to B cell activation, clonal expansion and 
specific antibody production. Antibodies are produced by terminally differentiated B cells and span 
a vast range of specificities - each B cell clone producing one specific immunoglobulin. Antibody 
production by B cells of a single-antigen specificity was demonstrated in a seminal paper by Nossal 
and Lederberg, who showed that single-cell suspensions of B cells isolated from mice inoculated 
with two different types of Salmonella antigen produced an immobilising agent – presumed to be 
antibody – to only one of the antigens (Nossal and Lederberg, 1958).  
The development of humoral responses requires virus-specific B cells to encounter viral antigens in 
secondary lymphoid organs, become activated, proliferate and enter specific differentiation 
programmes. Viruses are able to induce B cell activation as a function of their combined ability to 
cross-link the BCR and to deliver RNA/DNA signals to toll-like receptors. The efficacy of viruses 
to activate B cells is dependent on various factors, including the size of the viral particle, its 
geometry and its relative abundance (Zabel et al., 2013). B cell expression of cell-surface molecules 
can also modulate activation; for example, engagement of the B cell co-receptor molecule CD21 by 
complement-coated viral particles, significantly reduces the threshold of stimulation required for 
B cell activation and IgG production (Jegerlehner et al., 2002). Distinct from their production of 
antibodies, B cells can also exert additional antiviral functions, such as their ability to secrete 
cytokines (discussed in more detail in section 1.4.7).  
 
1.4.1 Early B cell development 
Initial diversity of the BCR is imparted through a complex rearrangement of germline 
immunoglobulin (Ig) genes in the bone marrow that occurs throughout early B cell development. 
B cells are generated from lymphoid precursors in the bone marrow, whereby cells progress 
through pro-B cell and pre-B cell stages of development. Stages of B cell development in the bone 
marrow are defined by phases of Ig gene arrangement of the pre-BCR, whereby V, D and J 
segments encoding the variable region of the Ig heavy and light chains recombine to form a 
functional BCR. This mechanism creates combinatorial diversity through the random pairing of 
V D J gene segments (within the heavy chain) or V J gene segments (within the light chain) 
resulting in large number of possible unique configurations. Additional diversity during V (D) J 
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recombination arises by the introduction or deletion of nucleotides at the junction of segments as 
they are linked together (Schroeder and Cavacini, 2010). Recombined heavy and light chains are 
then randomly paired to form an intact antibody molecule and tested for auto-reactivity; B cells that 
do not react strongly to self-antigen leave the bone marrow as immature transitional B cells, before 
eventually maturing into IgM+IgD+ mature naïve B cells. At rest, homeostasis of peripheral mature 
B cells is regulated by the co-ordination of several receptors, including the BCR and B cell 
activating factor receptor (BAFF-R). Deletion of the BCR - or associated transmembrane proteins 
CD79a and CD79b - results in the death of mature B cell subsets (Kraus et al., 2004; Lam et al., 
1997), whist blockade of BAFF-R, or its ligand BAFF/BlyS, leads to the loss of follicular and 
marginal zone B cells in mice (Gross et al., 2001; Rauch et al., 2009). Studies have since revealed a 
critical interplay between these two pathways, whereby BAFF-R signalling results in the 
phosphorylation of CD79a and spleen tyrosine kinase (Syk); inducible deletion of Syk in mature B 
cells resulted in a loss of ~80% of follicular B cells (Schweighoffer et al., 2013). These data suggest 
that BAFF-R derived survival signals are transduced via the BCR and activation of Syk. 
 
1.4.2 Progression of B cell differentiation during infection 
1.4.2.1 Antigen recognition within secondary lymphoid organs 
For the most part, B cell activation and clonal expansion following antigen-activation occurs within 
secondary lymphoid organs, the best characterised of these being the lymph node. Viruses that 
evade first-line innate immune responses are disseminated systemically via the lymphatic system, 
whereupon they encounter B cells in draining lymph nodes. These provide a specialised 
micro-environment for the presentation of virus-derived antigens and the activation of naïve B and 
T cell responses (von Andrian and Mempel, 2003; Denton and Linterman, 2017; Gatto and Brink, 
2010). Similar encounters are also detectable within the spleen, which filters blood-borne viruses 
enabling antigen capture and presentation by specialised populations of macrophages and dendritic 
cells. As such, the spatiotemporal dynamics of B cell activation in lymph nodes are closely mirrored 
by those occurring in the spleen (Heesters et al., 2016).  
The structure of a lymph node is broadly characterised by follicles comprised of IgM+IgD+ naïve B 
cells (referred to as B cell follicles), bordered by T cell rich areas (referred to as the T cell zone) 
(Figure 1.5). Antigen is shuttled into the lymph node via monocytes, dendritic cells, macrophages 
and marginal zone B cells, whereupon it is deposited on follicular dendritic cells (FDCs) and 
presented to B cells within the germinal centre. Engagement of BCRs with antigen retained on 
FDCs is critical for GC B cell activation, GC development, somatic hypermutation and affinity 
maturation, and the induction of secondary antibody responses (El Shikh and Pitzalis, 2012). 
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Early antigen interactions can also take place in the sup-capsular sinus (SCS) of the lymph node, 
defined as the space between the cortex (consisting of the B cell follicle and T cell zone) and the 
outer capsule (Kuka and Iannacone, 2014) (Figure 1.5). The SCS receives unfiltered lymph from 
afferent lymph vessels, and is populated with SCS macrophages that help to translocate large 
antigens, including immune complexes and inactivated viruses, to follicular B cells (Carrasco and 
Batista, 2007; Phan et al., 2007). Although small soluble antigens, less than ~70 kD in size, can 
readily infiltrate the B cell follicle (Pape et al., 2007), SCS macrophage capture of larger particulate 
antigens (e.g. intact viral particles) represents an important mechanism in the induction of antiviral 
humoral responses.  
 
Figure 1-5 Schematic of the structure of the lymph node 
Schematic of the lymph node, showing the sub-capsular sinus (SCS), T cell zone (area) and B cell follicle. 
Viruses can enter the lymph node via the afferent lymph where they are captured and retained by SCS 
macrophages (SSMs). Antigen-activated B cells relocalise to the B – T cell border in order to receive T cell 
help, and either differentiate into extra-follicular plasmablasts or localise back to the follicle and enter the 
germinal centre. [Figure adapted from (Kuka and Iannacone, 2017)] 
 
Naïve B cells are recruited to the B cell follicle via expression of CXCR5, allowing them to scan 
CXCL13-expressing follicular dendritic cells for cognate antigen (Ansel et al., 2000; Suzuki et al., 
2009). Upon antigen-recognition and binding, B cells undergo rapid proliferation and migrate 
towards the T - B border via the upregulation of the chemokine receptor CCR7, responding to 
gradients of CCL19 and CCL21 (Okada et al., 2005; Reif et al., 2002). Here, they form stable 
interactions with CD4 T cells that home to the B cell follicle via upregulation of CXCR5, 
whereupon they differentiate into T follicular helper cells (TFH) (Ansel et al., 1999). These crucial 
interactions facilitate the activation and proliferation of both B and T cells in a bidirectional 
manner. 
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1.4.2.2 T cell help 
Following antigen-activation, the BCR delivers bound antigen to intracellular sites where it is 
degraded and presented at the cell surface bound to MHC Class II molecules. Peptide - MHC 
molecules are then available to antigen-specific T helpers, activated by the same pathogen, which 
deliver activating signals to the B cell (known as linked recognition). The co-operation between CD4 T 
cells and B cells was first demonstrated by experiments showing that adoptive transfer of either 
B cells or T cells alone into irradiated mice was insufficient to generate a robust antibody response 
(Mitchell and Miller, 1968, 1968). Since then, many mechanisms have been identified that promote 
B cell activation (Crotty, 2015), including T cell production of IL-4, IL-21 and CXCL13, and 
interactions between CD40 and CD40-L, expressed on B cells and CD4 T cells respectively. 
Ligation of CD40 on naïve B cells, in particular, is key to B cell activation, and is required for their 
clonal expansion and proliferation (Armitage et al., 1993; Noelle et al., 1992; Nonoyama et al., 
1993).  
Within the B cell follicle, TFH-driven expression of IL-21 is postulated to stimulate differentiation 
to plasma cells, and along with IL-4, can induce class-switch recombination and somatic 
hypermutation in B cells. In this way, cytokine signals from T helper cells play a key role in driving 
the molecular events preceding class-switch recombination in B cells, whereby antigen-activated 
mature naïve B cells downregulate expression of IgM and IgD, and instead switch to expressing 
IgG, IgA or IgE with distinct effector functions. Finally, CXCL13 expression by TFH recruits 
CXCR5+ B cells to co-localise and form functional associations with TFH, whilst TFH expression of 
SAP helps to sustain T-B cell interactions, allowing sufficient time for B cell help to occur (Qi et al., 
2008). 
 
1.4.2.3 Extra-follicular responses 
Before differentiation into effector or memory B cell subsets, antigen-activated B cells have an 
initial fate decision: to enter the germinal centre (becoming a ‘germinal centre B cell’; GC B cell), 
differentiate into a germinal centre-independent memory B cell, or leave the B cell follicle as a 
short-lived plasma cell (or ‘extra-follicular plasma cell’). This decision is thought to be in part 
mediated by the antigen reactivity of the BCR, whereby high-affinity B cells are more likely to 
generate short-lived responses. Using a library of hen egg lysozyme (HEL) mutant proteins with 
divergent affinities for the BCR, Paus et al., showed that decreasing the affinity led to impaired 
formation of extra-follicular plasma cell responses but did not affect germinal centre responses 
(Paus et al., 2006). In contrast, low affinity interactions instead predisposed B cells towards long-
lived plasma cells and memory B cells (O’Connor et al., 2006).  
In T cell-dependent immune responses to viruses, the early antibody response is provided by 
activated B cells that differentiate into extra-follicular plasmablasts, transitioning to long-lived 
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plasma cells later in the humoral response. Extra-follicular plasmablasts are short-lived and generate 
much of the early-induced antiviral antibody responses; accordingly, antibody-secreting cells (ASCs) 
can be detected as early as three days after infection and secrete low-affinity antibody (Baumgarth, 
2013; Smith et al., 1996). During active immune responses, short-lived plasmablasts migrate 
towards sites of inflammation through the expression of CXCR3 (Hauser et al., 2002; 
Muehlinghaus et al., 2005).  
 
1.4.3 Generation of B cell memory 
Protective immunity against de novo or secondary infection depends on the longevity and rapid 
responsiveness of memory responses upon re-encountering antigen. During primary immune 
responses, a portion of B cells activated during initial cognate interaction with T cells do not 
differentiate into effector cells and instead establish a population of memory B cells. Upon 
secondary infection and subsequent antigen challenge, these cells can re-enter follicles and develop 
into antibody-secreting plasma cells or re-seed the memory B cell pool (Zhang et al., 2016). During 
this process, additional diversity is incorporated in order to tailor the response towards the infecting 
pathogen. Within humoral responses, first-line defence is provided by high-affinity pre-existing 
antibodies secreted by long-lived plasma cells, assuming that the concentration of antibodies at the 
site of reinfection is sufficiently high. Where levels of antibodies are not protective, pathogen-
experienced memory B cells are rapidly reactivated to produce antibodies. These secondary 
responses are typically faster and generate higher affinity antibodies of switched isotypes, reflective 
of B cells that have undergone expansion within the germinal centre.  
 
1.4.3.1 The germinal centre 
Key to the generation and diversification of protective humoral responses is the clonal expansion 
and maturation of antigen-activated B cells in the germinal centre. These are transient structures that 
form within peripheral lymphoid organs in response to T cell-dependent antigen, and facilitate BCR 
diversification and selection of high-affinity antibodies. Germinal centres were first described in 
1884 as distinct micro-anatomical regions thought to persist within lymphoid organs and provide a 
key source of lymphocyte generation. Follow-up work demonstrated that these sites developed only 
in response to antigen and consist predominantly of proliferating B cells (Nieuwenhuis and 
Opstelten, 1984). Indeed, rapidly proliferating B cells can be identified in the spleen and lymph 
nodes approximately six days after immunisation (Amitai et al., 2017; Jacob et al., 1991), with 
germinal-centre derived memory B cells and plasma cells detectable after one week (Blink et al., 
2005).  
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1.4.3.2 Diversification by somatic hypermutation and affinity maturation 
Antigen-activated B cells are committed to differentiate into germinal centre precursors outside of 
the follicle; migration into the centre of follicle, where they form early germinal centre responses, is 
dependent on the master transcriptional regulator of germinal centre B cells, Bcl-6 (Baumjohann et 
al., 2011; Kitano et al., 2011).  
In order to diversify their antibody repertoire and generate high-affinity responses, GC B cells 
undergo a process of somatic hypermutation and affinity-based selection, a process closely guided 
by an extensive network of stromal cells (reviewed in Denton and Linterman, 2017). Following 
activation, T and B cells move into the germinal centre, whereby GC B cells begin to rapidly divide 
and segregate into two zones, referred to as the dark and light zone (Figure 1.6). Cells populating 
these two zones can be distinguished by their rate of cell division. GC B cells in the dark zone are 
rapidly dividing, allowing them to undergo a process of somatic hypermutation that introduces 
random nucleotide exchanges into Ig genes encoding the variable region (IgV) (Mesin et al., 2016; 
Wagner and Neuberger, 1996). This process is dependent on DNA breaks, which in turn relies on 
the expression and activity of the enzyme activation-induced cytidine deaminase (AID). Signals 
delivered via TFH-secreted cytokines activates AID, which initiates breakage through the 
deamination of cytidines directly on DNA and thus facilitates gene recombination (Gatto and 
Brink, 2010). Error-prone repair then leads to the introduction of somatic mutations that further 
diversify IgV regions and lead to changes in BCR specificity and affinity (Di Noia and Neuberger, 
2007). The affinity of the BCR is then tested through cognate interactions with follicular dendritic 
cells and TFH situated within the light zone of the germinal centre (Victora and Nussenzweig, 2012).  
GC B cells within the light zone are non-dividing; here, cells undergo class-switch recombination 
and begin to differentiate into either long-lived plasma cells or memory B cells (Klein and Dalla-
Favera, 2008). Newly formed GC B cell clones compete for antigen and survival signals presented 
by FDCs and TFH cells (van Nierop and de Groot, 2002; Victora et al., 2010). Mutations that lead to 
increased affinity are selected for and selectively expand, whilst those that demonstrate impaired 
antigen binding are deleted by apoptosis (Hamel et al., 2012). As such, rates of cell division and 
hypermutation are directly proportional to the amount of antigen captured and presented by 
GC B cells to TFH (Gitlin et al., 2014). Importantly, GC B cells repeatedly migrate between the dark 
and light zones as they undergo iterative cycles of somatic hypermutation and selection. As a result, 
this process results in the progressive increase in the affinity of antibodies over time. Elegant 
multiphoton microscopy studies in mice visualised the process by which germinal centres become 
homogenous, demonstrating parallel maturation of individual clones within the germinal centre. 
This study further proposed that spontaneous ‘bursts’ of individual clones leads to drastic 
expansion of clonal variants and facilitates higher rates of diversification resulting in improved 
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affinity (Tas et al., 2016). The evolution of high-affinity antibodies throughout the course of 
infection was demonstrated by Liao et al., who tracked the evolution of a broadly neutralising 
antibody response in a single HIV-infected patient from shortly after inoculation to more than 
three years post-infection, at which point broadly neutralising antibodies were detected (Liao et al., 
2013). In sequencing antigen-specific B cells throughout the time course of infection, in 
combination with single-genome sequencing of HIV, they demonstrated concomitant antibody 
maturation and virus evolution (Liao et al., 2013). Whilst these data evidence the capacity of 
immune responses to evolve and mature over time, they simultaneously highlight the ability of 
viruses to mutate and escape adaptive immune responses. 
 
 
 
Figure 1-6 Schematic of the B cell follicle and germinal centre 
Simplified schematic outlining affinity maturation in the germinal centre in the B cell follicle. B cells present antigen to T 
helper cells at the T cell – B cell border and receive co-stimulatory signals. Antigen-activated B cells can differentiate into 
extra-follicular plasmablasts or enter the dark zone, where they undergo SHM and proliferate prior to migrating into the 
light zone. In the light zone, mutated BCRs are exposed to antigens, expressed by follicular dendritic cells. BCRs that 
detect antigen with low affinity do not receive survival signals and therefore undergo apoptosis. Surviving B cells compete 
for T cell help, whereby the highest affinity antibodies are selected. Selected cells either re-enter the dark zone (where they 
undergo further rounds of SHM and proliferation), or exit the germinal centre as plasma cells or memory B cells. 
[Abbreviations used: GC = germinal centre; SHM = somatic hypermutation; FDCs = follicular dendritic cells. Adapted 
from (Heesters et al., 2014)] 
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1.4.3.3 Outcome of the germinal centre: memory B cells versus long-lived plasma cells 
To date, no mechanism explaining the fate of germinal centre B cells (to develop into either 
memory B cells or plasma cells) has been identified. The current prevailing theory is that stochastic 
differentiation of germinal centre B cells to a memory cell fate confers a survival advantage, leading 
to the generation of memory B cell populations. In support of this, over-expression of pro-
apoptotic factors, inducing Bcl-2 interacting mediator of cell death (BIM) and p53-upregulated 
modulator of apoptosis (PUMA), expands the population of IgG1+ memory B cells (Clybouw et al., 
2011; Fischer et al., 2007). 
 
1.4.4 Memory B cell subsets 
Following primary immune challenge and the formation of the germinal centre, memory B cells 
circulate throughout the body as resting B cells until reactivation upon secondary antigen 
encounter. Whilst continuous production of high-affinity antibody by long-lived plasma cells 
provides ongoing immune defence, memory B cells require re-stimulation to provide enhanced and 
improved immune responses, typically dependent on signals from both antigen and TFH cells 
(Ochsenbein et al., 2000). Memory B cells can survive for decades, and differentiate far more 
efficiently upon antigen-specific or polyclonal stimulation than naïve B cells (Seifert and Küppers, 
2016). Subsequent responses are of higher affinity than naïve B cells as a result of affinity 
maturation in the germinal centre. B cells that have undergone class-switching in the germinal 
centre lose surface expression of IgM and IgD, and instead upregulate switched immunoglobulins, 
including IgG, IgA and IgE. IgA+ memory B cells are generally considered to be associated with 
mucosal responses, due to the role of IgA in mucosal defence (Mantis et al., 2011) and their 
preferential accumulation in mucosa-associated lymphatic tissue (Neutra et al., 1996). IgE+ memory 
B cells are extremely rare in the peripheral blood of healthy humans, but likely play a role in asthma 
and allergic diseases (He et al., 2015). 
Memory B cells are conventionally distinguished from naïve B cells by expression of CD27 and 
co-stimulatory molecules CD80 and CD86 (Maurer et al., 1990; Tangye et al., 1998). 
CD27 expression is associated with production of immunoglobulin, with CD70-ligation shown to 
promote differentiation of memory B cells to antibody-producing plasma cells (Agematsu et al., 
1997). Following T cell-derived stimulation, CD27+ memory B cells proliferate and enter the cell 
cycle more rapidly than naïve B cells, resulting in their accelerated production of antibodies 
following secondary antigenic challenge (Tangye et al., 2003). Accordingly, B cells carrying 
somatically hypermutated genes are often characterised by expression of CD27 (Klein et al., 1998; 
Tangye et al., 1998).  
Classically, studies addressing B cell memory have focused on IgG+ memory B cells as the 
dominant antibody associated with protective responses. Dependent on the type of antigenic 
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challenge, IgG+ memory B cells can express one of four different subclasses of antibody 
– IgG1-4 – that each proffer specific effector functions. IgG+ memory B cells are programmed to 
differentiate into plasma cells following antigen engagement through the repression of the 
transcription factor, Bach 2 (which otherwise inhibits Blimp-1, thus suppressing plasma cell 
formation) and enhanced BCR signalling capacity (Kometani et al., 2013; Lutz et al., 2015). Upon 
secondary activation, class-switched memory B cells can undergo further remodelling to boost 
immune responses (McHeyzer-Williams et al., 2015). 
However, additional subsets of germinal-centre independent memory B cells and IgM+ memory 
B cells have been identified that may have important roles in humoral immune responses 
(Capolunghi et al., 2013). The identification of germinal-centre independent memory B cells in 
humans is at present unclear; however, IgM+ memory B cells can represent up to 50% of peripheral 
blood memory cells. Although previously thought to represent an early, low-affinity subset that are 
redundant to IgG+ memory, emerging evidence now points to key effector functions of these cells 
in secondary immune responses. These cells can be identified within germinal centres and exhibit 
markers of somatic hypermutation and class-switch recombination (Dogan et al., 2009). 
IgM+ memory B cells appear to be more long-lived and outnumber class-switched memory B cells 
in the secondary response (Pape et al., 2011). In humans, these differentiate rapidly into plasma 
cells and show preferential homing to the B cell follicle, where they can re-enter the germinal centre 
response and undergo further affinity maturation and class-switch recombination (Seifert and 
Küppers, 2009; Seifert et al., 2015). In this way, antigen-specific IgM+ memory B cells were shown 
to be highly plastic and dominate the secondary response to Plasmodium rechallenge by quickly 
reactivating to produce high-affinity antibody (Krishnamurty et al., 2016). Subsequently, 
IgM+ memory B cells are postulated to provide long-lasting immunity against reinfection once 
IgG-mediated immunity wanes. Due to their highly plastic nature, these cells may have the potential 
to shape secondary immune responses in accordance with changes to the infecting pathogen. An 
additional population that co-expresses both IgM and IgD has also been described (Seifert and 
Küppers, 2016), although its contribution to humoral responses is not well understood.  
Finally, a population of memory B cells displaying low to negative expression of CD21 (component 
of the BCR co-receptor) and CD27 (classical memory marker for B cells) has been identified in 
epithelial tissues and in the periphery of patients with chronic infection, autoimmunity or in aged 
healthy individuals (Karnell et al., 2017; Portugal et al., 2017). These cells are mostly class-switched 
and expressed mutated hypervariable regions (Ehrhardt et al., 2005). Importantly, these cells are 
thought to represent an exhausted B cell subset that is hypo-responsive to BCR stimulation and 
poorly secretes antibody. CD27-CD21low/- B cells will be discussed in more detail in Chapter Four.  
The main characteristics of different memory B cell subsets identified in humans are summarised in 
Table 1.2.   
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Table 1-2 Summary of memory B cell subsets identified in humans 
Summary of the key features of memory B cell subsets in humans and the markers by which they can be identified 
 
Subset Identification Role 
IgG+ memory IgG+CD27+ 
CD24+CD38int 
Produce high-affinity antibody with specialised effector 
function 
IgM+ memory IgM+IgD-
CD27+CD24+ 
CD38int 
First-line protection 
Outnumber IgG+ memory B cells in the secondary 
response  
Can re-enter the germinal centre and produce high-affinity 
antibody  
Demonstrate rapid and plastic production of antibodies 
upon re-challenge 
IgM+IgD+ IgM+IgD+ 
CD27+CD24+ 
CD38int 
Naïve-like subset of memory B cells 
Exhibit lower levels of somatic hypermutation that IgM+ 
and IgG+ memory B cells 
Long-lived  
IgE+ memory IgE+ Involved in allergic responses  
IgA+ memory IgA+CD27+ Associated with mucosal responses  
CD27-
CD21low/- 
CD19hiCD27-
CD21low/-(IgG+) 
(FcRL4/5+) 
Arise due to persistent stimulation in the context of 
autoimmunity, ageing and chronic infection 
Represent an “exhausted” or “dysfunctional” subset 
Contain mutated hypervariable regions 
 
1.4.5 Long-lived plasma cells  
A proportion of GC B cells migrate to specialised niches within the bone marrow, whereupon they 
differentiate into long-lived plasma cells and continue to produce vast quantities of high-affinity 
antibody. Long-lived plasma cells are attracted to the bone marrow niche through the expression of 
CXCL12 and its ligand CXCR4 (Dörner and Radbruch, 2007; Nutt et al., 2015). Several cell-
extrinsic factors have been proposed that mediate survival within the bone marrow, including 
expression of the B cell survival factors, APRIL and BAFF, and cytokines IL-6 and TNF (Wilmore 
and Allman, 2017). However, plasma cells also possess several cell-autonomous features that 
enhance their survival and facilitate their ability to continuously produce antibody, including 
activation of the unfolded protein response and resistance to cell death pathways initiated by DNA 
damage (Benhamron et al., 2014; Calfon et al., 2002; Reimold et al., 2001; Wilmore and Allman, 
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2017). Accumulating data suggests that antigen-specific plasma cells can be extremely long-lived, 
persisting for up to 10 years following vaccination, and are maintained independently of memory 
responses (DiLillo et al., 2008; Hammarlund et al., 2017). Moreover, additional subsets of plasma 
cells have been identified that can regulate immune responses independently of antibody 
production. Most recently, a subset of ‘natural regulatory’ plasma cells has been demonstrated that 
secrete immune-modulatory IL-10 and have the capacity to suppress T cell responses through the 
expression of inhibitory receptor ligands, including LAG3, PD-L1 and PD-L2 (Lino et al., 2018). 
 
1.4.6 Antibody effector function in antiviral responses 
Antibodies recognise and bind to antigen through a specific amino acid sequence, referred to as a 
complementarity determining region, present in the variable Fab region of the antibody. However, 
antibody effector function is conferred by the Fc portion, which can in turn be modified by isotype 
switching and post-transcriptional modification. A fraction of antibodies produced by virally-
activated B cells have direct antiviral activity and are referred to as neutralising antibodies (nAb). 
These antibodies bind directly to the viral particle and prevent entry of the virus to target cells, 
either through steric obstruction or through directly binding to the receptor-binding site (Corti and 
Lanzavecchia, 2013; Hangartner et al., 2006). The ability of these antibodies to neutralise viral 
particles is dependent on the avidity of the antibody for exposed antigens on the virus (Bachmann 
et al., 1997). nAbs are critical for long-term viral control and protection against re-infection. 
Accordingly, high levels of protection, obtainable by the most efficient vaccines, is closely 
associated with the induction of cross-reactive neutralising antibody responses (Burton and 
Hangartner, 2016; McCoy and Burton, 2017) (discussed in more detail in section 1.5).  
The vast majority of antibodies produced during viral infection do not have neutralising capacity, 
predominantly because they are directed against fragments of the virus that are released from dying 
infected cells and therefore do not target intact antigens expressed by infected cells. However, these 
antibodies can still have important roles in the co-ordination of the immune response. In a similar 
way to neutralisation, antibodies (most commonly polymeric IgA and IgM) can also bind directly to 
pathogens and cause them to aggregate, thus blocking infectivity (Forthal, 2014). Antibodies that 
bind to the surface of viruses opsonise the pathogen and promote internalisation via Fc receptor 
engagement on phagocytic cells in a process referred to as antibody-dependent phagocytosis. 
(Excler et al., 2014; Kramski et al., 2013). Fc-receptor engagement by effector cells is likewise 
central to facilitating antibody-dependent cell-mediated cytotoxicity (ADCC) - an effective pathway 
in the clearance of infected cells. This occurs when an antibody cross-links antigen expressed by the 
target cell and Fc-receptors on effector cells, initiating a cascade of events that results in the death 
of the pathogen or the pathogen-infected cell (Forthal and Moog, 2009; Jennewein and Alter, 
2017). Such Fc-mediated effector functions of antibodies are associated with favourable outcomes 
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in numerous contexts of chronic infection, including HIV (reviewed in Lewis, 2014). However, 
how Fc-mediated protection is affected in chronic infections is less well understood. In chronic 
HCV, activated NK cells that downregulate expression of the Fc-receptor CD16, result in impaired 
ADCC-mediated killing of infected target cells and may represent a previously unappreciated 
mechanism underpinning viral persistence (Oliviero et al., 2017).  
Antibodies also activate the complement cascade resulting in the generation of complement-derived 
products that target the cell for degradation (Karsten and Köhl, 2012). This effect is predominantly 
mediated by the aggregation of IgM and IgG3 antibodies to the surface of the infected cell or 
pathogen, that recruit C1q and initiate a cascade resulting in the formation of the membrane attack 
complex and lysis of the pathogen or infected cell (Diebolder et al., 2014; Jennewein and Alter, 
2017; Noris and Remuzzi, 2013). The extent by which complement is able to induce cell lysis is 
considered to be dependent on the level of antigen expression on the cell surface (Olivier Schwartz, 
unpublished data). This role of complement in enhancing antibody responses is demonstrated in 
individuals that have lost critical components of the complement cascade and have impaired 
primary and secondary responses to antigen (Sörman et al., 2014). 
The effector function of antibodies can be further enhanced by post-transcriptional modifications, 
including glycosylation of the Fc portion. Such modifications improve the ability of the antibody to 
interact with Fc- and complement-receptors and deposit antigen in the form of immune complexes 
in the germinal centre (Lux et al., 2013; Nimmerjahn and Ravetch, 2008; Phan et al., 2009). In 
doing so, it is thought that glycosylated antibodies potentiate germinal centre reactions and drive 
affinity maturation, therefore leading to enhanced production of nAb (Chung et al., 2015; Lofano et 
al., 2018). Manipulation of the Fc portion thus represents a promising angle in the development of 
vaccines to improve the neutralising activity of antibodies. 
Finally, it is worth considering that nAb are not preferentially selected for in the immune response. 
In contrast, antibodies are selected by virtue of the ability of the B cell to capture and present viral 
antigens. As a result, only a small fraction of virus-specific memory B cells make nAbs. For classic 
viral infections or therapeutic vaccination, having a variety of antibodies with a range of different 
effector functions is key. 
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1.4.7 Effector functions of B cells – beyond antibodies 
1.4.7.1 Cytokine production 
Through the secretion of cytokines, B cells are able to guide the development of lymphoid tissues, 
shape T cell responses and negatively regulate immunity. Early in the development of lymphoid 
tissue, lymphotoxin-α1β2 (LTα1β2) -expressing B cells actively secrete tumour necrosis factor 
(TNF), required for the development of follicular dendritic cells and the subsequent organization of 
the B cell follicle (Shen and Fillatreau, 2015). During viral infection, expression of LTα1β2 by B 
cells is responsible for the expansion of the lymph nodes and germinal centre response, implicating 
a direct role for B cell cytokine production in the generation of memory B cell responses (Kumar et 
al., 2010).  
LTα1β2, IL-2 and IL-17 expression by B cells has also been demonstrated to directly regulate Th2-
type responses in bacterial and parasitic infections (reviewed in (Shen and Fillatreau, 2015)). More 
relevant to viral infection however is the production of pro-inflammatory cytokines and the 
promotion of Th1-type responses by B cells. Following engagement of the BCR and CD40, B cells 
produce TNFa, IL-6 and lymphotoxin (Duddy et al., 2004). Indeed, some of the first evidence 
describing the ability of B cells to produce pro-inflammatory cytokines demonstrated that B cell 
depletion ameliorated symptoms of disease in treatment of autoimmune diseases, independent of 
changes in autoantibody titres (Barr et al., 2012; Sanz et al., 2007). IL-6 production by B cells is 
induced rapidly upon influenza infection and drives IL-21 expression in CD4 T cells, thus 
promoting their differentiation to TFH cells and driving the initiation of antiviral immune responses 
(Karnowski et al., 2012). Similarly, absence of B cell-derived IL-6 decreased the formation of TFH 
cells, resulting in fewer GC B cells and a reduction in class-switched antibody (Arkatkar et al., 
2017). Combined, these data suggest that B cell derived IL-6 is important in the formation of 
germinal centre responses and the generation of humoral immunity.  
Through the production of immunosuppressive cytokines, B cells also have a role in the 
suppression of adaptive immune responses, predominantly mediated through secretion of IL-10. A 
major population of IL-10-producing B cells has been defined as B regulatory cells (Bregs). These 
cells have a role in suppressing immunopathology by prohibiting the expansion of pathogenic T 
cells and other pro-inflammatory cell types (Rosser and Mauri, 2015). This effect is predominantly 
mediated by the biasing of T cell responses away from Th1 responses and towards functionally 
suppressive regulatory T cells (Flores-Borja et al., 2013). As such, numerical and functional 
deficiencies in Bregs are associated with worse outcomes in autoimmune diseases, including SLE, 
RA and MS (Mauri and Menon, 2017; Rosser and Mauri, 2015).  
Bregs have also been demonstrated in the context of chronic viral infection whereby expansion of 
IL-10-producing cells with regulatory phenotypes suppresses protective antiviral responses (Dai et 
al., 2017). In particular, IL-10hi Bregs are increased in patients with HIV and correlate with markers 
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of disease progression and exhausted T cell responses (Siewe et al., 2013). In CHB, the frequency 
of Bregs is associated with hepatic flares; an expansion of Bregs suppressed antiviral CD8 T cell 
responses in an IL-10-dependent manner (Das et al., 2012), discussed in more detail later. IL-10 
production has also been demonstrated within additional B cell subsets, including plasmablasts and 
plasma cells. For example, IL-10 production by plasmablasts was shown to limit inflammation in 
experimental autoimmune encephalomyelitis (EAE), whilst IL-10-producing plasma cells 
suppressed inflammatory responses during EAE and Salmonella infection (Lino et al., 2018; 
Matsumoto et al., 2014; Shen and Fillatreau, 2015).  
Thus, B cells have important roles in adaptive immune response beyond the production of 
antibodies; throughout their progression towards terminally differentiated plasma cells, B cells have 
the potential to modulate immune responses through the types of cytokines they secrete.  
 
1.4.7.2 Antigen presentation 
In addition to cytokine production, B cells are also capable of presenting antigen whereupon they 
can prime CD4 T cell responses (section 1.4.2.2) (Chen and Jensen, 2008; Rodríguez-Pinto, 2005). 
Crosslinking of the BCR by antigen results in B cell activation, growth and survival (Ackermann et 
al., 2015; De Silva and Klein, 2015). Antigen-activated B cells upregulate expression of co-
stimulatory molecules, CD80 and CD86, required for naïve T cell activation. Activated B cells that 
have received T cell help via CD40-ligation demonstrate enhanced antigen processing and 
presentation, imparted by increased expression of MHC Class-II molecules and stabilisation of 
CD80/86 expression (Roy et al., 1995; Wu et al., 1995).  
In vivo, antigen-specific B cells form cognate interactions with T cell responses (Lanzavecchia, 1985) 
allowing antigen-specific B cells to act as professional antigen presenting cells (APC) during initial 
CD4 T cell priming and the activation/maturation of TFH cells in the germinal centre. However, as 
antigen-specific B cells represent only a low frequency of cells prior to immunisation, it currently 
thought that B cells minimally contribute to the initial activation of naïve CD4 T cells. Moreover, 
the degree to which B cells participate in T cell priming is thought to be dependent on the type and 
form of antigen used, and as such has been shown to vary significantly according to the setting 
(Constant et al., 1995; Macaulay et al., 1998; Rodríguez-Pinto, 2005). However, the antigen-
presenting capacity of antigen-specific B cells represents a favourable target in the development of 
vaccines against infectious diseases. Recent vaccine trials have shown superior induction of CD4 
and CD8 T cell responses following antigen-presentation by B cells, rather than classical APCs, 
such as dendritic cells (von Bergwelt-Baildon et al., 2002; Hong et al., 2018). Despite existing at a 
lower frequency than DCs, the capture of antigens through specific, high-affinity BCR binding is 
thought to enhance the amount of antigen that can be presented and thus provide stronger TCR 
stimulation.  
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1.5 B cells and neutralising antibodies in the control of persisting viruses 
B cells predominantly contribute to the control of persistent viral infections through the production 
of antibodies that neutralise the virus. Natural HIV or HCV infection elicit the production of 
affinity-matured class-switched antibodies that target viral proteins but fail to control the disease. 
However, between 10 and 25% of patients infected with HIV develop antibodies that are capable 
of neutralising virus isolates. These are detectable ~3-12 months following infection (Hraber et al., 
2014; Landais et al., 2016; Li et al., 2009) whereupon they exert a strong selection pressure for HIV 
to mutate and evade specific antibody responses (Richman et al., 2003; Wei et al., 2003). As a result, 
these antibodies tend not to supress viral replication in infected patients, but can contribute to 
sustain low viral loads in some individuals (Bonsignori et al., 2014). Their role in the control of 
HIV was elegantly demonstrated in a case study where an HIV-infected patient received Rituximab 
for the treatment of low-grade lymphoma. B cell depletion resulted in a decrease in nAb titres and a 
concomitant rise in HIV viral load (Huang et al., 2010). Decreased prevalence of nAbs facilitated an 
increase in genetic diversity of the virus, which in turn led to a transient decrease in the neutralising 
activity of resulting antibodies. Of note, this study also illustrated the effect of Rituximab on 
triggering HBV reactivation in HBV-resolved individuals, discussed in more detail in section 1.6.2.  
Hence, the most efficient antibody responses are those that can detect a variety of viral isolates and 
allow the humoral response to keep pace with viral diversification, termed broadly neutralising 
antibodies (bnAb). Approximately 1% of HIV seropositive individuals develop cross-reactive nAbs 
that are capable of targeting hundreds of different viral isolates (Simek et al., 2009). These 
antibodies have provided a target for the development of vaccines and therapeutic monoclonal 
antibodies (mAb) that aim to supplement or replace humoral responses during, or prior to, viral 
infection.  
Therapeutic vaccination at the time of primary infection or early in the course of infection has been 
proposed as a method to limit establishment of the viral reservoir and promote viral eradication. 
Whilst preliminary trials testing an HIV therapeutic vaccine have demonstrated induction of nAbs 
(Ensoli et al., 2015), these have failed to consistently reduce levels of plasma viraemia (Pantaleo and 
Levy, 2016; Sneller et al., 2017). Instead, passive immunisation of mAb, designed to reflect bnAbs, 
has been proposed as a method of preventing infection and neutralising circulating virus. Careful 
testing of mAb against a large panel of HIV pseudoviruses has permitted the selection of antibodies 
that have shown potent abilities in suppressing viraemia and can elicit host immune responses (Bar-
On et al., 2018; Caskey et al., 2015; Mendoza et al., 2018). Importantly, by using a combination of 
two bnAbs, Mendoza et al., were able to demonstrate potent viral suppression in the absence of 
antiretroviral therapy that prevented the development of resistant viruses (Mendoza et al., 2018). 
Likewise, bnAbs have shown potent affects in abrogating HCV infection in a human liver chimeric 
mouse model (de Jong et al., 2014). bnAbs with the capacity to neutralise diverse HCV strains can 
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be detected and isolated from HCV-infected individuals, despite the large genetic diversity of HCV 
(Giang et al., 2012; Hadlock et al., 2000; Keck et al., 2012; Kong et al., 2012; Merat et al., 2016). 
Control of HCV infection is associated with the development of broadly neutralising antibody 
responses that target the viral envelope proteins (Osburn et al., 2014). While it is possible to detect 
nAbs in the serum of patients with chronic HCV, these antibodies fail to control infection, likely 
due to repeated mutational change resulting in loss of recognition (von Hahn et al., 2007).  
Isolation of nAbs from patients that spontaneously clear HCV has identified critical epitopes that 
favour early selection and development of bnAbs during infection, providing putative targets to 
guide the development of immunogenic vaccines (Bailey et al., 2017). Recent work has 
demonstrated that different combinations of nAbs may alter the efficacy of these approaches. It 
showed that using certain combinations of nAbs could increase their potency by simultaneously 
targeting three different HCV receptors (Mankowski et al., 2018), suggesting that vaccine 
development should aim to induce multiple nAbs with distinct neutralisation profiles. These 
paradigm-changing findings have reignited interest in understanding how nAbs develop and the 
types of B cells required for antibody-mediated viral control. 
 
1.5.1 Viral subversion of humoral immune responses 
As alluded to previously, the extensive co-evolution of viruses and hosts has resulted in the fruition 
of a number of defence strategies employed by viruses to evade protective antibody responses. In 
this way, viruses have been postulated to interfere with multiple steps of early B cell activation and 
differentiation, resulting in negligible or low-level polyclonal antibody responses (Kuka and 
Iannacone, 2017). Viruses can also have direct cytopathic effects on B cells through infection via 
the BCR or specific cellular receptors. This results in the elimination of early antigen-specific B 
cells, thus interrupting early antibody responses and maximising viral transmission, as demonstrated 
by influenza A virus (Dougan et al., 2013). Similarly, virus infection of B cells can modulate the 
proliferative capacity of B cells and perturb their differentiation. Early studies investigating 
infection of B cells by measles virus or cytomegalovirus, demonstrated the ability of these viruses to 
suppress proliferation and differentiation of B cells into antibody-secreting cells (McChesney et al., 
1986, 1987; Rice et al., 1984).  
Viral proteins, such as HIV-derived negative factor protein Nef, have also been shown to 
accumulate within B cells, where they are able to suppress immunoglobulin class-switching through 
the inhibition of intracellular signalling pathways, including nuclear factor-kB signalling (Qiao et al., 
2006). Similarly, engagement of CD81 expressed on B cells via HCV viral proteins induces 
hypermutation of the immunoglobulin heavy chain, reducing the affinity and specificity of HCV-
specific antibodies (Machida et al., 2005, 2008). Collectively, these data demonstrate how viruses 
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and associated proteins can modulate the formation of high-affinity antibodies and enable viral 
escape from immune surveillance.  
Within the lymph node, virally-induced inflammation disrupts the organisation of macrophages 
within the SCS, thus reducing the capacity of SCS macrophages to acquire antigen (Gaya et al., 
2015). Whilst this may not directly influence short-term responses to antigen, perturbation of the 
SCS macrophage responses is postulated to affect the generation of humoral responses to 
secondary infections through impairing the subsequent induction of GC B cells and plasma cells. 
Finally, virus-specific CD8 T cells have been shown to hinder humoral immune responses, either 
through killing of antigen-specific B cells or elimination of antigen-presenting cells. Virally-infected 
B cells present viral antigens on MHC Class I molecules, and as such become a target for virus-
specific cytotoxic T cells (Battegay et al., 1993; Planz et al., 1996). Similarly, non-infected B cells can 
also become targets for cytotoxic deletion through the cross-presentation of exogenous viral 
antigens, as previously demonstrated in HBV infection (Barnaba et al., 1990).  
Other recognised mechanisms adopted by viruses to evade antibody responses include antigenic 
mutation and the induction of B cell anergy and exhaustion, discussed in more detail in Chapter 
Four.   
  
 
57 
1.6 B cell responses in CHB 
1.6.1 Humoral immunity in HBV 
The kinetics of HBV-specific antibody responses can be used to distinguish different stages of 
HBV infection (Gerlich, 2013). Polyclonal antibodies generated by HBV infection are directed 
against a range of viral antigens, including HBcAg, HBeAg and the large, middle and small forms of 
HBsAg. HBcAg-specific IgM (anti-HBc) appears early on in infection and can co-exist with a high 
level of HBV replication (Hoofnagle et al., 1973). Thus, the detection of anti-HBc is one of the first 
indicators of active HBV infection and is the only confirmatory marker of previous or current 
infection (Wang et al., 2017). The immunogenicity of anti-HBc responses is postulated to derive, in 
part, from the capacity of B cells to present HBcAg. Murine B cells were demonstrated to display 
enhanced receptor-mediated uptake of HBcAg, compared to professional APCs, that was required 
for efficient priming of naïve T cells and antibody production following immunisation with HBcAg 
(Milich et al., 1997). Following this, it was later found that B cells are also required for priming of 
cytotoxic T cell responses to exogenous, but not endogenous, particulate HBcAg (Lazdina et al., 
2003). Thus, as a consequence of its potent immune stimulatory properties, HBcAg has been 
proposed as a powerful carrier and basis for vaccines against less immunogenic antigens (Whitacre 
et al., 2009). 
In contrast to HBcAg, antibodies specific for HBsAg and HBeAg appear much later, and are 
associated with favourable outcome of the infection. Antibodies against HBeAg are regarded as a 
predictor of long-term clearance of HBV, with seroconversion commonly associated with normal 
serum ALT levels and low levels of HBV DNA (<2000IU/ml) (Gill and Kennedy, 2015). 
Following successful control of the virus, HBsAg is lost from the blood and HBsAg-specific 
antibodies (anti-HBs) become detectable. Thus, anti-HBs are considered to be protective and 
associated with resolution of disease. 
Generally, measurements of HBV-specific antibodies have been used in the serological definition 
of disease phases and functional cure, and their role in immune control has been little studied. 
However, two classes of anti-HBs antibodies have demonstrated neutralising activity. Until the 
recent discovery of the HBV entry receptor, NTCP, the ability of anti-HBs antibodies to confer 
protection was poorly understood. Precise mapping of NTCP facilitated identification of HBV 
regions essential for infectivity, namely the pre-S1 domain and the a-determinant of HBsAg (Figure 
1.7). The first class of neutralising antibody (nAb) described recognises the a-determinant region of 
the antigenic loop of HBsAg, and is thus capable of blocking interactions with the HSPG (Sureau 
and Salisse, 2013) and inhibiting secretion of HBsAg from infected hepatocytes (Neumann et al., 
2010; Schilling et al., 2003). A second class of antibodies recognises the NTCP-binding site of the 
Pre-S1 (Ni et al., 2014; Yan et al., 2012), preventing de novo infection of hepatocytes (Yan et al., 
2012). In contrast, antibodies specific to other HBV regions not involved in HBV infection, such as 
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the Pre-S2 region, appear to have no relevance to natural HBV immunity (Hellström et al., 1986; Ni 
et al., 2010; Seyec et al., 1998).  
Hence, vaccine-induced production of anti-HBs has an important role in pre-exposure prophylaxis 
and protection against de novo infection. Once established through vaccination, immunity against 
HBV is usually maintained for life, despite waning levels of anti-HBs (McMahon et al., 2009). The 
latest generation of vaccines, that include epitopes for Pre-S1/2, have shown enhanced 
immunogenicity, resulting in faster and higher rates of seroconversion. Importantly, these vaccines 
also result in lower rates of non-responders and are less affected by extraneous variables, including 
body weight (Krawczyk et al., 2014; Shouval et al., 2015). 
The neutralising capacity of anti-HBs antibodies is underscored by their ability to block HBV 
infection (Cerino et al., 2015; Glebe et al., 2003), and has been demonstrated in primate models, 
whereby inoculation of chimpanzees with human mAbs prior to viral challenge prevented the 
development of infection (Hong et al., 2004; Kim et al., 2008). Accordingly, transfer of antibodies 
directed against HBV proteins can have protective effects in the settings of liver transplant and 
post-exposure prophylaxis in neonates born to HBsAg-positive mothers (Beasley et al., 1981; 
Shouval and Samuel, 2000). In settings of liver transplantation, polyclonal hepatitis 
B immunoglobulins, isolated from the plasma of HBV-vaccinated or HBV-resolved healthy donors, 
is routinely administered prior to and repeatedly following surgery to maintain protective levels of 
anti-HBs and prevent HBV recurrence (Varghese et al., 2014).  
 
 
 
Figure 1-7 Structure of HBsAg 
Schematic representation of the conformation of HBsAg, showing the PreS1 region and a determinant region that 
interact with neutralising antibodies [Adapted from (Bertoletti and Ferrari, 2016)] 
 
Current efforts are now focused on alternative strategies of pre-exposure and post-exposure 
prophylaxis, including the development of mAbs against HBsAg or Pre-S1, similar to those 
identified in HIV (Corti et al., 2018). Numerous mAbs have now been developed that show potent 
neutralising activity (Cerino et al., 2015; Kucinskaite-Kodze et al., 2016; Shin et al., 2007b) including 
HB-C7A, which possesses the capacity to prevent HBV infection in chimpanzees (Kim et al., 
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2008). This mAb is now in clinical trials to evaluate its efficacy in protecting against infection 
following liver transplantation, and in the event of HBV exposure.  
In addition to their capacity to block viral entry via Fab recognition of virions, mAbs can also act in 
vivo through Fc-dependent mechanisms. Murine studies using novel nAbs targeted against the a-
determinant (mAb E6F6 (Zhang et al., 2015)) or Pre-S1 region (mAb 2H5-A14 (Li et al., 2017)) 
significantly reduced the levels of HBsAg and HBV DNA in HBV-transgenic mice through Fc-
dependent mechanisms. The suppressive abilities of these antibodies were inhibited when Fc-
receptor binding was impeded through mutation of the Fc portion. Administration of E6F6 in 
transgenic mice promoted viral clearance and blocked viral infection, dependent on Fc-mediated 
phagocytosis; when the Fc-portion was mutated, less effective suppression of HBV was observed. 
Similarly, 2H5-A14, but not its Fc-mutated variant, significantly reduced levels of cccDNA in 
HBV-infected mice. HBV suppression was mediated through sequestration of viral and sub-viral 
particles by antibody-dependent cellular phagocytosis (ADCP), in addition to NK cell-mediated 
killing of infected hepatocytes (ADCC). Human mAbs have shown promise in reducing HBsAg to 
undetectable levels in patients with CHB, corresponding with a decrease in HBV DNA (Galun et 
al., 2002). Despite being well tolerated, monotherapy was insufficient to maintain low levels of 
antigen and virus. Alternative approaches proposed include clearance of extracellular antigen via 
inoculation with nAbs, followed by prophylactic vaccination to restore protective HBsAg-specific 
CD4 and B cell responses (Zhu et al., 2016). Combined, these data suggest that antibodies targeting 
HBsAg may provide an important arm of combination therapies in patients with CHB. Currently, 
numerous groups are working on developing therapeutic nAbs through the characterisation of anti-
HBs produced by virus-controllers.  
Despite evidence showing that anti-HBs is protective and can have neutralising properties, robust 
data regarding the frequency of nAb-producing cells during CHB are lacking. However, the 
identification of antibodies that can block HBV viral entry presents the possibility that neutralising 
anti-HBs may play a role in modulating the development of persistent infection through blocking 
HBV spread to non-infected hepatocytes. The ability of HBV to spread via NTCP was clearly 
demonstrated in murine models of HBV infection, where blockade of NTCP with Myrcludex B 
peptide prevented HBV spread in infected livers (Petersen et al., 2008). Lack of detectable anti-HBs 
in patients with CHB would suggest that B cells producing nAb are numerically or functionally 
defective. As such, humoral immunity in CHB may be improved through thorough characterisation 
and targeting of anti-HBs-producing cells. 
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1.6.2 Evidence for a role of B cells in the immune control of CHB 
Relatively little is known pertaining to the role of B cells in the persistence of CHB. Patients with 
CHB are characterised by a failure to seroconvert against the envelope protein of the virus 
(HBsAg) with detection of antibodies against HBsAg (anti-HBs) regarded as the hallmark of 
functional cure. To date, few studies have specifically addressed the potential for defective B cell 
responses to underpin the failure of patients with CHB to undergo HBsAg seroconversion.  
Patients with CHB do not have global defects in antibody production and reportedly display an 
increased frequency of activated global B cells of memory or naïve phenotype that are functionally 
intact (Oliviero et al., 2011; Xu et al., 2015). Despite showing impaired proliferative capacity relative 
to healthy controls, B cells retain the ability to differentiate into plasma cells and can robustly 
produce global immunoglobulin upon simulation (Oliviero et al., 2011). Furthermore, gene 
expression profiling of peripheral B cells in HBV-infected patients of varying clinical and 
virological phases of disease, identified a gene-signature consistent with robust B cell activation in 
patients with chronic active hepatitis (characterised by high ALT levels and viral load) 
(Vanwolleghem et al., 2015). Although the functional consequences of these studies are as yet 
unclear, at the very least they provide evidence for HBV infection modulating B cell activity. 
The importance of the B cell response in CHB is underscored by the clinical observation that B cell 
depletion by anti-CD20 or anti-CD52 antibody therapies in the management of lymphoma can lead 
to the risk of HBV-reactivation in HBV-resolved patients (reactivation determined by the 
reappearance of HBsAg and HBV DNA in previously negative patients) and HBsAg+ inactive 
carriers (Huang et al., 2010; Loomba and Liang, 2017; Shouval and Shibolet, 2013). Rituximab 
depletion in patients prior to kidney transplantation showed a direct relationship between the 
administration of rituximab and HBV reactivation (Lee et al., 2017). The risk of HBV reactivation 
has been associated with both host and viral factors, including the genotype of the infecting strain, 
mutations within the core promoter region and HBV serological markers (Borentain et al., 2010). 
Of note, meta-analysis of cases of HBV-reactivation in resolved patients showed some protection 
conferred by existing levels of detectable levels of anti-HBs (Paul et al., 2017). As plasma cells are 
not depleted by Rituximab, these observations suggest that viral control is mediated by B cell 
populations that express CD20. Furthermore, it is theorised that Rituximab is not able to deplete B 
cells from within lymphoid tissue (Hammarlund et al., 2017; Kamburova et al., 2013; Mamani-
Matsuda et al., 2008), suggesting that formation and function of HBsAg-specific B cells within 
lymphoid tissue is not sufficient for adequate control of HBV infection. Crucially, evidence 
demonstrating suppression of B cell immunity leading to HBV reactivation provides key evidence 
that B cells may play a previously unappreciated role in ongoing HBV immune control, not just 
prevention of de novo infection.  
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Previous work from our group has also identified an expansion of circulating and intrahepatic IL-
10-producing Bregs, typified by high expression of CD24 and CD38, that correlated with serum 
levels of IL-10 in patients with CHB undergoing spontaneous disease flares. Co-culture of 
CD24hiCD38hi immature B cells suppressed HBV-specific CD8 T cells in an IL-10-dependent 
manner; blockade of IL-10 significantly boosted exhausted HBV-specific CD8 T cell functionality, 
suggestive of a role for Bregs in suppressing functional T cell responses in CHB (Das et al., 2012).  
 
1.6.3 HBV-specific B cell responses 
Production of anti-HBs is generally considered T cell dependent (Milich and McLachlan, 1986) 
with HBsAg-primed CD4 T cells shown to be essential for anti-HBs production (Wang et al., 
2018b). However, possible deficiencies in CD4 T cells cannot solely explain defects in anti-HBs 
production; co-culture of B cells from patients with CHB with T cells from HBsAg-vaccine 
responders failed to induce anti-HBs production, pointing to a B cell-specific defect (Barnaba et al., 
1985). Moreover, anti-HBs production is unlikely to be completely impaired in all patients with 
CHB, as demonstrated by the clinical observation of anti-HBs:HBsAg immune complexes in a 
subset of patients with CHB (Madaliński and Bragiel, 1979) and the capacity to measure low level 
anti-HBs in some patients with CHB. These data also point to the existence of HBsAg-specific B 
cells, at least in a subset of patients with CHB (Gerlich, 2007).  
As reported for HBV-specific T cells, frequencies of anti-HBs B cells have been shown to be 
decreased in the periphery of patients with CHB relative to those with acute-resolving infection 
(Barnaba et al., 1985; Böcher et al., 1999; Dusheiko et al., 1983; Wang et al., 2015; Xu et al., 2015). 
One potential mechanism for their depletion was proposed to be the deletion of B cells capable of 
cross-presenting HBsAg on MHC-Class I by cytotoxic T lymphocytes (Barnaba et al., 1990). 
However, these studies have traditionally relied on functional readout of anti-HBs production for 
quantification of HBsAg-specific B cells and therefore cannot distinguish between functional or 
numerical defects in HBsAg-specific B cell responses (discussed in more detail in Chapter Three).  
Furthermore, the enumeration of anti-HBs producing B cells in the periphery might not be fully 
informative. During infection, memory B cells and plasma cells home to inflamed tissues sites and 
to bone marrow, allowing them to efficiently contribute to the immune response at the site of 
infection (Kunkel and Butcher, 2003). B cells capable of producing antibodies against the core 
protein, HBcAg, have been shown to localise to the intrahepatic environment during HBV acute 
liver failure where they are postulated to drive liver pathology (Farci et al., 2010). CD20+ B cells can 
also infiltrate the liver vasculature and parenchyma, although the function of these cells in CHB is 
as yet unknown (Mohamadkhani et al., 2014). Further investigations are required to address the 
possibility that HBsAg-specific B cells can localise to the liver and play a role in the local immune 
response (discussed in more detail in Chapter Five). 
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1.7 Thesis hypothesis 
Patients with chronic HBV infection are characterised by their failure to produce detectable 
protective responses to the HBV envelope protein, HBsAg. Due to their emerging role in the 
control of viral infections through the production of neutralising antibodies and cytokines, it was 
thought that reduced antiviral B cell function may contribute to the persistence of HBV. This 
concept is underpinned by the key finding that Rituximab depletion of CD20+ B cells can trigger 
HBV reactivation in functionally-resolved patients, and worsening of disease in patients with 
chronic infection, suggesting that B cells support viral control.  
Specifically, it was hypothesised that the high HBsAg-load in patients with CHB may result in 
defects in the frequency and function of HBsAg-specific B cells that underlie their inability to form 
protective anti-HBs responses.  
 
1.8 Thesis aims 
- To determine whether frequencies of HBsAg-specific B cells are decreased in patients with 
CHB relative to those with protective immunity; 
- To determine whether HBsAg-specific B cells in patients with CHB are capable of 
producing protective anti-HBs, implicated by the lack of anti-HBs production in patients’ 
serum; 
- To characterise HBsAg-specific B cells directly ex vivo from patients with CHB to identify 
putative targets for boosting anti-HBs responses in patients with CHB; 
- To assess the possibility that intrahepatic global and antigen-specific B cells localise at the 
site of viral replication. 
 
1.9 Thesis highlights 
1. HBsAg-specific B cells persist at a similar frequency in patients with CHB, compared to 
those with acute-resolving infection and HBV-vaccine induced immunity; 
2. HBsAg-specific B cells from patients with CHB exhibit defective production of protective 
anti-HBs; 
3. HBsAg-specific B cells demonstrate an accumulation of atypical memory B cells (atMBCs), 
characterised by high levels of inhibitory receptor expression and impaired antiviral 
function; 
4. HBsAg-specific B cells can be identified within HBV-infected liver yet show similar 
enrichment of dysfunctional B cell subset. 
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Chapter 2 Materials and Methods 
 
2.1 Study participants 
Samples utilised within this study were obtained from patients attending clinics at four separate 
sites across London: 
- Mortimer Market Sexual Health Clinic – Central and North-West London NHS 
Foundation 
- Royal Free Hospital  
- University College London Hospital (UCLH)  
- Royal London Hospital – Barts Health NHS Trust 
This study was approved by the local ethical boards of London-Brent (REC number 16/LO/1699) 
and Brighton and Sussex (REC number 11/LO/0421). Each participant gave written informed 
consent. All storage of samples obtained complied with the requirements of the Data Protection 
Act 1998 and the Human Tissue Act 2004.  
Samples from a total of 118 patients with CHB and 6 patients with HCV were used within this 
study. For comparison to HBV-naïve controls, 74 age and sex matched healthy volunteers were 
recruited from staff, students, and friends of University College London. A separate cohort of 24 
HBV-unvaccinated healthy controls was collected for the purpose of confirming negativity of 
HBsAg-specific B cells in HBV-naïve controls.  
All patients with CHB were anti-HCV and anti-HIV antibody negative and treatment naïve, unless 
otherwise stated. Patients were stratified by a number of clinical disease parameters throughout the 
study. These were obtained as part of routine diagnostic assessments by the relevant NHS 
laboratories and include the following: 
1. HBeAg status (defined as either positive or negative) 
2. HBV viral load (IU/ml, determined by real-time polymerase chain reaction) 
3. Levels of HBsAg (IU/ml, Abbott Architect Quantitate HBsAg)* 
4. Biochemical evidence of liver inflammation, determined by serum levels of alanine 
transaminase (IU/L) 
5. Anti-HBs (defined as either positive or negative) 
*Where unavailable, assessments were made in-house using highly sensitive chemiluminescent 
immunoassays, described in more detail in section 2.6.3 
 
The full sample cohort is detailed in Table 2.1.  
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2.1.1 HBV acute-resolving patients 
Eight patients were identified as having acute HBV infection upon presentation in the clinic and 
were tracked longitudinally throughout resolution of disease. Acute HBV infection was diagnosed 
on the basis of new HBsAg positivity or recent exposure, and serological evolution (i.e. detection of 
anti-HBc IgM/IgG). Samples were considered from the acute phase when HBV DNA was still 
detectable and ALT was greater than 40IU/L. Patients were identified as resolved when HBV 
DNA and HBsAg were undetectable and ALT levels were normalised (below 40IU/L). 
Longitudinal acute-resolved samples are numbered and referred to consistently throughout. 
 
2.1.2 Intrahepatic samples 
Resected liver samples from the healthy margins of colorectal metastatic tumour resections were 
obtained through the Tissue Access for Patient Benefit scheme at The Royal Free Hospital 
(approved by the University College London Royal Free Hospital BioBank Ethical Review 
Committee; Research Ethics Committee reference number 11/WA/0077). Perfusion liquid was 
obtained from healthy livers prior to solid-organ transplantation (RIPCOLT clinical trial; Research 
Ethics Committee reference number 11/H0720/4; trial number 8191; trial registered at 
clinicaltrials.gov: NCT00796588). 
For HBV+ liver, tissue was obtained from liver biopsies deemed surplus to diagnostic requirements 
from 10 patients with treatment-naïve CHB, attending clinics at The Royal London Hospital 
(approved by East London and The City Research Ethics Committee; Research Ethics Committee 
reference number P/01/023). Four additional HBV+ liver samples were obtained from explanted 
livers with end-stage HBV-associated disease (Tissue Act for Patient Benefit Scheme) 
Full details of liver samples used are detailed in Table 2.2.  
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2.2 Sample isolation and preparation 
2.2.1 Preparation of Peripheral Blood Mononuclear Cells (PMBC) 
Venous blood samples were collected in sterile 9ml BD VacutainersÒ containing lithium-heparin 
and processed immediately. Peripheral blood mononuclear cells (PBMCs) were isolated by density 
centrifugation using FicollÒ Paque Plus (GE Healthcare). Whole blood was diluted in RPMI 1640 
(GIBCOÔ) and layered at a 2 : 1 ratio on FicollÒ Paque Plus, followed by centrifugation at 
2200 rpm at 30°C for 22 min with minimum acceleration and brake. PBMCs were carefully 
extracted from the interface using Pasteur pipettes and washed twice via dilution with RPMI 1640 
and centrifugation at 1800 rpm for 15 min. Cell counts were determined using a Neubauer counting 
chamber under light-microscopy; to count, cells were first diluted in RPMI 1640, then 1 : 1 in 
trypan blue (a viability dye that stains the nucleus of dead cells). The number of cells was 
determined using the following formula: 
N = M ´ D ´ 104 
N = number of cells/ml 
M = number of cells counted in grid of 16 squares (taken as an average of 3 grids) 
D = dilution factor  
PBMCs were either used immediately or frozen in foetal bovine serum (Invitrogen) supplemented 
with 10% DMS0 (Sigma-Aldrich). 
 
2.2.2 Freeze/thawing of PBMC 
Isolated cells not used directly for experiments were re-suspended at 5 ´ 106 cells/ml in heat-
inactivated foetal bovine serum (FBS) (InvitrogenÔ) supplemented with 10% dimethylated 
sulfoxide (DMSO) (Sigma-AldrichÒ). Cells were aliquoted in cryovials (Corning) and stored in 
freezing containers containing isopropanol (Mr FrostyÔ, Thermo ScientificÔ) at -80°C for a 
minimum of 24 h. As soon as possible, cells were transferred for long-term storage in gas-phase 
nitrogen tanks. When required, PBMC were thawed rapidly at 37°C and washed by centrifugation 
in 15ml of RPMI 1640. 
 
2.2.3 Preparation of serum samples 
During sample collection, additional blood was collected in BD VacutainersÒ containing no anti-
coagulant. This sample was left for a minimum of 30 min at room temperature (RT) before 
centrifugation at 1800 rpm. Serum was removed, aliquoted into cryovials, and stored at -80°C for 
later use. 
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2.2.4 Preparation of intrahepatic lymphocytes (IHL) 
HBV+ infected liver biopsies: IHL from CHB liver biopsies deemed surplus to diagnostic requirement 
were isolated by mechanism disruption. Biopsies were re-suspended in RPMI 1640 and macerated 
using a cell-scraper in small Petri dishes. The resulting single-cell suspension was filtered through 
70 µm cell strainers to remove debris and prevent cell clumping. Isolated cells were diluted in RPMI 
1640 and washed by centrifugation at 1800 rpm at 22°C for 15 min.  
Healthy perfusates samples: To isolate IHL from perfusate samples, liquid was first concentrated by 
centrifugation at 1800 rpm at 22°C for 15 min. Concentrated cells were re-suspended in RPMI 1640 
and IHL isolated by density centrifugation using FicollÒ Paque Plus (GE Healthcare), as with 
PBMCs.  
Explants, including margins from colorectal metastases (CRC): With larger explant tissues, sections were cut 
into small pieces in specimen pots using sterilised scissors, and incubated at 37°C for 30 min in 
0.01%-collagenase IV (Thermo Fisher ScientificÔ) and 0.001%-DNase I (Sigma-AldrichÒ). 
Mechanical digestion was performed using a gentleMACSÔ tissue dissociator (Miltenyi BiotecÒ). 
Single-cell suspensions were filtered as before, before dilution in HBSS (GibcoÒ) and centrifugation 
1800 rpm at 22°C for 15 min. Cells were re-suspended in 30%-PercollÒ (Sigma-AldrichÒ) diluted in 
HBSS (GibcoÒ), and centrifuged at 2000 rpm at 22°C for 10 min. Following centrifugation, 
parenchymal cells were removed using a Pasteur pipette. The remaining pelleted cells were then 
diluted in RPMI 1640 and IHLs isolated by density centrifugation using FicollÒ Paque Plus (GE 
Healthcare), as before. 
In all instances, IHL were counted as before or using an automated cell counter (ADAM-MCÔ) 
that provides a count of viable cells with a higher degree of accuracy. In all instances, IHL were 
used directly for ex vivo experimentation and characterization.  
Liver-draining lymph node from one patient with HBV-associated end-stage liver failure was 
processed as per HBV-liver biopsies.  
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2.3 Multi-parametric Flow Cytometry 
All antibody staining for flow cytometry was performed on a single-cell suspension either in 96-well 
pates (U-bottomed) or in 5ml polypropylene tubes. 
 
2.3.1 Surface staining of PBMC and IHL for B cell frequency and phenotype 
To determine B cell frequencies and phenotypes, a minimum of 2 ´ 106 cells was used. Cells were 
initially stained with a fixable viability dye (LIVE/DEADÔ, InvitrogenÔ) for 15 min at 4°C, to 
permit identification and removal of dead cells during analysis. Following staining, the dye was 
washed off using 1´ PBS and centrifugation at 1800 rpm for 4 min at 4°C. Cells were blocked to 
prevent unwanted binding of antibody to Fc-receptor-expressing cells (FcR blocking reagent, 
Miltenyi BiotecÒ) for 15 min at 4°C. Samples were stained in the presence of FcR blocking reagent 
using saturating concentrations of relevant directly-conjugated anti-human mAbs for 30 min at 4°C 
in the dark. Antibodies were diluted in 50%-Brilliant Stain buffer (BD HorizonÔ, BD 
BiosciencesÔ) and 50%-PBS to minimize interactions between multiple fluorescent dyes. 
Appropriate isotype controls were used where necessary. Cells were washed in 1´ PBS and fixed 
with BD Cytofix/CytopermÔ (BD BiosciencesÔ). All samples were acquired on either an LSRII or 
Fortessa-X20 flow cytometer (BD BiosciencesÔ) immediately or the following day, and analysed 
using FlowJo (Tree Star). Full details pertaining to surface mAb used are listed in Table 2.3.  
 
2.3.2 Identification of HBsAg-specific B cells 
For identification of HBsAg-specific B cells, a minimum of 1 ´ 106 cells was stained with an Alexa 
Fluor 488-conjugated recombinant HBsAg (ayw strain; F. Hoffman-La RocheÔ). All staining was 
performed in parallel with mAb staining (as above) and incubated for 30 min at 4°C in the dark. To 
reduce non-specific staining, mAb were diluted in PBS supplemented with 0.5%-FBS and 2 mM 
Ethylenediaminetetraacetic acid (EDTA). Stringent gating criteria were applied with doublet, dead, 
and CD19-negative cell exclusion to minimize non-specific binding contamination. Cells stained 
with an identical panel minus HBsAg-bait (FMO; fluorescence-minus-one), were used to control 
for non-specific binding, with corresponding FMO frequencies subtracted. The phenotype of 
HBsAg-specific B cells was not analysed in instances where there were fewer than 50 HBsAg-bait+ 
cells recorded. 
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2.3.3 Flow cytometric staining for intracellular and intranuclear antigens 
For the detection of intracellular antigens, cells were blocked and extracellular markers were stained 
as in section 2.3.1. Once stained, cells were fixed in BD Cytofix/CytopermÔ (BD BiosciencesÔ) 
for 20 min at 4°C in the dark. After fixation and permeabilisation, cells were washed and stained 
with relevant directly-conjugated mAb in the presence of 0.1%-saponin for 30 min at 4°C in the 
dark. Appropriate isotype controls were used where necessary. After staining, the cells were washed 
and re-suspended in PBS, before acquisition. 
For the detection of intranuclear antigens, cells were blocked and extracellular markers were stained 
as in section 2.3.1. A minimum of 5 ´ 106 cells were used. Once stained, cells were fixed and 
permeabilised using FoxP3 Buffer Set (BD BiosciencesÔ) according to manufacturer’s instructions. 
Briefly, cells were fixed for 10 min in Buffer A before washing and permeabilisation in buffer B for 
a further 30 min. Cells were washed and then incubated at 4°C for 30 min with relevant directly-
conjugated mAb diluted in 1´ PBS. After staining the cells were washed and re-suspended in PBS, 
before acquisition. Full details pertaining to intracellular and intranuclear mAb used are listed in 
Table 2.3. 
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Table 2-3 Full details of mAb used 
Directly-conjugated anti-human mAbs against extracellular, intracellular and intranuclear antigens for the phenotypic and 
functional description of B cell subsets 
 
Antigen Fluorochrome Clone Manufacturer Cat No. Dilution 
Extracellular antigens 
CD45 BUV805 HI30 BD BiosciencesÔ 564914 0.5:100 
CD19 BV786 SJ25C1 BD BiosciencesÔ 563325 2:100 
CD20 Alexa-FluorÒ 700 2H7 BD BiosciencesÔ 560631 1:100 
CD3 BV711 OKT3 BioLegend 317328 1:100 
CD3 BV510 OKT3 BioLegend 317332 1:100 
CD10 BV605 Ber-ACT8 BioLegend 350218 2:100 
CD21 BV421 B-Ly4 BD BiosciencesÔ 562996 2:100 
CD27 BUV395 L128 BD BiosciencesÔ 561767 1:100 
IgM APC/Cy7 MHM-88 BD BiosciencesÔ 314520 1:100 
IgD PE/Cy7 IA6-2 BD BiosciencesÔ 561314 1:100 
IgD PerCP-Cy5.5 IA6-2 BioLegend 348208 1:100 
PD-1 PE EH12.2H7 BioLegend 329906 2:100 
FcRL5 APC 509f6 BioLegend 340306 2:100 
CD32b PE FUN-2 BioLegend 303205 2:100 
BTLA APC/Cy7 MIH26 BioLegend 344517 2:100 
CD22 PE/Cy7 HIB22 BioLegend 302514 1:100 
CD80 BV510 L307.4 BD BiosciencesÔ 563084 1:100 
CD11c BV711 3.9 BioLegend 301630 2:100 
CXCR5 APC/Cy7 J252D4 BioLegend 356925 3:100 
CXCR3 PerCP-Cy5.5 IC6/CXCR3 BD BiosciencesÔ 560832 2:100 
CD24 PE/Cy7 ML5 BioLegend 311120 1:100 
CD38 PE-dazzle HIT2 BioLegend 303532 0.5:100 
Intranuclear antigens 
T-bet EFluor666 EBio4B10 eBioscience 50-5825-82 1:100 
Ki67 PE-Cy7 20Raj1 eBioscience 25-5699-42 1:100 
Blimp-1 PE 6D3 BD BiosciencesÔ 564702 1:100 
Bcl-2 Alexa-FluorÒ 488 100 BioLegend 658703 2:100 
Intracellular antigens 
TNFa FITC MAb11 BD BiosciencesÔ 554512 1:100 
IL-6 APC MQ2-13A3 BioLegend 501112 3:100 
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2.4 B cell functional assays 
For functional experiments, cells were cultured in supplemented RMPI 1640 (referred to as 
complete RPMI and abbreviated to cRPMI) unless otherwise stated. This consisted of the 
following: 
- 10% heat-inactivated FBS (InvitrogenÔ) 
- 100 U/ml penicillin/streptomycin (InvitrogenÔ) 
- MEM essential amino acids (InvitrogenÔ) 
- MEM non-essential amino acids (InvitrogenÔ) 
- Hydroxyethyl piperazineethanesulfonic acid (HEPES; InvitrogenÔ)  
- b-mercaptoethanol (Sigma-AldrichÒ) 
- Sodium pyruvate (InvitrogenÔ) 
 
2.4.1 B cell enrichment 
PBMCs were thawed and re-suspended in PBS supplemented with 0.5%-FBS and 2 mM EDTA.    
B cells were enriched by magnetic separation according to manufacturer’s instructions (EasySepÔ 
B cell Enrichment Kit, StemCellÔ Technologies). Representative examples of the purity achieved 
using this protocol are shown in Figure 2.1. Enriched B cell populations were used for ELISPOT 
assays, detection of apoptosis, and calcium flux experiments. 
 
 
Figure 2-1 B cell enrichment achieved using EasySepÔ B cell Enrichment Kit 
Representative examples demonstrating the purity achieved following B cell enrichment. Frequency shown represents the 
frequency of CD19+ cells as a percentage of total live events. 
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2.4.2 Calcium flux 
B cells were separated through magnetic separation according to section 2.4.1 and stained for B cell 
memory phenotype, as before. Following staining, cells were washed in PBS and incubated with 
1 µM of Fluo-4-AM dye (Thermo ScientificÔ) in the dark for 30 min at 37°C. Fluo-4-AM was 
diluted in RPMI containing 250 mM probenecid to reduce dye efflux from the cell (Thermo 
ScientificÔ). Cells were then washed in PBS and rested in the dark at RT for 20 min before 
analysis. 5 ´ 105 cells were analysed for 20 s on a LSR-Fortessa-X20Ô (BD BiosciencesÔ) to 
establish baseline prior to stimulation with anti-IgM/IgG/IgA (50 µg/ml; Jackson 
ImmunoResearch) or Ionomycin (1 µg/ml). Cells were immediately returned to the machine and 
fluorescence recorded for a further 150 s. Data were analysed using Kinetics software on FlowJo. 
 
2.5 Phosphoflow 
Thawed PBMCs were re-suspended in cRPMI and plated in a 96-well plate prior to staining for cell 
surface markers to permit identification of memory B cell subsets. mAb were carefully chosen to 
withstand methanol fixation (detailed in Table 2.4). mAbs was washed off prior to stimulation with 
anti-IgG/A/M (20 µg/ml; Jackson ImmunoResearch) for 30 s. Cells were immediately fixed in pre-
warmed cytofix (BD BiosciencesÔ) and left at 37°C for 10 min. Cells were then pelleted and re-
suspended in Phosflow Buffer (BD BiosciencesÔ) for 30 min at -20°C. Following permeabilisation, 
cells were stained with rabbit monoclonal specific for phosphorylated BLNK (p-BLNK; Cell 
Signalling TechnologyÒ) for 30 min at 4°C. Antibody was washed off, before incubation with PE-
secondary (Thermo ScientificÔ) for a further 30 min at 4°C. Cells were washed and analysed on 
LSR-Fortessa-X20Ô (BD BiosciencesÔ). Unstimulated cells and a stimulated FMO were 
performed for each individual as gating controls.  
Immune complex assays: Recombinant anti-HBs (isolated from single-cell HBsAg-specific B cells; 
experiments performed by Dr. Laura McCoy) was purified using Protein G beads (Dr. Laura 
McCoy), and concentrated using AmiconÒ Ultra Centrifugal Filters (Merck-Millipore) and repeated 
centrifugation at 3500 rpm. Purified anti-HBs was tested for specificity using standard anti-HBs 
ELISA and confirmed by UCLH, Health Services Laboratory. Immune complexes were made 
through incubation of 100 µg/ml of purified anti-HBs with 100 µg/ml of recombinant HBsAg (F. 
Hoffman-La RocheÔ) for 2 h at 37°C. To test their effect on BCR signalling, purified B cells were 
incubated ± 10 µg/ml of immune complexes prior to stimulation, and stained for p-BLNK, as 
above. 
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Table 2-4 Cell surface markers for subset identification in phosphoflow assays 
Antigen Fluorochrome Clone Manufacturer Cat No. Dilution 
CD19 eFluro450 HIB19 eBioscience 48-0199-42 2:100 
CD20 Alexa-FluorÒ 700 2H7 BD BiosciencesÔ 560631 1:100 
CD27 FITC M-5271 BD BiosciencesÔ 555440 1:100 
CD3 BV711  OKT3 BioLegend 317328 1:100 
CD21 APC B-Ly4 BD BiosciencesÔ 561767 2:100 
p-BLNK 
(Tyr96) 
- - Cell Signalling TechnologyÒ #3601 2:100 
 
2.5.1 Detection of B cell cytokine production 
To assess cytokine production, PBMCs were rapidly thawed, washed and re-suspended in cRPMI.  
2 ´ 105 PBMCs were stimulated in a 96-well plate for 16-18 h with either 10 µg/ml F(ab’)2 anti-IgM 
and -IgG-specific antibodies (Southern Biotech and Jackson ImmunoResearch, respectively) in 
combination with 0.5 µg/ml mega-CD40-ligand (Enzo Life Sciences); or 1 µg/ml R848 
(Resiquimod; TLR-7/8 agonist; InvivoGen) diluted in complete RPMI (cRPMI). All stimulations 
were performed in the presence of 1 µg/ml brefaldin-A (Sigma AldrichÒ) at 37°C. Unstimulated 
cells, cultured in cRPMI and BFA only, were used as a negative control. After incubation, cells were 
washed and cytokine responses analysed by intracellular cytokine staining for IL-6 and TNFa 
(detailed in Table 2.3), along with cell surface staining to identify memory B cell populations. To 
assess the effect of PD-1 blockade, cells were stimulated as above in the presence of 10 µg/ml anti-
PD-1 mAb or matched isotype control (LEAFÔ purified; clone EH12.2H7; BioLegend).  
 
2.5.2 Detection of apoptotic cells – Annexin-V staining 
For analysis of apoptosis, cells were stained for Annexin-V ex vivo. PBMCs were thawed and cell 
surface markers stained, as in section 2.3.1. Cells were then washed in Annexin-V binding buffer 
and incubated with Annexin-V - PerCP/Cy5.5 in the presence of buffer for 15 min, according to 
manufacturer’s instructions (BioLegend). Once stained, cells were washed in PBS and fixed using 
Cytofix/Cytoperm (BD BiosciencesÔ). 
For analysis of apoptosis during culture, 2 ´ 105 PBMCs were stimulated for 4 d with 1 µg/ml 
F(ab’)2 anti-IgM- and -IgG specific antibodies, plus 500 ng/ml mega-CD40-ligand (ENZO). Cells 
were then stained for B cell phenotype, followed by incubation with Annexin-V - PerCP/Cy5.5 in 
the presence of Annexin-V binding buffer for 15 min, according to manufacturer’s instructions 
(BioLegend). To assess the effect of PD-1 blockade, cells were stimulated as above in the presence 
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of 10 µg/ml anti-PD-1 mAb or matched isotype control (LEAFÔ purified; clone EH12.2H7; 
BioLegend).  
 
2.6 Antibody-secreting cell (ASC) assays 
2.6.1 Differentiation protocol 
To promote the differentiation of plasma cells, B cells were cultured using a two-step 
differentiation protocol (Jahnmatz et al., 2013; Jourdan et al., 2009; Walsh et al., 2013). B cells were 
first activated in a 96-well plate using polyclonal stimulus (CpG-B ODN 2006 InvioGen; 50ng/ml) 
± soluble HBsAg (F. Hoffman-La RocheÔ; ayw, 1 µg/ml).  
Step one: Activated cells were expanded using a mixture of B cell homeostatic cytokines, containing 
IL-2 (50 U/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml) and IL-21 (100 ng/ml) plus CpG-B (50 ng/ml), 
diluted in DMEM (supplemented with 10%-FBS, 1%-penicillin/streptomycin and 10%-non-
essential amino acids). Cells were incubated for 4 d at 37°C.  
Step two: Following activation, cells were switched into DMEM containing IL-2, IL-10, IL-15, (as 
above), plus IL-6 (50 ng/ml) and IFNa (500 U/ml) and cultured for a further 3 d at 37°C to 
promote their differentiation. 
 
2.6.2 ELISPOT 
ELISPOT plates (multiscreen HTS-IP 0.45µm, Merck/Sigma-AldrichÒ) were pre-coated with 
HBsAg (2 µg/ml), or F(ab’)2 anti-IgG (1 µg/ml; Jackson ImmunoResearch) for detection of total 
antibody-secreting cells, and blocked with RPMI plus 1%-milk. For ELISPOT analysis of HBsAg-
specific memory B cells, B cells were purified from frozen PBMC samples using magnetic 
separation (as in section 2.4.1). Enriched B cells were cultured as in section 2.6.1. At the end of the 
culture period, cells were washed in cRMPI and counted as in section 2.2.1. For the detection of 
HBsAg-specific memory B cells, 2 ´ 105 cells were added to the plate and incubated at 37°C in 5%-
CO2 for 18 h. Approximately 500 cells were added to IgG-coated wells as a positive control. 
Following incubation, plates were washed 3 times with PBS-Tween (0.05%), then 3 times with PBS. 
Goat anti-human IgG-horse-radish peroxidase (Jackson ImmunoResearch; diluted 1/800 in PBS-
10% FBS) was added and incubated for 4 h at RT in the dark. Cells were again washed 3 times with 
PBS-Tween (0.05%), 3 times with PBS, and developed with AEC substrate (BD BiosciencesÔ), 
according to manufacturer’s instructions. ELISPOT plates were then washed with ddH2O, before 
analysis using VirusSpot (AID). All assays were performed in triplicate.  
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2.6.3 Isolation of HBsAg-specific B cells and detection of anti-HBs 
In order to isolate HBsAg-specific B cells, ~ 5 ´ 106 B cells were enriched, as described in section 
2.4.1, from 8 ´ 107 – 1 ´ 108 freshly isolated PBMCs (where possible). B cells were incubated with 
FcR-blocking reagent in PBS supplemented with 10%-FBS and 2mM EDTA, prior to incubation 
with a combination of mAb (detailed in Table 2.5). Cells were stained for 30 min at 4°C with gentle 
shaking every 10 min to prevent clumping of cells. Once stained, PBMC were washed twice in ice-
cold PBS 10%-FBS with 2 mM EDTA, and re-suspended in a volume of cRPMI corresponding to 
5 ´ 107 cells/ml. Before sorting, cells were filtered through a 70 µm filter-capped polystyrene tubes 
(BD BiosciencesÔ). 
Cells were sorted at low speed on a FACS AriaÔ (BD BiosciencesÔ) in either category two or 
category three conditions (for healthy vaccinated controls or patients with CHB, respectively). 
Stringent gating was applied to exclude doublet forming cells. Gates defining HBsAg-specific B 
cells were set using comparison to an FMO (representative gating strategy in Figure 2.2). Sorted 
cells were collected into polypropylene tubes (BD BiosciencesÔ) containing collection media 
(cRPMI supplemented with 20%-FBS). Following isolation, cells were washed and cultured as in 
section 2.6.1. 
 
Table 2-5 Cell surface markers for subset identification in FACS-isolation of HBsAg-specific B cells 
Antigen Fluorochrome Clone Manufacturer Cat No. Dilution 
CD19 APC/Cy7 SJ25C1 BD BiosciencesÔ 557791 2:100 
CD3 BV510 OKT3 BioLegend 317332 1:100 
AF488-HBsAg-bait N/A F. Hoffman-La RocheÔ N/A 2:100 
 
For the detection of anti-HBs, HBsAg-specific B cells were sorted and stimulated for 7 d, as above. 
The number of cells isolated ranged from between 3 ´ 103 and 1.7 ´ 104. Culture supernatants 
(from the second differentiation step) were sent for anti-HBs quantification (Health Services 
Laboratory, UCLH; Abbott Architect anti-HBs). Samples were also tested in parallel in-house using 
anti-HBs CLIA kit (AutoBio), according to manufacturer’s instructions. CLIA kits were also used 
for the measurement of serum anti-HBs, where clinical information was unavailable.  Serum was 
diluted 1:100 and tested according to manufacturer’s instructions. 
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Figure 2-2 Gating strategy for FACS-isolation of HBsAg-specific B cells 
Sequential gating strategy used for the isolation of HBsAg-specific B cell by FACs-sorting. B cells were pre-enriched using 
magnetic separation. Stringent gating was used to isolate viable, single lymphocytes. HBsAg-specific B cells were 
distinguished through comparison to an FMO (fluorescence-minus-one).  
 
2.6.4 Differentiation of memory B cell subsets into antibody-secreting cells 
PBMCs were stained as in section 2.6.3 using mAb detailed in Table 2.6 and sorted into atypical 
memory and classical memory populations using a FACS AriaÔ (BD BiosciencesÔ), as before. 
Stringent criteria were applied to identify lymphocytes, based on FSC vs SSC, and to remove 
doublet contamination (Figure 2.3). Between 5 ´ 104 and 2 ´ 105 atypical memory B cells were 
purified using this method; in all cases, a matched number of classical memory B cells were sorted 
and stimulated as below. 
 
 
 
Figure 2-3 Gating strategy for FACS-isolation of memory B cell subsets 
Sequential gating strategy used for the isolation of classical (CD27+CD21+; blue) and atypical (CD27-CD21low/-; red) 
memory B cell subsets by FACs-sorting. B cells were defined as CD19+ single lymphocytes. Immature B cells were 
excluded based on CD10 expression.  
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Sorted cells were first activated using CpG-B ODN 2006 (InvioGen; 500 ng/ml) and cultured as in 
section 2.6.1. Cells activated with CpG-B but cultured in cRPMI only were used as a control 
comparison. After culture, cells were stained for plasma cell differentiation using mAb detailed in 
Table 2.6 and analysed on an LSR-Fortessa-X20Ô. 
For detection of antibody produced during culture, supernatants (from the second differentiation 
step) were diluted 1:20 and analysed using cytometric bead array for total IgG (BD BiosciencesÔ). 
Data were collected on a FACS VerseÔ (BD BiosciencesÔ). Concentrations of IgG produced 
were extrapolated through comparison to a standard curve. 
CD40-ligand cell line: For some experiments, enriched B cells were cultured in the presence of CD40-
ligand expressing Chinese Hamster Ovary cells (CHO) and counterpart CD40-negative cells 
(obtained from Prof. Claudia Mauri). Prior to culture, cells were deemed mycoplasma negative 
through commercial testing (GATC Biotech). Cells were cultured in DMEM supplemented with 
10%-FBS and 1%-penicillin/streptomycin, and grown to 80% confluency, before irradiation using 
50 Gy. 2 ´ 105 irradiated cells were plated per well and allowed time to settle prior to the addition 
of B cells. 
 
Table 2-6 Combinations of mAb used for the isolation of memory B cell subsets and the subsequent 
detection cells with a plasma cell phenotype 
Antigen Fluorochrome Clone Manufacturer Cat No. Dilution 
Pre-sort mAb – for the identification of memory B cell subsets 
CD19 BV786 SJ25C1 BD BiosciencesÔ 563325 2:100 
CD3 BV711  OKT3 BioLegend 317328 1:100 
CD10 BV605 Ber-ACT8 BioLegend 350218 2:100 
CD21 BV421 B-Ly4 BD BiosciencesÔ 562996 2:100 
CD27 BUV395 L128 BD BiosciencesÔ 561767 1:100 
Post-culture mAb – for the identification of plasma cell differentiation 
CD19 BV786 SJ25C1 BD BiosciencesÔ 563325 2:100 
CD20 Alexa-FluorÒ 700 2H7 BD BiosciencesÔ 560631 1:100 
CD3 BV711  OKT3 BioLegend 317328 1:100 
IgD PE/Cy7 IA6-2 BD BiosciencesÔ 561314 1:100 
CD38 PE-dazzle HIT2 BioLegend 303532 0.5:100 
CD138 APC DL-101 BioLegend 352307 2:100 
CD27 BUV395 L128 BD BiosciencesÔ 561767 1:100 
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2.7 tSNE 
tSNE analysis was performed on concatenated flow cytometry data from 10 patients with CHB and 
10 healthy controls using default parameters (Iterations, 1,000; perplexity, 20; and θ, 0.5). Analysis 
was applied to expression data for CD27, CD21, PD-1, FcRL5, CD24, CD38, IgM and IgD for all 
live CD45+CD19+CD3-CD20-CD10- events.  
 
2.8 Statistical analyses 
Statistical analyses were performed in Prism (GraphPad) using the appropriate tests, with significant 
differences marked on all figures. All test were carried out as two-tail tests. Significance levels were 
defined as: * = p<0.05, ** = p<0.005, *** = p<0.001, **** = p<0.0001.  
 
2.9 Reagents 
Table 2-7 Full details, including manufacturers and catalogue number of reagents used through this 
study 
Product Manufacturer Catalogue No. 
ADAM AccuChip Kit NanoEnTek AD4K-200 
AEC substrate BD BiosciencesÔ 551951 
AF488-HBsAg-bait F. Hoffman-La RocheÔ N/A 
AmiconÒ Ultra Centrifugal Filters Merck-Millipore (Sigma-AldrichÒ) UFC905024 
anti-HBs CLIA kit AutoBio CL0311-2 
Brefaldin-A Sigma-AldrichÒ B6542 
Brilliant Stain Buffer BD BiosciencesÔ 563794 
Collagenase IV Thermo ScientificÔ 17104-019 
Compensation beads BD BiosciencesÔ 51-90-9001229 
CpG-B ODN 2006 InvivoGen tlrl-2006 
Cryovials Greiner bio-one 123277 
CytofixÔ BD BiosciencesÔ 554655 
Cytofix/CytopermÔ BD BiosciencesÔ 554722 
DMEM GlutaMAXÔ-I GibcoÒ 61965-026 
DMSO Sigma-AldrichÒ D2650 
DNase Roche 11284932001 
EasySepÔ Human B cell Enrichment Kit StemCellÔ Technologies 19054 
EDTA Sigma-AldrichÒ E7889 
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AffiniPure goat anti-human F(ab’)2 anti-IgG Jackson ImmunoResearch 109-006-097 
AffiniPure goat anti-human F(ab’)2 anti-IgG + 
-IgM (H+L) + IgA Jackson ImmunoResearch 109-006-064 
F(ab’)2 goat anti-human IgM – UNLB Southern Biotech 2022-01 
FcR Blocking Reagent Miltenyi BiotecÒ 130-059-901 
FicollÒ Paque Plus GE Healthcare 17-1440-02 
Fluo-4AM Thermo ScientificÔ F14201 
FoxP3 Buffer Set BD BiosciencesÔ 560098 
Goat anti-human IgG-horse-radish peroxidase Jackson ImmunoResearch 109-035-088 
[Recombinant] HBsAg ayw F. Hoffman-La RocheÔ N/A 
HBsAg CLIA kit AutoBio CL0310-2 
HBSS GibcoÒ 24020-091 
Heat-inactivated FBS Thermo ScientificÔ 10500064 
HEPES GibcoÒ 15630-056 
IFNa PBL assay sci 11100-1 
IL-10 BioLegend 571006 
IL-15 R&D Systems 247-ILB-005/CF 
IL-2 Peprotech 200-02 
IL-21 GibcoÒ PHC0214 
IL-6 (research grade) Miltenyi BiotecÒ 130-093-929 
Ionomycin Sigma-AldrichÒ 10634 
LEAFÔ Purified anti-human PD-1 BioLegend 329911 
LEAFÔ Purified mouse IgG1k BioLegend 401403 
LIVE/DEADÔ InvitrogenÔ L23105 
Mega-CD40-ligand Enzo ALX-522-100-C010 
MEM essential amino acids InvitrogenÔ 11130036 
MEM non-essential amino acids InvitrogenÔ 11140035 
MultiScreen-IP Filter Plate, 0.45 µm Merck-Millipore (Sigma-AldrichÒ) MAIPS4510 
PBS Sterile GibcoÒ 14190-094 
PBS Tablets Sigma-AldrichÒ P4417-100TAB 
PE-secondary Thermo ScientificÔ A10542 
Penicillin/streptomycin InvitrogenÔ 15140122 
PercollÒ Sigma-AldrichÒ P1644 
Phosflow Buffer BD BiosciencesÔ 558050 
phosphorylated BLNK (Tyr96) Cell Signalling TechnologyÒ #3601S 
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Probenecid Thermo ScientificÔ P36400 
Resiquimod InvivoGen tlrl-r848 
RPM1 1640 GibcoÒ 21875-034 
Saponin Sigma-AldrichÒ S-7900 
Sodium pyruvate InvitrogenÔ 11360039 
Total IgG Flex Set CBA BD BiosciencesÔ 558679 
Trypan Blue Sigma-AldrichÒ 31350010 
Trypsin-EDTA GibcoÒ 25300-062 
Tween Thermo ScientificÔ BP337-500 
UV (Blue) Live/Dead stain Life TechnologiesÔ L23105 
b-mercaptoethanol Sigma-AldrichÒ 31350010 
96-well plate Sarstedt 83.3925.500 
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Chapter 3 HBsAg-specific B cells persist in CHB with impaired 
potential to produce antibody 
 
Chapter summary 
Immune control in HBV infection is associated with the presence of functional virus-specific T 
cells, coinciding with the serological detection of anti-HBs antibodies. However, persistent 
infections are often distinguished by significant alterations to antigen-specific T and B cell 
compartments. An important feature of HBV infection is the over-production of HBsAg sub-viral 
particles: persistently high levels of circulating antigen, along with the tolerogenic environment of 
the liver, is speculated to promote the functional exhaustion of virus-specific T cell responses in 
patients with CHB. Taken together, these factors represent a significant challenge to the 
development and function of HBsAg-specific B cells.  
Whilst the quantity and function of HBV-specific T cells has been clearly defined, similarly detailed 
characterization of HBV-specific B cell responses is lacking. In this chapter, I outline a method to 
visualise HBsAg-specific B cells directly ex vivo in the blood of patients with CHB. 
  
 
 
82 
3.1 Introduction 
3.1.1 Identification of antigen-specific lymphocytes 
A key arm of the adaptive immune system is the instruction of antigen-specific T and B 
lymphocytes that are able to respond to and generate immunological memory against pathogenic 
challenge. Central to this ability is a fundamental aspect of the adaptive immune system: antigen 
specificity. Both T and B lymphocytes – the key effectors of the adaptive immune system - are 
equipped with receptors that confer their specificity. Similar to B cells, T lymphocytes express a 
heterodimer consisting of an a and b polypeptide, with structural homology to immunoglobulins. 
This is referred to collectively as the T cell receptor (TCR). However, unlike B cells that can bind 
soluble antigen, T cells only recognise peptides presented by MHC. Crucially, both TCRs and BCRs 
are formed in a process of extensive rearrangement of germline encoded genes, permitting the 
generation of up to ~1010 different specificities.  
Quantitative analyses of antigen-specific lymphocytes have provided important insights into the 
formation of natural immune responses to infection and immunisation. Previous efforts to identify 
antigen-specific lymphocytes have utilised ELISA-based limiting dilution assays (LDA). These work 
by measuring the biological activity of specific responder cells on the basis that activity decreases in 
line with dilution of cells, thereby permitting estimation of the original number of responding cells 
in culture. This type of assay has the advantage that multiple memory subsets of different antigen 
specificity can be enumerated from the same sample. When quantifying B cell responses, however, 
without pre-amplification of antigen-specific populations, cells must be cultured for 2-4 weeks for 
enough specific antibody to accumulate to a detectable level.  
Enzyme-linked immunosorbent spot assays (ELISPOT) circumvent this by quantifying antibody-
secreting daughter cells of the memory B cells, rather than accumulated antibody (Slifka and 
Ahmed, 1996). Accordingly, plasma cells can be detected directly ex vivo through ELISPOT, due to 
their status as a terminally differentiated, antibody-secreting cell. However, this method does not 
allow for direct characterisation of antigen-specific B cells, nor permit recovery for downstream 
analyses. Furthermore, both ELISA-LDA and ELISPOT assays rely on the adequate differentiation 
of memory B cells and assume functional production of antibody. Therefore, they are arguably not 
representative in settings where there is evidence that antibody secretion or differentiation to 
antibody-secreting cells (ASCs) may be malfunctioning, as they may underestimate responses 
through their inability to detect cells that have no proliferative or functional capacity. 
In chronic HBV, adaptive immune responses are characteristically weak and transient in nature 
(Bertoletti and Maini, 2000), thus impeding the description of antigen-specific immune responses. 
HBV-specific cytotoxic lymphocytes were first demonstrated by chromium release assays following 
stimulation with synthetic peptides derived from HBcAg and HBeAg in vitro (Bertoletti et al., 1991; 
Penna et al., 1991). These data have since been confirmed by ex vivo quantification of these cells 
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using HLA Class I tetramers (Maini et al., 2000), intracellular cytokine staining (Webster et al., 
2004), and ELISPOT analysis post stimulation with either HLA-A2 restricted viral peptides or 
overlapping pools of peptides spanning the entire HBV genome (Boni et al., 2007). These studies 
have revealed critical insights into the kinetics of HBV-specific T cells during hepatitis, showing 
that T cells are profoundly exhausted and depleted in persistent infection, yet are maintained even 
after clinical recovery in acute hepatitis (Bertoletti and Ferrari, 2016).  
Comparatively, very little has been done to study antigen-specific responses against HBsAg; the key 
viral protein capable of inducing protective antibody responses in HBV (Table 3.1). HBsAg-specific 
B cells are readily induced by HBsAg-vaccination and can be detected in the periphery and 
lymphoid tissue, in accordance with detection of protective anti-HBs responses (Barnaba et al., 
1985; Böcher et al., 1999; Wang et al., 2015; Ward et al., 2008; Xu et al., 2015). However, 
frequencies of anti-HBs producing cells are thought to be decreased in the periphery of patients 
with CHB relative to HBV-vaccinated individuals and compared to patients with acute-resolving 
infection (Barnaba et al., 1985; Dusheiko et al., 1983; Xu et al., 2015). ELISPOT data enumerating 
HBsAg-specific IgG-producing cells suggested that the frequency or function of HBsAg-specific B 
cells may fluctuate according to disease phase, with some patients with active CHB (characterised 
by raised ALT and viral load) capable of producing anti-HBs to similar levels as HBV-vaccinated or 
–resolved controls (Xu et al., 2015). However, the majority of these studies are limited by their 
dependency on antibody production as a readout for HBsAg-specific B cell frequency. Thus, 
despite these studies, it remains unclear as to whether there is a numerical defect in the formation 
and persistence of HBsAg-specific B cells, or whether HBsAg-specific B cells persist but are 
functionally defective. Moreover, co-culture studies using allogeneic T cells from HBV-vaccinated 
responders and B cells from patients with CHB failed to produce detectable anti-HBs responses, 
pointing to the existence of B cell specific defects (Barnaba et al., 1985; Dusheiko et al., 1983).  
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To date, there have been no studies that have directly analysed the frequency and phenotype of 
HBsAg-specific B cells in CHB. Our approach was to use a fluorescently conjugated antigen-bait 
system, thereby facilitating co-characterisation by monoclonal antibody staining. This system works 
on the premise that antigen binds specifically to the immunoglobulin of the BCR. Antigen binding 
can then be detected via coupling to a fluorophore and quantified using flow cytometry (Figure 
3.1). Flow-cytometric probes, such as these, were first used in mouse models of infection (Doucett 
et al., 2005; Hayakawa et al., 1987; McHeyzer-Williams et al., 1993), and have since been used to 
identify and isolate HIV-specific B cells (Kardava et al., 2014; Knox et al., 2017) and HCV-specific 
B cells (Boisvert et al., 2016) from human PBMCs, amongst other studies of immunisation. The 
efficacy of antigen-coupled bait reagent systems to enumerate frequencies of protective HBsAg-
specific B cells was first demonstrated in HBV-vaccinated healthy controls. Using a two-step 
magnetic cell-sorting procedure, HBsAg-specific B cells were enriched from the PBMCs of 
vaccinated healthy controls at significantly higher frequencies than HBV-naïve controls (Ward et 
al., 2008). The frequency of HBsAg-specific B cells detected by this method did not correlate with 
the levels of anti-HBs production quantified by ELISPOT or ELISA, thus demonstrating the ability 
of this method to detect antigen-specific B cells independent of antibody production.  
 
 
Figure 3-1 Method for detecting antigen-specific B cells using an HBsAg-bait system 
Approach used for the identification of HBsAg-specific B cells. HBsAg-specific B cells are detected using flow cytometry 
via a recombinant HBsAg coupled to an Alexa Fluor-488 fluorophore 
 
  
BCR
AF488-labelled HBsAg
B cell
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3.2 Hypothesis and aims: 
In this chapter, I aim to understand how chronic HBV infection may impact the development and 
function of antigen-specific B cells. It was hypothesised that chronic antigen stimulation, in the 
form of high levels of circulating HBsAg, may result in HBsAg-specific B cell dysfunction 
analogous to T cell exhaustion described in CHB. Defects in the frequency or function of HBsAg-
specific B cells may contribute to the failure of B cells in patients with CHB to overcome high 
levels of circulating HBsAg.  
 
The work presented in this chapter will aim to:  
1. Test the specificity and sensitivity of a HBsAg-bait system (F. Hoffman-La RocheÔ) for 
the identification of HBsAg-specific B cells; 
2. Enumerate HBsAg-specific B cells in patients with CHB compared to vaccinated healthy 
controls and patients with acute-resolving HBV infection; 
3. Correlate HBsAg-specific B cell responses with the outcomes of CHB, in particular HBsAg 
seroconversion and viral control; 
4. Assess the ability of HBsAg-specific B cells to produce anti-HBs/form anti-HBs secreting 
cells. 
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3.3 Results 
3.3.1 HBsAg-bait as a method of detecting HBsAg-specific B cells in PBMCs 
To examine whether HBsAg-specific B cells circulate in chronic infection, we first developed and 
optimised a sensitive method for their direct ex vivo detection. Recombinant HBsAg was coupled to 
AF488-fluorophore (produced in house by F. Hoffman-La RocheÔ) and used to identify antigen-
specific B cells in PBMCs by flow cytometry. The concentration of the HBsAg-bait was carefully 
titrated to increase the likelihood of detecting true antigen-specific B cells and limit non-specific 
binding. Rudimentary comparison to a labelled native HBsAg, purified from the serum of active 
HBV patients, indicated that the frequencies estimated by these two separate methods did not 
differ significantly (data not shown); for batch consistency, all data was collected using the 
recombinant antigen.  
Stringent gating was used to identify HBsAg-specific B cells. Lymphocytes were delineated on the 
basis of forward and side scatter, and CD45 expression. Dead cells were excluded from analysis 
using a fixable live-dead stain. Within the live, lymphocyte population, B cells were identified by 
CD20 and CD19 expression, with T cells excluded through expression of CD3 (Figure 3.2A). Gates 
defining HBsAg-specific B cells were set using fluorescence-minus-one staining (FMO; Figure 
3.2B) and cross-checked through comparison to CD19-CD3+ T cells, which do not express a BCR 
and therefore should not bind the bait specifically (representative example in Figure 3.2C). HBsAg-
specific B cells were calculated as a percentage of CD45+CD3-CD19+CD20+ B cells with 
background fluorescence, determined via corresponding FMO staining, subtracted for each 
individual. Some non-specific binding was detected in unexposed controls (Figure 3.2B). 
This system was validated using a cohort of HBsAg-vaccinated (Engerix B; recombinant HBsAg 
adsorbed on aluminium hydroxide) and unexposed healthy controls (Figure 3.2D). Only known 
HBV-vaccine responders were analysed, pre-determined by detectable serum anti-HBs responses. 
The frequency of circulating HBsAg-specific B cells estimated by this method was in the range of 
vaccinated donors assessed previously using a 2-step enrichment staining protocol (Ward et al., 
2008). A threshold level of detection was set using the mean plus the standard deviation of 
background staining seen in the unexposed cohort (0.18% of B cells, Figure 3.2D); individuals that 
had frequencies of HBsAg-bait-binding cells above threshold level were deemed to have a 
detectable population HBsAg-specific B cells that was absent in unexposed controls. It is noted 
that this cut-off left 4/24 unexposed donor stains around the limit of detection, indicating that 
responses around the threshold frequency should be interpreted with some caution. 
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Figure 3-2 Flow cytometric identification of HBsAg-specific B cells 
A. Sequential gating strategy for the identification of HBsAg-specific B cells. HBsAg-specific B cells were estimated as a 
proportion of total B cells, defined as CD45+CD19+CD3-CD20+ B. Representative staining of HBsAg-specific B cells in 
HBV-unexposed and HBV-vaccinated healthy controls (vac HC) identified using an AF488-HBsAg-bait, and compared 
to FMO (fluorescence-minus-one). C. Representative staining using the AF488-HBsAg-bait on CD3+CD19- T cells in a 
vac HC. D. Frequency of HBsAg-specific B cells (% of total CD45+CD3-CD19+CD20+) in HBV-unexposed (n=24) and 
HBV-vaccinated (n=29) healthy controls. Error bars indicate mean ± SEM; ****, P < 0.0001; p-values were determined 
by Mann-Whitney U test for unpaired data. 
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To assess the specificity of this bait system for detecting HBsAg-specific B cells, we used it to track 
the appearance of protective HBsAg-reactive B cells following HBV vaccination in previously 
unexposed individuals. Analysis of peripheral B cells, from healthy donors sampled repeatedly 
during the course of preventative HBV vaccination (Engerix B), revealed that detection of HBsAg-
specific B cells, above the background threshold of staining, coincided with the development of a 
detectable anti-HBs antibody response in sera (Figure 3.3A, B). Two donors who did not complete 
the course of the vaccination failed to develop a detectable antibody response by ELISA and 
correspondingly did not develop a population of HBsAg-specific B cells above threshold (Figure 
3.3C). 
 
Figure 3-3 Development of HBsAg-specific B cells increase following HBsAg-vaccination 
A. Representative staining of HBsAg-specific B cells across the course of HBV-vaccination with Engerix (Donor 2). 
Samples taken two weeks prior to first dose and seven days post each dose (given 1 and 6 months after the initial dose). 
B. HBsAg-specific B cells (red bars; % of total CD45+CD3-CD19+CD20+) across the course of HBV-vaccination in two 
healthy donors and C. in two healthy donors who did not complete their course of HBV-vaccination. Dashed line 
represents serum anti-HBs titre (IU/ml) determined by ELISA. Red line delineates threshold level based on mean + s.d 
of unexposed controls (0.18). 
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To further validate the sensitivity and specificity of the reagent for the detection of antigen-specific 
cells, we FACS-sorted the HBsAg-bait-binding and bait-negative B cell fractions from three HBV-
vaccinated donors and assessed their functionality after culture using ELISPOT and ELISA. A two-
step protocol was employed to promote the activation and differentiation of B cells to plasmablasts 
and plasma cells (referred to collectively as antibody-secreting cells; ASCs) (Jourdan et al., 2009) 
(Figure 3.4). anti-HBs produced was measured in the supernatant following ASC differentiation 
when levels were highest. Cells that bound HBsAg-bait differentiated into HBsAg-specific plasma 
cells, detectable by ELISPOT, and produced >1000IU/ml of anti-HBs antibody by ELISA (Figure 
3.4; UCLH Health Services Laboratory). In contrast, cells from the bait-negative fraction were 
devoid of HBsAg-reactive responses by ELISPOT and produced no detectable anti-HBs antibody 
when cultured in vitro (Figure 3.4). 
 
 
Figure 3-4 In vitro differentiation protocol for the differentiation of ASCs  
AF488-HBsAg-bait binding and HBsAg-bait deplete cells were FACs-sorted from an HBV-vaccinated control and 
stimulated polyclonally to activate B cells and promote ASC differentiation. anti-HBs ELISA and anti-HBs ELISPOT 
assays were performed on culture supernatants and on cultured cells, respectively. Representative of three individual 
experiments. 
 
3.3.2 HBsAg-specific B cells are detectable in the circulation of patients with CHB 
Having validated the specificity of the HBsAg-bait, we then used it to test for circulating HBsAg-
specific B cells in a cohort of 84 subjects with CHB. Despite their lack of detectable serum anti-
HBs antibodies, we were able to detect HBsAg-specific B cells above the background threshold in 
68% of the cohort, at comparable frequencies to a cohort who had been previously vaccinated with 
HBsAg (representative example and summary data; Figure 3.5A). Both subjects with CHB and 
vaccinees had significantly higher frequencies of HBsAg-bait-staining B cells than unexposed 
controls or patients infected with HCV (Figure 3.5A).  
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Figure 3-5 HBsAg-specific B cells persist in the circulation of patients with CHB  
A. Representative staining of HBsAg-specific B cells in a patient with CHB, compared to FMO (fluorescence-minus-one). 
Summary plot shows frequency of HBsAg-specific B cells in unexposed healthy controls (n=24), HBV-negative HCV+ 
patients (n=6), HBV-vaccinated healthy controls (vac HC; n=29) and patients with chronic HBV (CHB; n=84), identified 
by AF488-HBsAg-bait staining. Frequencies are presented minus paired FMO. B. Frequency of HBsAg-specific B cells 
plotted against serum HBsAg levels (IU/ml; n=48). C. Summary plot of the frequencies of HBsAg-specific B cells 
stratified by HBV viral load: n=29 vac HC; n=13 with HBV DNA <2x103 IU/ml; and n=39 with HBV ≥ 2x103 IU/ml. 
D. Correlative analysis of the frequency of HBsAg-specific B cells and serum ALT (IU/l; n=84). E. Summary plot of the 
frequencies of HBsAg-specific B cells stratified by CHB disease phase: n=10 ‘HBeAg+ chronic infection’ (eAg+ CI, 
HBeAg+, HBV viral load > 107 IU/ml, serum ALT < 40 IU/litre); n=5 ‘HBeAg+ chronic hepatitis’ (eAg+ CH, HBeAg+, 
HBV viral load > 5 x 105 IU/ml, serum ALT > 60 IU/litre); n=17 ‘HBeAg- chronic infection’ (eAg- CI; HBeAg-, HBV 
viral load < 2000IU/ml, serum ALT < 40 IU/litre); and n=6 ‘HBeAg- chronic hepatitis’ (eAg- CH, HBeAg-, HBV viral 
load > 5 x 105 IU/ml, serum ALT > 60IU/litre). F. Cross-sectional analysis showing the frequency of HBsAg-specific B 
cells at HBV-acute and -resolved time points (n=8). Red line delineates threshold level based on mean+s.d of unexposed 
controls (0.18). Error bars indicate mean ± SEM; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; p-values determined by 
Kruskal-Wallis test with a Dunn’s post hoc test for pairwise multiple comparisons (a, c and e); Spearman’s Rank 
correlation (b and d); and Wilcoxon signed-rank test (f). 
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To explore the association between HBsAg-specific B cells and disease activity, we next sought to 
analyse their frequency according to pre-defined clinical parameters. The clinical and virological 
parameters considered included: serum alanine transaminase (ALT) levels, used as an indicator of 
liver inflammation; levels of circulating HBsAg; and HBV viral load. Repeated clinical assessment 
also facilitated comparison of HBsAg-specific B cells according to clinical disease phase, as defined 
by clinical guidelines (European Association for the Study of Liver; EASL) (Table 1.1).  
These were defined as follows: 
- HBeAg+ chronic infection: HBV DNA >107 IU/ml, ALT <40IU/L 
- HBeAg+ chronic hepatitis: HBV DNA >5 x107 IU/ml, ALT >60IU/L 
- HBeAg- chronic infection: HBV DNA <2000IU/ml, ALT <40IU/L 
- HBeAg- chronic hepatitis: HBV DNA >5x105IU/ml, ALT >60IU/L 
 
The frequency of HBsAg-specific B cells showed no clear relationship with serum HBsAg 
concentration, HBV DNA, or serum ALT levels, suggesting that there is no direct correlation 
between the frequency of circulating HBsAg-specific B cells and the levels of viral proteins and/or 
inflammation (Figure 3.5B-D). Moreover, there were no differences in the frequency of HBsAg-
specific B cells according to clinical disease phase (Figure 3.5E), in contrast to previous reports 
demonstrating an increased frequency of anti-HBs producing cells in immune active phases of 
disease (Xu et al., 2015).  
 
3.3.3 HBsAg-specific B cells in acute-resolving HBV infection 
We next investigated the frequency of HBsAg-specific B cells in patients who control infection and 
produce protective anti-HBs, by comparing HBsAg-specific B cells in valuable samples of patients 
sampled during acute and resolved HBV infection. Patients were identified as having resolved 
infection when HBV DNA and HBsAg were undetectable and ALT levels were normalised (for the 
purpose of this thesis, ALT levels were considered normal when below 40IU/ml). Paired analysis 
of HBsAg-specific B cells at HBV-acute versus -resolved time points suggested that HBsAg-
specific B cells circulated at similar frequencies in acute compared to chronic infection, and 
decreased marginally when patients were resampled around the time of HBsAg clearance, although 
this was not statistically significant (Figure 3.5F).  
By obtaining pre-existing clinical information from additional time points (where PBMCs were 
unavailable), we were able to assess the frequency of HBsAg-specific B cells according to the 
progression of acute-resolving infection. In doing so, we could examine how the frequency of 
HBsAg-specific B cells changes as patients develop immunity to HBsAg. Of note, patients with 
acute HBV infection often present late in clinic, at the onset of clinical symptoms and post the 
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initial peak in HBV viral load and serum ALT levels. As a result, acute-resolving patients are often 
sampled towards the resolution of disease, and rarely capture patients in the pre-clinical phase of 
acute HBV. HBsAg-specific B cells showed a tendency to decrease towards the resolution of 
disease, although this was not consistent in all patients sampled (Figure 3.6). Where samples were 
captured earlier in infection, the frequency of HBsAg-specific B cells showed a more marked 
decrease following the peak of viraemia and serum ALT levels (patients 01-03; Figure 3.6). 
Combined, these data suggested that the HBsAg-specific B cell compartment displays a tendency to 
contract following resolution of infection and clearance of HBsAg. 
 
 
Figure 3-6 Cross-sectional analysis of HBsAg-specific B cells in HBV-acute versus HBV-resolving 
infection 
Clinical data from longitudinal sampling of 5 acute-resolving patients, showing viral load (dotted line; IU/ml), serum ALT 
(dashed line; IU/litre), and serological data, indicated by the bars (solid bars delineate presence of HBV-viral antigen; 
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clear bars delineate presence of HBV-viral IgG; dashed bars used where data is not known). Frequency of HBsAg-specific 
B cells (% of CD20+CD19+) measured at cross-sectional time points during infection is indicated by the red bars. 
 
Longitudinal analysis of precious samples, taken throughout the time course of acute-resolving 
infection, permitted more detailed analysis of HBsAg-specific B cell kinetics according to changes 
in disease parameters. Temporal batch analysis throughout the course of acute-resolving HBV 
showed no consistent relationship with viral load, serology or liver inflammation (Figure 3.7A).  
Finally, analysis of a rare patient with CHB experiencing a flare in disease activity, allowed us to 
assess the effects of fluctuating levels of viral load and inflammation on HBsAg-specific B cells 
within the context of CHB. The frequency of HBsAg-specific B cells did not change considerably, 
despite substantial increases in HBV DNA and ALT (Figure 3.7B). Combined, these data suggest 
that differences in the clinical manifestation of CHB, and the level of viral replication/control, does 
not significantly impact the frequency of HBsAg-specific B cells that can be detected in the 
periphery. 
 
 
Figure 3-7 Temporal analysis of HBsAg-specific B cells in HBV-acute-resolving infection 
Longitudinal analysis of HBsAg-specific B cells (% of CD20+CD19+) during A. acute-resolving infection and B. a patient 
with CHB undergoing hepatic flare. Percentage of HBsAg-specific B cells (black line) are plotted in relation to viral load 
(dotted line; IU/ml), serum ALT (dashed line; IU/litre) and serological status, as indicated by the bars.  
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3.3.4 B cells in patients with CHB show defective anti-HBs production in vitro 
Our results thus far indicated that HBsAg-specific B cells persist in the circulation of patients with 
CHB at comparable levels to those with acute or resolved HBV infection, and their frequency is 
not significantly altered by changes in viral load, inflammation or levels of circulating antigen. In 
light of this, it appears that the apparent lack of anti-HBs in the sera of patients with CHB is not 
due to a reduced numbers of HBsAg-specific B cells, but instead may arise due to their defective 
production of anti-HBs. Accordingly, we next investigated whether the HBsAg-specific B cells 
detected in CHB were capable of differentiating into anti-HBs-producing ASCs.  
B cells were magnetically separated from the blood of HBV-unexposed and HBV-vaccinated 
healthy controls, and patients with CHB, yielding B cells of ~98% purity (Figure 2.1). Cells were 
cultured using the two-step differentiation protocol utilised in Figure 3.4. Briefly, purified B cells 
were first activated using polyclonal stimulus (CpG-B ODN 2006) ± antigen-specific stimulus 
(soluble HBsAg). CpG was used due to its relevance in HBV-physiology and the identification of 
CpG motifs in HBV DNA (Zhong et al., 2015), alongside its efficacy in promoting plasmablast 
differentiation and antigen-specific IgG responses (Jahnmatz et al., 2013; Jourdan et al., 2009; 
Walsh et al., 2013).  
Activated cells were expanded using a mixture of B cell homeostatic cytokines, including IL-2, IL-
10, IL-15, IL-21, over four days. Following activation, cells were switched to culture medium 
containing IL-2, IL-10, IL-15, IL-6 and IFNa to promote their differentiation in ASCs and 
cultured for a further three days. HBsAg was removed from culture through washing. Following 
differentiation, the number of viable cells was assessed and anti-HBs responses determined by 
ELISPOT. Analogous wells of stimulated B cells were simultaneously tested for global IgG 
production to ensure that viable B cells were seeded. This combinatorial approach of B cell 
activation and cytokine stimulation was required for adequate differentiation to anti-HBs secreting 
ASCs (Figure 3.8A). HBsAg-reactive responses were detected as large, diffuse spots that 
approximated responses seen in total-IgG producing controls and were not observed when using 
an HIV antigen in HIV seronegative individuals (representative example in Figure 3.8B).  
Analysis of HBsAg-specific plasma cell differentiation by ELISPOT suggested that global B cells 
isolated from patients with CHB had defective differentiation compared to healthy vaccinated 
controls (Figure 3.8B-D). 14/17 patients with CHB had fewer than 10 anti-HBs spot forming cells, 
compared to 1/7 vaccinated healthy controls (Figure 3.8D). The mean number of spot forming 
cells of each group was tested for significance using Kruskal-Wallis non-parametric ANOVA. 
B cells isolated from vaccinated healthy controls were significantly more able to form anti-HBs 
responses compared to unexposed healthy controls (***) and patients with CHB (*). Conversely, 
anti-HBs responses were undetectable in unexposed controls (n=5) and were not significantly 
different to patients with CHB (Figure 3.8D).  
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Figure 3-8 Frequency of anti-HBs-producing cells in vaccinated healthy controls and patients with CHB 
A. Polyclonal activation of B cells CpG and HBsAg was required in combination with cytokine stimulation to promote 
differentiation to anti-HBs secreting cells, as shown by ELISPOT in 3 HBV-vaccinated healthy controls. B. 
Representative ELISPOT-well image showing anti-HBs secreting B cells in HBV-vaccinated healthy controls, compared 
to total-IgG production and control well image using an HIV antigen. Large, diffuse spots were counted (circled). C. 
Representative ELISPOT-well image of anti-HBs secreting B cells in HBV-unexposed controls and patients with CHB, 
and compared to total IgG production. D. Summary plot: anti-HBs-secreting B cells in unexposed controls (n=5), 
vaccinated healthy controls (vac HC; n=7) and patients with CHB (CHB; n=14), determined by ELISPOT. SFC; Spot 
Forming Cells. TNTQ; too numerous to quantify. All ELISPOTS were performed using magnetically purified global B 
cells. Each assay was performed in triplicate and normalised according to the number of cells seeded. 
 
We next directly analysed the anti-HBs producing capacity of HBsAg-specific B cells from patients 
with CHB. HBsAg-bait-binding B cells that were FACS-sorted from donors with CHB, and 
cultured as above, failed to produce detectable levels of anti-HBs IgG (<10IU/ml; determined by 
clinical-grade ELISA, Health Services Laboratory). In contrast, comparable numbers of bait-sorted 
HBsAg-specific B cells from vaccinated healthy controls differentiated in vitro to produce robust 
levels of anti-HBs (>1000IU/ml) (Table 3.2). The viability of cells post culture was decreased in 
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patients with CHB relative to healthy controls; however, viable cells were present in both sample 
types (representative example in Figure 3.9). Direct comparison between cells stimulated with and 
without HBsAg suggested that residual antigen that may be present in the culture did not affect the 
detection of anti-HBs, as neither condition showed detectable levels of anti-HBs production. Thus 
HBsAg-specific B cells were detectable directly ex vivo in patients with CHB but showed reduced 
capacity to produce anti-HBs antibodies upon in vitro differentiation, relative to vaccinated healthy 
controls and consistent with undetectable antibody production characteristic of this stage of 
infection.  
 
Table 3-2 anti-HBs production of FACs-sorted HBsAg-specific B cells upon in vitro stimulation 
anti-HBs (IU/ml) in supernatants from stimulated FACS sorted HBsAg-specific B cells (n=3 vac HC; n=4 patients with 
CHB). Table shows the number of cells seeded and the level of anti-HBs detected (determined by ELISA; performed by 
Health Services Laboratory, UCLH). 
 
 Identifier No. of cells 
stimulated/well 
anti-HBs 
(IU/ml)  
HBV-vaccinated 
healthy controls 
HC 01 8834 >1000 
HC 02 5600 >1000 
HC 03 ~1.2x104 >1000 
Patients with CHB CHB 01 5520 <2 
CHB 02 ~1.16x104 <2 
CHB 03 9906  <2 
CHB 04 1.7x104 <2 
 
 
 
 
Figure 3-9 Viability of HBsAg-specific B cells post-culture 
Representative staining: viability was assessed in FACS-sorted HBsAg-bait binding fractions and HBsAg-deplete fractions 
following 7-day culture using fixable live/dead staining.   
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3.4 Discussion 
Key elements in the control and elimination of HBV infection include a broad and robust antigen-
specific T cell response, as well as the development of neutralizing anti-HBs antibodies leading to 
HBsAg clearance. Clearance of HBsAg, accompanied by anti-HBs seroconversion, is considered the 
hallmark of functional cure in HBV; accordingly, chronic hepatitis B infection is characterised by a 
lack of detectable serum anti-HBs. However, it was not yet known whether this was due to a failure 
in the development or persistence of HBsAg-specific B cells, or whether dysfunctional HBsAg-
specific B cells produce insufficient anti-HBs antibody to overcome the high HBsAg load in 
patients with CHB.  
Our study, in collaboration with a back-to back publication from the group of Antonio Bertoletti 
(Salimzadeh et al., 2018), is the first to definitively show that HBsAg-specific B cells can persist in 
the circulation of patients with CHB, yet exhibit defective production of anti-HBs antibodies. This 
study builds on previous reports of HBsAg-specific B cells in patients with CHB by using a 
HBsAg-bait system to directly identify HBsAg-specific B cell ex vivo. This method has the 
significant advantage that it bypasses the requirement of antibody production by B cells as a 
readout for the quantitation of HBsAg-specific B cell numbers, and allows phenotypic 
characterisation of persisting responses. Thus, unlike previous studies that suggested that HBsAg-
specific B cells are depleted (demonstrated via anti-HBs ELISPOT) (Xu et al., 2015), we show that 
antigen-specific B cells circulate in patients with CHB at comparable frequencies to patients with 
acute or resolved HBV, and HBV-vaccinated healthy controls. We also present the first direct 
evidence to show that HBsAg-specific B cells in patients with persistent infection have defective 
production of anti-HBs, relative to vaccinated healthy controls.  
The causes of this functional defect are not yet clear. In vivo, HBsAg-specific B cells likely interact 
directly with circulating HBsAg through their B cell receptor. Prolonged interactions in the instance 
of chronic infection may result in an overstimulation of the B cell and induce terminal 
differentiation and exhaustion, analogous to that described in HBV-specific T cells (Bertoletti and 
Ferrari, 2016). Previous studies have demonstrated functional hyper-activation of global (i.e. non-
antigen-specific) B cells in CHB, characterised by elevated expression of CD69 and CD71, that 
could be exacerbated by CD40-ligand and IFNa stimulation (Xu et al., 2015). Therefore, in the 
following chapter, I examine the phenotype of HBsAg-specific B cells, compared to functional 
HBsAg-specific B cells from vaccinated healthy controls, to understand how chronic B cell 
activation might impair antibody secretion. 
Based on our evidence and others, it appears that anti-HBs production is widely heterogeneous 
between patients with CHB. In vitro analysis of anti-HBs production by FACS-sorted HBsAg-bait-
binding B cells suggested that antigen-specific B cells in four patients with CHB produce negligible 
amounts of anti-HBs, in agreement with findings from Salimzadeh et al (Salimzadeh et al., 2018) 
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and the lack of detectable anti-HBs in patient serum. It is possible that low levels of anti-HBs 
production by these cells could have been sequestered by residual HBsAg added during B cell 
activation, thereby leading to an underestimation of the levels of antibody produced. However, 
direct comparison to cells activated in the absence of HBsAg suggested that this was not the case, 
and HBsAg-specific B cells isolated from vaccinated healthy controls and stimulated in the same 
way, still produced robust levels of anti-HBs, in line with the detection of anti-HBs in the serum of 
HBV-vaccinated individuals.  
Building on this, analysis of HBsAg-specific frequencies by ELISPOT also indicated that 
differentiation to anti-HBs secreting cells is impaired in patients with CHB, relative to vaccinated 
healthy controls. However, B cells from a small subset of patients possessed anti-HBs producing 
capability at similar levels to vaccinated healthy controls, in line with previous studies that identified 
B cells with the potential to form anti-HBs secreting cells (Barnaba et al., 1985; Böcher et al., 1996; 
Dusheiko et al., 1983). These findings are consistent with the clinical observation that some 
patients have low anti-HBs serum titre. Low-level production of anti-HBs would also fit with the 
identification of HBsAg:anti-HBs immune complexes, postulated to exist in patients with CHB 
(Gerlich, 2007; Madalinski et al., 1991; Madaliński and Bragiel, 1979; Rath and Devey, 1988). Thus, 
the availability of robust assays for quantitating and/or dissociating circulating HBsAg/anti-HBs 
complexes would permit a better assessment of the influence of antigen load on HBsAg-specific 
B cell frequencies and antibody detection.  
Our data did not identify a correlation between HBsAg-specific B cells and HBsAg quantified in 
the serum, nor with the level of HBV DNA, suggesting that there is no direct effect of antigen load 
on the persistence of HBsAg-specific B cells in the circulation of HBV-infected patients. However, 
levels of HBsAg in the circulation are not necessarily representative of levels within the liver, and 
can fluctuate significantly throughout the course of infection. Therefore, correlations between 
HBsAg-specific frequency and HBsAg load at a single time point is perhaps too simplistic. 
Although some studies have shown that B cell responses are enhanced (both HBsAg-specific cells 
and anti-HBs production) in patients in ‘immune active’ phases of disease association 
(Vanwolleghem et al., 2015; Xu et al., 2015), our data and others showed no consensus between 
HBsAg-specific B cell responses and disease phase (Salimzadeh et al., 2018). Instead, our findings 
point to an overarching impact of HBV infection on the co-ordination of the humoral immune 
response, for example in the interactions between T helper cells and B cells. This finding perhaps 
has important implications for the efficacy of therapeutic approaches aiming to rescue the adaptive 
immune response through the reduction of circulating HBsAg, as it suggests that the reducing 
antigenemia may help to rescue humoral immune responses.  
Circulating antigen-specific B cell frequencies are also unlikely to be representative of memory B 
cells compartmentalised in lymphoid tissues, particularly after resolution of infection when humoral 
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immune responses contract. This concept might explain the trend towards fewer HBsAg-specific B 
cells observed in PBMCs of patients with resolved HBV infection. Follow-up studies, in patients 
who have long-term resolved infection (i.e. up to 20-30 years post viral clearance), may reveal more 
striking kinetics of HBsAg-specific B cell responses. In addition, investigation of secondary 
lymphoid organs could provide important insights into the apparent defects in humoral immunity 
in CHB. For instance, a diminished propensity to secrete antibody could be indicative of a lack of 
appropriate CD4 T cell help and/or germinal centre formation. Differences in the formation of 
germinal centre responses, either in secondary lymphoid organs or ectopically in the liver, may also 
have relevance in explaining the heterogeneity in anti-HBs production between patients with CHB. 
Therefore, it will be imperative to sample these sites, where available, and phenotype lymphocytes 
present. This concept will be discussed in more detail in Chapter Five.  
The results of this chapter describe a robust method for the detection of HBsAg-specific B cells in 
PBMCs of HBV-infected patients. The use of HBsAg-baits for direct ex vivo quantification and 
phenotyping will facilitate further studies of B cell immunity in CHB, but has a number of caveats. 
Similar to MHC-peptide multimer detection of HBV-specific T cells (Maini et al., 1999), HBsAg-
specific B cells are often low frequency and can in some instances approximate levels observed in 
uninfected controls. Due to the secretion of specific anti-HBs by HBsAg-bait sorted B cells in 
vaccinated healthy controls, we are confident of the capacity of our bait reagent to detect HBsAg-
specific B cells. However, it is likely that non-specific background staining has contaminated our 
HBsAg-specific population with false positive cells, thus leading to an over-estimation of the levels 
of HBsAg-specific B cells in our patient cohorts.  
Use of a dual-staining antigen-bait can reduce non-specific staining by using two fluorescent 
parameters to detect a single epitope (Townsend et al., 2001). Non-specific staining from within the 
normal distribution of the negative population is therefore split between the detection parameters. 
Accordingly, background staining from each reagent pertains directly to a single fluorescent 
parameter, reducing the probability of identifying non-specific staining with both reagents (Amanna 
and Slifka, 2006; Townsend et al., 2001). An alternative approach would be to use a secondary 
probe with different antigen-specificity to detect background, non-specific staining. Of note, data 
acquired using a dual-specific bait system, showed comparable frequencies of HBsAg-specific 
B cells in acute, resolved and chronic stages of infection, once adjusted for background staining 
(Salimzadeh et al., 2018).  
It is also conceivable that HBsAg-specific B cells may be further under-estimated if endogenous 
HBsAg bound to their BCR in vivo prevents bait staining in vitro, or if the antibody-binding site on 
HBsAg in the bait differs from that produced in vivo. Antibodies recognise not only linear but also 
conformational epitopes. Therefore, the recombinant antigen used in this study may have a 
different conformation to natural envelope protein expressed on the surface of the virion and sub-
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viral particles synthesised by HBV-infected hepatocytes. Cells labelled in this way may also include 
some B cells with low affinity for the antigen. These cells likely would not have the capacity to 
recognise and generate a response against the antigen in vivo (Smith et al., 2017).  
 
With further manipulation of the culture medium it may be possible to enhance the differentiation 
of B cells from patients with CHB. For instance, studies have indicated that the co-stimulation by 
CD40-ligand expressing feeder cells can improve differentiation to anti-HBs secreting cells 
(Salimzadeh et al., 2018). In line with this, a recent report demonstrated the potential importance of 
the OX40/OX40-ligand axis in maintaining HBV chronicity in a transgenic mouse model of CHB 
(Publicover et al., 2018). OX40 agonists were shown to successfully promote CD8 and B cell 
responses, ultimately leading to an increased likelihood of HBV clearance. These data provide 
important insights into new therapeutic approaches towards functional cure of HBV that should 
aim to induce co-ordinated T and B cell approaches. In order to identify targets, we must first 
understand the mechanisms by which this population may be functionally restrained. To do so, it 
will be critical to ascertain the phenotype of HBsAg-specific B cells, addressed in the next chapter.  
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Chapter 4 B cells with an atypical memory phenotype are 
expanded in CHB 
 
Chapter overview 
It is increasingly recognised that chronic infections can be accompanied by substantive changes to 
the composition of the memory B cell compartment. These alterations have been postulated to 
result in significant impairments in the generation of humoral immunity. In the previous chapter, I 
showed that HBsAg-specific B cells persist in the circulation of patients with CHB, yet have an 
impaired ability to differentiate into anti-HBs-producing cells. In this chapter, I address 
mechanisms that may be responsible for restraining the antiviral potential of antigen-specific 
B cells, by examining the phenotype and antiviral function of memory B cell subsets within the 
global and antigen-specific compartments of patients with CHB.  
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4.1 Introduction 
4.1.1 CD27-CD21low/- B cells – atypical memory B cells 
Chronic immune stimulation is associated with perturbations of B cell and T cell responses. One 
such phenomenon is the expansion of CD27-CD21low/- B cells in response to chronic antigen 
stimulation that have several characteristics of dysfunctional memory B cells. These cells are 
referred to variously as “exhausted memory B cells” or “tissue-like memory B cells” in HIV and 
“atypical memory B cells” in malaria; however, cells with a similar phenotype are also found to be 
expanded in a number of autoimmune conditions and in ageing healthy individuals, although their 
role is yet to be properly elucidated. For ease, these cells will be referred to as atypical memory 
B cells (atMBCs) throughout, unless otherwise specified.  
First described in the tonsils, CD27-CD21low/- B cells were shown to produce immunoglobulin 
(IgM/G/A) when stimulated with IL-2, IL-10 and CD40-L (Ehrhardt et al., 2005). These cells 
displayed morphological similarities to plasma cells, yet were transcriptionally distinct, expressing 
lower levels of Blimp-1, spliced XBP1 and IRF4 – key transcriptional regulators of plasma cell fate. 
Despite transcriptionally resembling plasma cells, CD27-CD21low/- B cells displayed many markers 
characteristic of memory populations, including CD69, CD80 and CD86. However, unlike 
conventional memory B cells, they lacked expression of CD27, and expressed high levels of the 
integrin CD11c, alongside a newly characterised inhibitory receptor, Fc receptor-like protein 4 
(FcRL4) - shown to bind IgA. In vitro studies demonstrated that CD27-CD21low/- were unresponsive 
to BCR stimulation, yet could proliferate and produce immunoglobulin in response to cytokines 
and CD40 stimulation. Follow-up work, using more discriminatory antibodies, has since 
characterised subsets within the CD27-CD21low/-  population that express the closely related 
receptor, Fc receptor-like protein 5 (FcRL5) (Li and Tolnay, 2017). Due to their location in the 
tonsils, it was postulated that these cells might be adapted to their local environment; however, the 
function of CD27-CD21low/- B cells in this setting remains unclear. 
 
Humoral dysfunction in infectious and inflammatory settings has previously been associated with a 
reduction of CD21 expression on B cells in both human HIV infection (Benedetto et al., 1992; 
Scott et al., 1993) and in animal models of inflammatory disease (Takahashi et al., 1997; Takamatsu 
et al., 1999). CD21 (complement receptor 2; Cr2) is expressed on the surface of mature 
lymphocytes and interacts with CD19 and CD81 to form the B cell co-receptor (Carroll, 1998). 
Co-ligation of the BCR and co-receptor complex assists in lowering the threshold level of antigenic 
stimulation required by the cell to activate. This was first demonstrated through experiments using 
anti-IgM and anti-CD21 monoclonal antibodies whereby co-ligation of CD21 decreased the 
amount of anti-IgM required by the cell in order to proliferate (Carter and Fearon, 1992). In line 
with this, cross-linking of CD21 in instances where B cell activation is sub-optimal (i.e. without 
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BCR stimulation), can assist in B cell activation (Tedder et al., 1994). In particular, the presence of 
CD21 within the co-receptor complex has been postulated to act as an important focal point in the 
transduction of signals from the innate immune system to regulate humoral immunity. These 
signals are transduced through the binding of CD21 to its ligand C3d - a component of the 
complement pathway that binds to the pathogen surface and targets it to B cells and FDCs. Initial 
evidence for the role of CD21 in regulating humoral immunity came from the finding that CD21-/- 
mice had significant impairments in antibody production, and both primary and secondary humoral 
immune responses to T cell dependent antigens (Ahearn et al., 1996). Additional work later 
suggested that the expression of the CD19/CD21 complex leads to enhanced processing of 
complement-tagged antigens and augmented presentation to T-helper cells (Cherukuri et al., 2001).  
 
4.1.2 atMBCs in chronic viral infection 
Early work suggested that HIV-viraemia was associated with an expansion of a B cell 
subpopulation that expressed lower levels of CD21. In comparison to CD21high B cells, CD21low 
B cells exhibited reduced proliferation and increased propensity towards cell death (Moir et al., 
2001, 2004). Upon further investigation, it was suggested that among CD21low B cells were two 
distinct populations of memory B cells – “activated memory B cells” CD27+CD21low/- B cells and 
“tissue-like memory B cells” CD27-CD21low/- – that were expanded in the peripheral blood of 
HIV-infected patients compared to healthy controls (Moir et al., 2008). This latter population could 
be further defined by the expression of FcRL4 - a Fc receptor homologue with the ability to inhibit 
BCR signalling via recruitment of the Src homology 2 domain-containing phosphatase 1 (SHP-1) 
(Ehrhardt et al., 2003). These cells also expressed additional B cell inhibitory molecules, including 
CD22, CD72, LAIR-1 and CD85j (Moir et al., 2008). Akin to inhibitory receptor expression on 
exhausted T cells in models of chronic infection (Wherry et al., 2007), these cells were suggested to 
represent an equivalent population of dysfunctional B cells that accrued as a result of chronic 
antigenic exposure.  
Indeed, tissue-like memory B cells were shown to have defective proliferation and decreased 
immunoglobulin diversification, leading to the production of lower specificity antibodies (Moir et 
al., 2008). siRNA knock-down of inhibitory molecules on their cell surface led to moderate rescue 
of BCR-mediated proliferation, and improved differentiation to HIV-specific antibody secreting 
cells (Kardava et al., 2011). Importantly, cells of this phenotype were shown to be concentrated in 
HIV-specific B cell populations (Kardava et al., 2014; Knox et al., 2017) pointing to a role in 
chronic antigen exposure in the development of this dysfunctional population. Comparatively, B 
cells against short-lived infections such as influenza and tetanus were enriched within classical 
memory, CD27+CD21+ populations (Kardava et al., 2014). 
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In HIV-infection, activated memory B cells (CD27+CD21low/-) also constitute a significant 
proportion of gp-140-specific B cells (Moir and Fauci, 2013). These cells are generally described as 
an intermediary population between classical IgG+ memory B cells and CD27-CD21low/- B cells 
(Kardava et al., 2014; Moir et al., 2008). Activated memory B cells express the highest levels of 
activation markers of all subsets considered, including CD95 and CD80, and demonstrate a 
predisposition towards apoptosis (Moir and Fauci, 2013). Overall, an expansion of dysregulated 
antigen-specific cells is postulated to contribute to the inefficiency of the humoral immune 
response in HIV-infected patients.  
 
4.1.3 atMBCs in malaria 
In a manner similar to chronic viral infections, protective immunity to Plasmodium falciparum (Pf.) can 
take years to develop and requires repeated exposures. In the absence of re-exposure, 
immunoglobulin levels decline and humoral immunity to infection wanes (Kinyanjui et al., 2007). 
Thus, it is thought that humoral immunity is not efficiently formed, or is functionally impaired in 
malaria. Evidence for the formation of memory B cells in malaria is conflicting: memory B cells 
were undetectable despite the presence of antibodies to blood-stage antigens (Dorfman et al., 2005; 
Wipasa et al., 2010), yet others found that memory B cells were induced incrementally with 
repeated seasonal exposure (Weiss et al., 2010) and could be long lived (Ndungu et al., 2012). 
Combined, these data suggest that Pf. infection induces memory B cell responses, but is less 
efficient than other infections or vaccinations that induce long lasting protection. 
In accordance with B cell responses in HIV infection, one explanation for this may be antigen-
driven expansion of dysregulated atypical memory B cells (atMBC). These cells are significantly 
enriched in individuals living in malaria-endemic areas and, similar to tissue-like memory B cells, 
express high levels of inhibitory receptors, including FcyRIIB, CD85j and CD22. Indeed, genome 
wide expression profiling of B cells in malaria patients revealed a high degree of overlap between 
genes found to be highly expressed in atMBCs, and tissue-like memory B cells in HIV-infected 
individuals (Portugal et al., 2015). However, in contrast to tissue-like memory B cells, malaria-
induced atMBCs did not express FcRL4, and instead expressed high levels of the closely related 
molecule FcRL5. atMBCs expressing FcRL5 were significantly more impaired in their ability to 
secrete antibody, relative to FcRL5-negative counterparts (Sullivan et al., 2015). In line with high 
FcRL5 expression, atMBCs displayed an impaired ability to respond to BCR cross-linking through 
reduced phosphorylation of key BCR signalling molecules (Portugal et al., 2015). In contrast, other 
reports suggest that atMBCs are highly activated and can secrete neutralising antibody (Muellenbeck 
et al., 2013). Several observations have since linked the expansion of atMBCs to chronic exposure 
to Pf., showing clear correlations between the frequency of atMBCs and the intensity of parasite 
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transmission (Ayieko et al., 2013; Illingworth et al., 2013; Muellenbeck et al., 2013; Nogaro et al., 
2011; Portugal et al., 2012, 2015; Weiss et al., 2009).  
 
4.1.4 CD27-CD21low/- B cells in ageing and autoimmunity  
An expansion of CD21low B cells with many similarities to atMBCs has now been described in 
numerous models of autoimmunity, where they are thought to directly contribute to the production 
of autoreactive humoral responses. In contrast to chronic viral infections, these cells are more 
commonly characterised by expression of the integrin CD11c, in combination with low or negative 
expression of CD21. 
CD21lowCD11c+ B cells are enriched in the blood of elderly individuals (³65 years) relative to 
younger controls (Colonna-Romano et al., 2009; Frasca et al., 2017), and in the spleen of aged mice 
(Hao et al., 2011; Knode et al., 2017; Ratliff et al., 2013; Rubtsov et al., 2011; Rubtsova et al., 2015). 
These cells were shown to proliferate robustly in response to TLR stimulation, yet demonstrated 
diminished responses to BCR ligation. At present, their role in healthy individuals is poorly 
understood. One possible outcome of their expansion in healthy individuals may be the 
dysregulation of TFH responses. Whilst it was shown that age-associated B cells were potent 
antigen-presenting cells (Rubtsov et al., 2015), in vitro co-culture of age-associated B cells skewed 
differentiation of naïve CD4 T cells towards a Th17 phenotype (Hao et al., 2011). Therefore, it is 
possible that the antigen-presenting capacity of age-associated B cells differs from that of 
conventional APCs. In addition, age-associated B cells have also been postulated to inhibit the 
survival of early B cell subsets (pro-B cells), thereby disrupting normal lymphopoesis in aged 
individuals (Riley et al., 2017). 
Several groups have described an expansion of CD21lowCD11c+ B cells in settings of autoimmunity, 
including in patients with common variable immune deficiency (CVID) and rheumatoid arthritis 
(Isnardi et al., 2010; Rakhmanov et al., 2009; Warnatz et al., 2002). These cells expressed a unique 
array of chemokine receptors, including CXCR3 and CXCR6, supporting their migration towards 
inflammatory tissue sites, and their accumulation in the bronchoalevolar space and synovial fluid 
(Rakhmanov et al., 2009). Similar to atMBCs, these cells were hyporesponsive to BCR triggering, 
demonstrated by decreased calcium flux and proliferation upon stimulation. Importantly, these cells 
are thought to contribute to the formation of humoral autoimmunity. CD21low populations in 
CVID are enriched for autoreactive BCRs capable of recognising nuclear and cytoplasmic 
structures (Isnardi et al., 2010); likewise, in murine models of lupus-like disease, depletion of 
CD11c+ age-associated B cells reduced the amount of autoantibodies detected in the serum 
(Rubtsov et al., 2011). 
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CD10-CD27-CD21low/- B cell populations similar to atMBCs, that fail to respond to either BCR or 
TLR stimulation, are also expanded in settings of HCV-associated mixed cryoglobulemia (Charles 
et al., 2008; Visentini et al., 2012). Similar cells were also enriched in HCV-associated cirrhosis, 
where they were again hypo-proliferative in response to BCR stimulation, but retained a similar 
capacity for antibody production relative to conventional memory B cells (Doi et al., 2014). 
The commonalities of CD27-CD21low/- B cells in chronic infection and autoimmunity are 
summarised in Figure 4.1. 
 
 
 
Figure 4-1 Summary of CD27-CD21low/- B cells described in HIV infection, malaria and autoimmunity 
CD27-CD21low/- B cells are expanded in settings of HIV-infection, malaria and autoimmunity where they demonstrate 
hypo-responsiveness to BCR stimulation and altered expression of lymphoid homing receptors. In particular, CD27-
CD21low/- B cells in chronic infection can be characterised by upregulation expression of inhibitory receptors.  
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4.1.5 T-bet expression in B cells 
Common to atMBCs, tissue-like memory B cells and age-associated B cells is the expression of 
molecules not generally expressed by classical memory B cells, including CD11c and the 
transcription factor T-box expressed in T cells (T-bet) (Myles et al., 2017). T-bet was first identified 
as an essential regulator of naïve CD4 T cell differentiation within the Th1 lineage. Since then, 
T-bet has also been shown to be influential in regulating the development and effector functions of 
NK cells, CD8 T cells, dendritic cells, monocytes and now B cells (Kallies and Good-Jacobson, 
2017; Simonetta et al., 2016; Zhang et al., 2018). Co-ordinated expression of T-bet throughout the 
immune system is thought to promote Th1 responses; for instance, T-bet expression has been 
shown to drive cytolytic responses in CD8 T cells, whilst simultaneously repressing Th2 responses 
(Oestreich and Weinmann, 2012). One of the first observations of T-bet in murine B cells showed 
that expression promoted production of IFNg, where B cells had been stimulated through CD40-
ligation and in the presence of Th1 cytokines (Szabo et al., 2000). IFNg production by B cells was 
in turn associated with promotion of CD4 T cell differentiation, and accordingly Th1 polarisation 
of B cell responses. To date, numerous studies have shown T-bet expression on memory B cells in 
inflammatory and infectious disease settings (reviewed in Karnell et al., 2017).  
T-bet+ B cells have recently been shown to expand in both HCV and HIV infection (Knox et al., 
2017), with commonalities in cell surface marker expression linking this increased expression of 
T-bet to the previously described expansion of CD27-CD21low/- B cells. In HIV, peripheral T-bethi 
B cells demonstrate decreased expression of CD21, concurrent with inhibitory receptor expression 
and in line with descriptions of dysfunctional tissue-like memory B cells (Knox et al., 2017; Moir et 
al., 2004, 2008). Moreover, T-bet+ memory B cells expressed elevated levels of CXCR3, in 
accordance with its elevated expression on atMBCs (Moir et al., 2008; Weiss et al., 2009) and other 
CD21low B cell subsets (Rakhmanov et al., 2009). 
T-bet expression in B cells isolated from patients with HCV has been directly linked to persistent 
antigenemia. T-bet+CD27-CD21low/- B cells were significantly increased in the periphery of patients 
with chronic HCV infection, relative to healthy controls (Chang et al., 2017). Maintenance of T-bet 
expression was dependent on sustained viraemia, whereby effective antiviral treatment reduced the 
number of T-bet+ atMBCs. In vitro experiments demonstrated that exposure of B cells to HCV-
viraemic plasma led to an expansion of T-bet+ B cells with a CD27-CD21low/- phenotype. In 
contrast, exposure of B cells from HCV-resolved individuals to pre-treatment serum re-induced 
T-bet expression (Chang et al., 2017).  
A recent study shed light on the mechanisms by which viral infection may promote T-bet 
expression, demonstrating that engagement of the BCR, TLR-7 (capable of detecting viral single-
stranded RNA (Sepehri et al., 2016)) and IFNγ receptors in B cells played a synergistic role in 
driving the expression of T-bet in B cells (Rubtsova et al., 2013). In line with this, malaria-induced 
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IFNg stimulation similarly induced the expansion of T-bethi atMBCs, whereby exposure of naïve 
B cells to the supernatants of malaria-exposed PBMCs led to the induction of T-bethi cells with 
commonalities to atMBCs, that could be abrogated via IFNg blockade (Obeng-Adjei et al., 2017). 
Thus, viral infection can be a significant driver in the expression of T-bet in memory B cells. In the 
absence of IFNg, T-bet expression can be induced in TLR-activated B cells via a complex 
reciprocal relationship of TFH-associated cytokines, namely IL-4 and IL-21 (Naradikian et al., 
2016a). IL-21 has since been shown to drive age-associated B cells in autoimmune mice via 
regulation of the transcription factor, interferon-regulatory factor-5 (IRF5) (Manni et al., 2018). 
The common expression of inhibitory and migratory markers, coupled with decreased expression 
of CD21, on atMBCs and T-bethi memory B cells in chronic infection, make it tempting to suggest 
that a T-bet driven transcriptional program may regulate the formation of atypical memory. 
However, how these cells contribute to viral disease remains unclear and appears to contradict the 
description of atMBCs as a dysfunctional cell population. Recent studies in murine LCMV infection 
have implied that T-bet+ B cells may be critical to control of persistent viral infections. Specifically, 
T-bet regulates immunoglobulin class-switching to IgG2a/c in mice (Peng et al., 2002; Rubtsova et 
al., 2013) – the key antibody isotype involved in murine Th1 responses. Furthermore, sustained 
T-bet expression was required by IgG2a+ memory B cells for their survival and functionality (Wang 
et al., 2012). As IgG2a (equivalent of IgG1 in humans) is the most efficient inducer of antibody-
mediated cellular cytotoxicity (Kipps et al., 1985), T-bet expression in B cells was postulated to 
drive viral clearance. Thus, mice that have lost T-bet expression in B cells develop persistent viral 
infection (Barnett et al., 2016). In humans, T-bet+ B cells positively correlated with the levels of 
antiviral IgG1 and IgG3 in patients with HIV infection, and were found to dominate the antigen-
specific response f. Thus, in the same way it promotes Th1 responses in T cells, T-bet can also be 
said to directly regulate antiviral responses by B cells.   
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4.2 Hypothesis and aims 
In this chapter, I assess the impact of HBV infection on global and antigen-specific B cells. As 
reviewed, chronic antigen stimulation has been postulated to drive the expansion of dysfunctional 
memory B cell subsets. As such, it was hypothesised that persistent stimulation of antigen-specific 
B cells by circulating HBsAg may lead to perturbations in the composition of HBsAg-specific 
memory B cells. An expansion of dysfunctional cells within this population may contribute to 
defects in humoral immunity, as observed in patients with CHB.  
 
The work presented in this chapter will aim to:  
1. Dissect the composition of HBsAg-specific memory B cells according to well-described 
memory B cell populations in vaccinated healthy controls and patients with acute-resolving 
and chronic HBV infection; 
2. Compare the phenotype of HBsAg-specific B cells in HBV-vaccinated healthy controls to 
patients with CHB; 
3. Analyse the antiviral function of memory B cell subsets with regard to BCR signalling, 
cytokine production and differentiation to antibody secreting cells; 
4. Identify putative targets for the rescue of HBsAg-specific responses in patients with CHB. 
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4.3 Results  
4.3.1 B cells with an atypical phenotype are enriched in the HBsAg-specific compartment in 
patients with chronic infection 
To investigate the noted defect in antibody production by HBsAg-specific cells circulating in CHB 
(Section 3.3.4), we first sought to dissect their composition according to well-described memory 
B cell subsets discussed above. To do this, we took advantage of the capacity to stain HBsAg-
specific B cells directly ex vivo, thereby allowing their characterisation by surface phenotype.  
Memory B cell subsets were defined using a multi-parametric sequential gating strategy, shown in 
Figure 4.2A. B cells were identified according to CD19 expression compared against CD3. By 
gating on CD19+CD3- lymphocytes, we excluded CD19-CD3- NK cells and CD19-CD3+ T cells 
from analysis. Expression of CD10 and CD20 was used to exclude immature transitional B cells 
and plasma cells/blasts respectively, on the basis that they may otherwise represent a proportion of 
CD21low/- B cells. Within the CD10- mature B cell population, memory B cell subsets were defined 
as follows: classical memory B cells (cMBC) CD27+CD21+; activated memory B cells (actMBC) 
CD27+CD21-; and atypical memory B cells (atMBC) CD27-CD21low/-. These gates were set through 
comparison to fluorescence minus one controls (FMO) (example in Figure 4.2B) and/or cross-
referenced to non-B cell populations of CD21low/- lymphocytes (namely T and NK cells) and CD27 
expression on total lymphocytes (expressed divergently on B, NK and T cells) (example in Figure 
4.2C). Mature naïve B cells, defined as CD27-CD21+CD10- B cells, were also excluded. 
Alternative flow cytometric approaches have also been described that distinguish naïve B cells from 
memory B cell subsets based on the expression of two developmentally regulated markers, CD38 
and CD24. This strategy identified peripheral B cell subsets as follows: CD19+CD38highCD24high as 
immature and transitional B cells; CD19+CD38intCD24int as mature naïve B cells; and 
CD19+CD38int/−CD24high as memory B cells (Vossenkämper et al., 2013). Within this latter 
population, atMBCs have been described to have decreased or negative expression of CD24 (Buffa 
et al., 2013; Rakhmanov et al., 2009; Thorarinsdottir et al., 2016). Therefore, we cross-referenced 
our gating strategy to this alternative phenotypic classification. In doing so, we showed that 
atMBCs have decreased expression of CD38 and CD24 relative to naïve and immature B cells 
(Figure 4.2D). Expression of CD38 was moderately diminished on atMBCs compared to CD24hi 
CD38int classical and activated memory B cells, with CD24 expression more significantly reduced, 
in line with previous reports. Thus, atMBCs are clearly distinct from other circulating populations, 
including naïve B cells and conventional memory B cell subsets.  
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Figure 4-2 Flow cytometric identification of peripheral atMBCs 
A. Sequential gating strategy for the identification of memory B cell subsets. Memory B cell subsets were identified on the 
expression of CD27 and CD21; (atypical ‘atMBC’ CD27-CD21-; activated ‘actMBC’ CD27+CD21-, classical ‘cMBC’ 
CD27+CD21+; gated on CD45+CD19+CD3-CD20+CD10- lymphocytes). B. Representative example of CD27 and CD21 
flow cytometric staining on mature B cells (blue; CD20+CD19+CD10-) compared to FMOs. C. Representative example 
of CD27 and CD21 staining on mature B cells (blue; CD20+CD19+CD10-) compared to CD45+ lymphocytes (grey). D. 
Representative example of the expression levels of CD38 and CD24 on memory B cell subsets, compared to naïve and 
transitional B cells.  
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Pre-gating on live CD45+CD3-CD20+CD19+CD10- HBsAg-specific B cells, we compared the 
contribution of each subset as a proportion of HBsAg-specific memory B cells in healthy 
vaccinated controls and patients with CHB (Figure 4.3A). Naïve B cells (CD10-CD27-CD21+) were 
excluded from analysis. Cells with a cMBC phenotype were the principal component of HBsAg-
specific B cells in healthy vaccinated controls (Figure 4.3B), consistent with generation of protective 
antibody responses upon vaccination. However, in patients with CHB, the HBsAg-specific cMBC 
population was contracted and replaced by B cells with an atMBC phenotype, alongside a smaller 
expansion of activated memory B cells (Figure 4.3B). atMBCs, and to a lesser extent activated 
memory B cells, constituted a larger proportion of HBsAg-specific B cells in patients with CHB 
compared to vaccinated healthy controls; in contrast, cMBCs were decreased as a proportion of 
HBsAg-specific B cells in patients with CHB relative to healthy vaccinated controls (Figure 4.3C). 
Given the limited expansion of actMBCs within HBsAg-specific B cells, analysis of HBsAg-specific 
memory B cells concentrated on comparative differences between cMBCs and atMBCs, henceforth. 
 
Figure 4-3 atMBCs are enriched within the HBsAg-specific compartment in patients with CHB 
A-B. Representative staining and cumulative data: HBsAg-specific memory B cell subsets (atypical ‘atMBC’ CD27-CD21-; 
activated ‘actMBC’ CD27+CD21-, classical ‘cMBC’ CD27+CD21+; gated on CD45+CD19+CD3-CD20+HBsAg+CD10-) in 
HBV-vaccinated healthy controls (vac HC; n=27) and patients with chronic HBV (CHB; n=73). Subsets are presented as 
a proportion of memory subsets (mature B cells (CD10-) minus naïve B cells (CD27-CD21+)). Each bar represents an 
individual. Individuals are ordered by increasing age (range: vac HC = 21-89yrs; CHB = 23-71yrs). C. Summary plots 
comparing the frequencies of HBsAg-specific memory subsets between vac HC (n=27) and patients with CHB (n=73). 
Error bars indicate means ± SEM; *, P < 0.05; ****, P < 0.0001; p-values determined by Wilcoxon signed-rank test (c). 
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We next examined factors that might be driving this expansion of atMBCs within the antigen-
specific compartment by comparing the frequency of HBsAg-specific atMBCs to pre-defined 
clinical parameters (outlined in Section 3.3.2). As CD27-CD21low/- B cells have previously described 
to expand with ageing (Colonna-Romano et al., 2009; Frasca et al., 2017), we first ruled out that the 
observed expansion was not attributable to age. The proportion of atMBCs within HBsAg-specific 
B cells did not correspond with the age of the individual, as indicated by the order of the bars 
(Figure 4.3B); thus, the expansion of atMBCs within HBsAg-specific B cells in patients with CHB 
was not associated with ageing. Likewise, the frequency of HBsAg-specific atMBCs was not 
affected by the degree of liver inflammation, as indicated by serum ALT level, nor showed any 
association with clinical phase of disease and viral load, as defined by EASL guidelines (Table 1.1.) 
(Figure 4.4A-C). However, the frequency of atMBCs as a proportion of HBsAg-specific memory B 
cells showed a weak inverse correlation with HBsAg load (R=-0.434; Figure 4.4D).  
 
Figure 4-4 Frequency of HBsAg-specific atMBCs according to clinical parameters 
A. Frequencies of atMBC as a proportion of HBsAg-specific memory B cells, correlated with levels of serum ALT (n=42) 
and B. stratified by disease phase: n=8 ‘HBeAg+ chronic infection’ (eAg+ CI; HBeAg+, HBV viral load > 107 IU/ml, 
serum ALT < 40 IU/litre); n=5 ‘HBeAg+ chronic hepatitis’ (eAg+ CH, HBeAg+, HBV viral load > 5 x 105 IU/ml, serum 
ALT > 60 IU/litre); n=10 ‘HBeAg- chronic infection’ (eAg- CI; HBeAg-, HBV viral load < 2000 IU/ml, serum ALT < 
40 IU/litre); and n= 6 ‘HBeAg- chronic hepatitis’ (eAg- CH, HBeAg-, HBV viral load > 5 x 105 IU/ml, serum ALT > 60 
IU/litre). C. Frequency of HBsAg-specific atMBC stratified by viral load: n=9 with HBV DNA < 2 x 103 IU/ml; n=11 
with HBV DNA 2 x 103 – 2 x 106 IU/ml; and n=15 with HBV ≥ 2 x 106 IU/ml; and D. correlated with HBsAg (IU/ml; 
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n=38). Error bars indicate mean ± SEM; p-values were determined by Spearman’s Rank correlation (a and d) and 
Kruskal-Wallis test with a Dunn’s post hoc test for pairwise multiple comparisons (b and c); where no p-value is shown, 
significance was not reached. 
 
This type of analysis only provided a snapshot of the antigen-specific memory compartment at the 
sampled time point. Thus, to expand on these data, we next examined the kinetics of HBsAg-
specific atMBCs in patients undergoing HBsAg-seroconversion during acute-resolving infection, in 
samples where there were sufficient numbers of HBsAg-specific B cell to reliably dissect antigen-
specific memory populations (cut off set at a minimum of 50 antigen-specific cells). Analysis of 
these samples facilitated temporal assessment of memory B cell subsets within the HBsAg-specific 
compartment according to dynamic changes in well-defined clinical characteristics within an 
individual, including viral load, ALT levels and presence/absence of viral proteins, namely HBsAg 
and HBeAg. The proportion of antigen-specific memory B cells with an atMBC phenotype (shown 
by the blue bars) decreased in line with falling levels of HBV DNA, and was particularly marked 
after HBsAg loss (Figure 4.5). Longitudinal sampling in one patient in particular (patient 08) 
allowed us to uniquely analyse HBsAg-specific atMBCs prior to the ALT flare characteristic of 
symptomatic acute infection i.e. during the pre-clinical phase of infection when viraemia is typically 
maximal (Dunn et al., 2009; Webster et al., 2000). These data suggested that HBsAg-specific 
atMBCs were elevated at the height of disease activity, and decreased following resolution of 
disease, supporting the role of HBsAg and disease activity in impairing antigen-specific B cell 
responses. 
 
 
Figure 4-5 Temporal analysis of HBsAg-specific atMBCs throughout the time course of acute-resolving 
HBV infection 
Temporal analysis of the frequency of HBsAg-specific atMBCs throughout acute-resolving HBV-infection. Percentage of 
HBsAg-specific atMBCs (blue bars) are plotted in relation to viral load (dotted line; IU/ml), serum ALT (dashed line; 
IU/litre) and serological status as indicated by the bars.  
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4.3.2 B cells with an atMBC phenotype are expanded in the global B cell compartment 
To investigate whether this expansion of atMBCs was exclusive to HBsAg-specific B cells, we next 
examined the global circulating B cell memory population (i.e. regardless of antigen-specificity). As 
in Section 4.3.1, memory B cell subsets were defined on the basis of CD27 and CD21 expression 
and are presented as a proportion of mature CD10- B cells. Whilst there was no significant 
difference in the frequency of global cMBCs between patients and healthy controls (Figure 4.6A), 
there was a significant expansion of atMBCs and activated memory B cells (actMBCs) in the global 
compartment of patients with CHB (Figure 4.6B). In contrast, naïve B cells were significantly 
decreased as a proportion of global B cells in patients with CHB (Figure 4.6C). Importantly, 
atMBCs represented a larger proportion of HBsAg-specific memory population (calculated as a 
proportion of combined memory B cell subsets) compared to the global B cell compartment, 
pointing to an enrichment of atMBCs within the antigen-specific pool (Figure 4.6D).  
 
 
Figure 4-6 atMBCs are expanded in the global B cell compartment in patients with CHB 
A-C. Frequency of global memory B cell subsets and (C) naïve B cells in patients with CHB (n=96) compared to healthy 
controls (vac HC; n=61). D. Paired analysis of cells with an atMBC phenotype in the global compared to HBsAg-specific 
compartment (n=49 patients with CHB). Frequency of atMBCs subsets are presented as a proportion of memory subsets 
(mature B cells (CD10-) minus naïve B cells (CD27-CD21+)). Error bars indicate means ± SEM; **, P < 0.01; ****, P < 
0.0001; p-values determined by Wilcoxon signed-rank test (a-d). 
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As previously, to investigate these changes in global atMBCs, we next examined the frequency of 
atMBCs according to clinical parameters. There was no difference in the frequency of global 
atMBCs when stratified by HBsAg load, serum ALT levels or disease phase (Figure 4.7A-C); 
however, there was a trend towards a higher frequency of atMBCs in patients with high viral loads 
indicative of hepatitis (³ 2x106IU/ml; defined by EASL guidelines; Figure 4.7D), suggesting that 
ongoing viral replication contributes to their accumulation. In line with this finding, the frequency 
of global atMBCs appeared to be higher in patients with acute HBV infection, and decreased when 
re-sampled at resolved time points, although this was not significant (Figure 4.7E).  
 
 
Figure 4-7 Association of global atMBCs according to clinical parameters 
A. Frequency of global atMBC correlated with HBsAg (IU/ml; n = 57) or B. serum ALT (n=84). C. Frequency of global 
atMBC stratified by disease phase, as defined in Fig. 4.4: n=12 ‘eAg+ CI’; n=11 ‘eAg+ CH’; n=30 ‘eAg- CI’; and n=13 
‘eAg- CH’; and D. stratified by viral load: n=26 with HBV DNA <2x103 IU/ml; n=24 with HBV DNA <2x103 - 2x106 
IU/ml; and n=25 with HBV ≥ 2x106 IU/ml. E. Analysis of the frequency of global atMBCs between HBV-acute and 
HBV-resolved time points. Error bars indicate mean ± SEM; p-values were determined by Spearman’s Rank correlation 
(a and b); Kruskal-Wallis test with a Dunn’s post hoc test for pairwise multiple comparisons (c and d); and Mann-Whitney 
U test for unpaired data (e); where no p-value is shown, significance was not reached. 
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To further investigate these results, we again extended our analysis to longitudinal data sets from 
three patients with acute-resolving infection. This revealed a tendency of global atMBCs to decrease 
in line with resolution of disease (Figure 4.8A). atMBC numbers appeared highest prior to the peak 
of serum ALT in two out of three patients. However, it is difficult to assess the starting levels of 
atMBCs in acute-resolving disease due to the late presentation of patients in clinic, typically around 
10-12 weeks following inoculation, by which point the burden of viral load has already been 
cleared. Instead, analysis of a chronically infected patient experiencing a flare in disease activity 
allowed us to examine changes in atMBCs frequencies in accordance with increasing viral load and 
ALT levels. This suggested that the frequency of atMBCs peaked prior to the rise in ALT levels and 
viraemia, and declined following the flare (Figure 4.8B). Combined, these data suggested that the 
expansion of global atMBCs is in part associated with disease activity and high levels of viral 
replication.  
 
Figure 4-8 Longitudinal sampling of global atMBCs during acute-resolving HBV-infection 
Longitudinal analysis of global atMBCs (% of CD20+CD19+CD10-) during A. acute-resolving infection and B. a patient 
with CHB undergoing hepatic flare. Percentage of atMBCs (black line) are plotted in relation to viral load (dotted line; 
IU/ml), serum ALT (dashed line; IU/litre) and serological status as indicated by the bars.  
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4.3.3 atMBCs are T-bethi and express markers indicative of impaired homing to lymphoid 
sites 
The differentiation of CD27-CD21low/- B cells has been previously associated with induction of 
T-bet following chronic exposure to antigen (section 4.1.5) (Myles et al., 2017). In line with this, 
T-bet expression was increased in atMBCs compared to counterpart cMBCs from within the same 
individual (Figure 4.9A). Accordingly, atMBCs represented the majority subtype within the T-bethi 
fraction (mean = 36%; Figure 4.9B). Gates delineating T-bethi/int/low fractions were set through 
comparison to the total lymphocyte fraction (representative example in Figure 4.9b): here, T-bet 
shows clear segregation, in line with data showing T-bet expression gradients in B and T cells 
(Knox et al., 2014; Obeng-Adjei et al., 2017).  
 
 
Figure 4-9 atMBCs in patients with CHB have upregulated expression of T-bet 
Representative examples and cumulative data. A. Expression of T-bet on global atMBC and cMBC (%; n=30). B. 
Percentage of memory B cell subsets within T-bethi, Tbetint or Tbetlo fractions (pre-gated on CD20+CD19+CD10-; n=15). 
Gates were drawn on total CD45+ lymphocytes, as shown. Error bars indicate means ± SEM; ****, P < 0.0001; p-values 
determined by Wilcoxon signed-rank test (a). 
 
CD27-CD21low/- B cells that are expanded in autoimmunity and ageing have been demonstrated to 
highly express the integrin CD11c, associated with their accumulation in inflammatory sites 
(Karnell et al., 2017). Accordingly, we next analysed the expression of CD11c, alongside other 
chemokine receptors responsible for directing the migration of B cells. atMBCs in CHB 
demonstrated an increased expression of CD11c when compared to cMBCs and to a matched 
isotype/FMO (Figure 4.10A). Expression of CD11c, and the liver homing chemokine receptor 
CXCR3, was increased within T-betint/T-bethi cells (Figure 4.10B), as previously described, 
indicative of localisation of T-bet+ B cells within inflammatory tissue sites (Karnell et al., 2017; 
Knox et al., 2017; Moir et al., 2008; Obeng-Adjei et al., 2017).  
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In contrast, expression of the lymph node homing receptor CXCR5 was decreased on atMBCs 
relative to cMBCs, suggestive of a decreased propensity to home to B cell follicles of lymph nodes 
(Figure 4.10C). 
 
 
Figure 4-10 Homing receptor profile on memory B cell subsets 
Represenative examples and cumulative data. A. Expression of CD11c (%; n=24) on global atMBC and cMBC in patients 
with CHB (solid lines), compared to FMO (shaded) and isotype control (dashed lines). B. Expression of CD11c (%; 
n=10) and CXCR3 (MFI; n=10) on Tbetlo (white), Tbetint (grey) or T-bethi (black) atMBCs. C. Expression of CXCR5 
(MFI; n=33) on global atMBCs and cMBCs in patients with CHB. Number displayed in representative plots indicate 
corresponding MFI. Error bars indicate mean ± SEM; **, P < 0.01; ****, P < 0.0001; p-values determined by Wilcoxon 
signed-rank test (a, and c); and Kruskal-Wallis test with a Dunn’s post hoc test for pairwise multiple comparisons (b). 
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In addition to decreased expression of lymphoid homing receptors, atMBCs also demonstrated 
reduced expression of co-stimulatory molecules, CD80 and CD40, compared to counterpart 
cMBCs (Figure 4.11A), suggestive of diminished activation and T cell help within lymphoid tissue. 
Accordingly, we next examined the levels of class-switching in memory B cell subsets. This was 
determined by ex vivo staining for IgM and IgD; cells that lack expression of both immunoglobulin 
isotypes can be deemed a class-switched population. The proportion of atMBCs that had 
undergone class-switching, and had down-regulated expression of IgM and IgD, was intermediate 
between cMBC and naïve B cells (Figure 4.11B) and in agreement with previous studies (Portugal et 
al., 2015). Activated memory B cells (CD27+CD21low/-) displayed the highest level of class-
switching, in line with their role as activated effector cells (Figure 4.11B).  
Combined, these data indicate that the expression profile of atMBCs does not support appropriate 
homing to secondary lymphoid organs, but may instead favour migration to inflamed tissue sites, 
such as HBV-infected liver. Impaired interactions with T helper cells, demonstrated by decreased 
expression of co-stimulatory molecules, may further impact on the functioning of these cells, as 
indicated by reduced levels of class-switching. 
 
 
Figure 4-11 Expression of co-stimulatory molecules on atMBCs compared to cMBCs 
A. Representative examples and cumulative data: expression of CD80 (MFI; n=30) and CD40 (MFI; n=30) on global 
atMBCs and cMBCs in patients with CHB, compared to FMO (shaded) and isotype control (dashed line). B. Frequency 
of class-switched cells (IgM-IgD-) as a percentage of naïve, cMBCs, actMBCs and atMBCs (n=39 patients with CHB). 
Error bars indicate mean ± SEM; *, P < 0.05; ****, P < 0.0001; p-values determined by Wilcoxon signed-rank test (a); 
and Kruskal-Wallis test with a Dunn’s post hoc test for pairwise multiple comparisons (b). 
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4.3.4 Global atMBCs in CHB express an array of inhibitory receptors 
Upon activation, lymphocytes transiently express co-inhibitory molecules that help to regulate 
responses - activated cells must overcome these signals in order to exert their full effector function. 
In chronic viral infections, virus-specific lymphocytes are often restrained by the persistent 
expression of co-inhibitory molecules, that are induced as a result of chronic antigenic stimulation 
(outlined in Chapter 1.3.3.1). Previous data have shown that atMBCs can be constrained by high 
levels of inhibitory receptors expression (Moir et al., 2008; Portugal et al., 2015). Therefore, we 
were interested to examine the expression of co-inhibitory signals on atMBCs as a possible 
mechanism by which antigen-specific B cells are suppressed in patients with CHB.  
To investigate this, we examined the relative expression levels of receptors shown to negatively 
regulate B cell activation. Expression of both B and T lymphocyte attenuator (BTLA) and CD22 – 
receptors involved in the negative regulation of BCR signalling - were significantly increased on 
atMBCs compared to counterpart cMBCs from within the same individual and above staining by a 
matched isotype (Figure 4.12A). Two additional receptors, FcgRIIB and FcR-like receptor-5 
(FcRL5; CD307), which bind to the Fc portion of antibodies (Franco et al., 2013; Karnell et al., 
2014), were also significantly enriched on atMBCs (Figure 4.12B). Finally the prototypic T cell 
checkpoint inhibitor, PD-1 (Zehn et al., 2016), was highly expressed on a subset of atMBCs but 
showed minimal expression on cMBCs (Figure 4.12C). PD-1 expression was particularly enriched 
on T-bethi atMBCs, at odds with the description of T-bethi B cells as key antiviral effector cells 
(Figure 4.12D). 
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Figure 4-12 Expression of inhibitory receptors on atMBCs compared to cMBCs 
Representative examples and cumulative data. Expression of A. BTLA (MFI; n=16) and CD22 (MFI; n=26); B. 
FcyRII1B (CD32b; MFI; n=30) and FcRL5 (%; n=83); and C. PD-1 (%; n=55) on atMBCs and cMBCs in patients with 
CHB, compared to FMO (shaded) and isotype control (dashed line). D. Expression of PD-1 (%; n=20) on Tbetlo (white), 
Tbetint (grey) or T-bethi (black) atMBCs. Error bars indicate mean ± SEM; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; 
p-values determined by Wilcoxon signed-rank test (a, b and c); and Kruskal-Wallis test with a Dunn’s post hoc test for 
pairwise multiple comparisons (d). 
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4.3.5 PD-1 expression is associated with antigen experience 
As receptor expression was not ubiquitous to all atMBCs, we next investigated whether there was a 
subset within CD27-CD21low/- B cells that preferentially expressed high levels of inhibitory 
receptors. To do so, we employed dimension reduction analysis on concatenated flow cytometric 
data of global B cells, using t-distributed stochastic neighbour embedding (tSNE). This analysis 
facilitates visualisation of high-dimensional data by grouping cells according to the similarity of cell 
surface marker expression. In doing so, tSNE is able to recognise associations between markers 
that may otherwise be missed using conventional gating (Thomas and Pallett, 2018).  
Visualisation by tSNE revealed that atMBCs clustered as two discrete populations when defined by 
the expression of FcRL5 in addition to the CD27-CD21low/- phenotype (Figure 4.13A). This 
segregation of FcRL5+atMBCs was driven by differential expression of IgM. As a result, atMBCs 
could be sub-divided into IgM+/-IgD+ cells and IgM-IgD- cells, likely representing a naïve-like, non-
class-switched sub-type and class-switched B cells respectively. Interestingly, when stratifying 
according to PD-1, we found that expression across all B cells was concentrated in CD27-CD21low/- 
B cells, particularly on those that were class-switched (IgM-IgD-FcRL5+ B cells lacking CD21 and 
CD27), implicating PD-1 as a hallmark of antigen-experienced atMBC in CHB (Figure 4.13A).  
Through examining healthy controls, HBV-inactive carriers (defined as having a viral load 
<2000IU/ml) and patients with elevated viral loads (defined as ³ 2000IU/ml), we showed that the 
subset of PD-1+ atMBCs was increased in patients with active HBV-infection; although some 
atMBC in healthy controls and low-level HBV carriers expressed PD-1, this proportion was more 
than doubled in HBV carriers with higher viral loads >2000IU/ml (Figure 4.13B). 
 
 
 
 
126 
 
Figure 4-13 Visualisation of PD-1 expression on B cell subsets 
tSNE analysis courtesy of Dr. Leo Swadling. A. Dimension reduction analysis visualised using tSNE identifying discrete 
populations of IgM+IgD+/- (red) and IgM-IgD- (blue) atMBCs based on the expression profile CD21-CD27- FcRL5+. PD-
1 expression on B cells was concentrated within IgM-IgD- atMBCs (purple cluster). tSNE analysis was performed on the 
expression data for the markers IgD, CD21, CD80, BAFF-R, CD10, CD11c, CD27, FcRL5, CD20, IgM, PD-1, CD38, 
CD24 as measured by flow cytometry on CD19+ events concatenated from patients with CHB (n=8) and vac HC (n=8). 
B. Frequencies of PD-1+ atMBC stratified by viral load (IU/ml): n=10 with HBV DNA <2x103; n=31 with HBV DNA 
≥2x103) and compared to healthy controls (HC; n=37). C. Clusters of CD24+FcRL5-CD27-CD21low/- B cells and 
CD38+FcRL5-CD27-CD21low/- B cells. Error bars indicate mean ± SEM; ***, P < 0.001; p-values determined by Kruskal-
Wallis test with a Dunn’s post hoc test for pairwise multiple comparisons (b). 
 
tSNE analysis also identified additional populations of CD38-CD24+ and CD38+CD24- atMBCs, 
although these were less discrete and did not express FcRL5, nor PD-1 (Figure 4.13C). CD38+ 
atMBCs in particular may represent a subset of antigen-experienced effector cells postulated to 
exist within CD27-CD21low/- fractions (Swain et al., 2017). 
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4.3.6 HBsAg-specific B cells in patients are enriched for markers of atMBCs 
To investigate whether these finding translate from global atMBCs to HBsAg-specific B cells in 
patients with CHB, we next examined the inhibitory receptor profile on HBsAg-bait binding cells 
identified directly ex vivo. Both FcRL5 and PD-1 were consistently enriched on HBsAg-specific 
B cells compared to their global B cell counterparts (Figure 4.14A, B). In addition, FcRL5- and PD-
1-expressing HBsAg-specific B cells were increased in patients with CHB relative to vaccinated 
controls (Figure 4.14A, B). Similarly, B cells expressing high levels of the transcription factor T-bet 
were increased by more than 2-fold in the HBsAg-specific compartment compared to global B cell 
compartment in patients with CHB, and compared to HBsAg-specific B cells in vaccinated healthy 
controls (Figure 4.14C). Accordingly, HBsAg-specific B cells also demonstrated elevated levels of 
CD11c expression and less CXCR5 compared to controls, suggestive of a preference for inflamed, 
non-lymphoid tissue (Figure 4.14D, E). Finally, CD40 expression was decreased on HBsAg-specific 
B cells from patients with CHB compared to vaccinated healthy controls, but showed no increased 
expression on HBsAg-specific compared to global B cells (Figure 4.14F). Combined, these data 
suggest that HBV-infection imparts significant changes on both global and HBsAg-specific B cells 
that may impact on their downstream function. 
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Figure 4-14 Phenotypic analysis of HBsAg-specific B cells in patients with CHB compared to HBV-
vaccinated healthy controls 
Representative examples and cumulative data: paired analysis of marker expression on HBsAg-specific B cells (black) 
compared to global B cells (grey) from within the same patient with CHB, and unpaired comparison of HBsAg-specific B 
cells in patients with CHB and vaccinated healthy controls (white). Expression levels of A. FcRL5 (%; n=60 patients with 
CHB; n=29 vac HC); B. PD-1 (%; n=66 patients with CHB; n=23 vac HC); C. T-bet (%; n=17 patients with CHB; n=11 
vac HC); D. CD11c (%; n=33 patients with CHB; n=16 vac HC); E. CXCR5 (MFI; n=33 patients with CHB; n=17 vac 
HC); and F. CD40 (MFI; n=15 patients with CHB; n=9 vac HC). Error bars indicate mean ± SEM; *, P < 0.05; **, P < 
0.01; ***, P < 0.001; ****, P < 0.0001; p-values were determined by Wilcoxon signed-rank test for paired data and Mann-
Whitney U test for unpaired data. 
 
4.3.7 atMBCs exhibit markers of attenuated BCR signalling  
Due to the dysfunctional phenotype of atMBCs and changes within HBsAg-specific B cells 
demonstrated ex vivo, we next examined the functional status of atMBCs compared to conventional 
cMBCs, aiming to understand how an enrichment of B cells with an atMBC phenotype, in 
conjunction with a decrease in cMBCs, within HBsAg-specific B cells may, contribute to impaired 
antiviral responses in CHB. Previous work has indicated that genes encoding BCR signalling and 
associated co-stimulatory molecules are down-regulated in atMBCs (Sullivan et al., 2015). This has 
been, in part, attributed to elevated expression of inhibitory receptors: FcRL5 expressing B cells are 
reported to be deficient in their ability to secrete cytokine and antibody in response to BCR 
stimulation, with FcRL5 shown to functionally impair memory B cells through direct suppression 
of B cell receptor signalling (Davis, 2015; Haga et al., 2007; Portugal et al., 2015; Sullivan et al., 
2015; Zhu et al., 2013).  
BCR signalling is central to regulating proliferation and effector function in B cells. Signal 
propagation from the BCR is mediated by multiple pathways, chiefly via phospholipase C-γ2 
(PLC-γ2) or phosphatidalyinositol-3-kinase (PI3K) pathways. PLC-γ2 activation, in particular, 
results in the accumulation of cytosolic calcium, which in turn induces the expression of 
transcription factors that contribute to the activation of B cells and determination of cell fate 
(Hogan et al., 2003).  
Therefore, to test the responsiveness of these cells to antigen, we measured calcium mobilisation 
following BCR engagement as a gauge of B cell signalling required for subsequent differentiation 
and effector function in B cells (Portugal et al., 2015). B cells were magnetically isolated from the 
PBMCs of patients with CHB and loaded with Fluo-4 AM calcium dye, prior to stimulation with 
F(ab’)2 anti-IgM/IgG/IgA specific antibodies or ionomycin. Calcium mobilisation was measured by 
flow cytometry. 5 x 105 B cells were stimulated and run at a high threshold to limit fluctuations in 
cell number that may otherwise account for variations in fluorescence and ensure that a continuous 
stream of each subset was recorded (Figure 4.15A, B). Ca2+ mobilisation was recorded over time 
and analysed according to B cell subset (Figure 4.15B). BCR crosslinking induced robust Ca2+ 
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mobilisation in cMBCs and activated memory B cells (actMBCs), in spite of the low frequency of 
actMBCs (Figure 4.15C). In contrast, Ca2+ mobilisation was markedly reduced in atMBCs following 
BCR-ligation, as shown by the difference in peak median fluorescence between the stimulated and 
unstimulated time points (Figure 4.15C). Naïve B cells showed weaker and delayed Ca2+ 
mobilisation compared to actMBCs and cMBCs, but above that of atMBCs, in line with data 
suggesting that naïve B cells require a greater threshold of activation following BCR engagement 
(Moens et al., 2016). When stimulated with ionomycin, overriding the BCR, all subsets 
demonstrated comparable ability to mobilise Ca2+, suggesting that impairment may be overridden 
by certain signals (Figure 4.15C). 
 
 
 
Figure 4-15 Ca2+ mobilisation in memory B cell subsets following BCR cross-linking 
A. Representative plot demonstrating the frequency of B cell subsets over the time course of BCR stimulation. B. 
Representative plot of staining identifying B cell subsets following BCR stimulation. C. Representative flow cytometric 
analysis of Ca2+ mobilisation (Fluo-4 AM; median fluorescence intensity) over time (s) in purified B cells after stimulation 
with either F(ab’)2 anti-IgG/IgA/IgM (anti-BCR; 50ug/ml) or ionomycin (1ug/ml) (n=10 patients with CHB). Basal 
fluorescence prior to stimulation is shaded in grey. Summary plot shows the difference in mean fluorescence intensity of 
Fluo-4 AM upon stimulation in B cell subsets compared to baseline. D. Expression of phosphorylated-BLNK (MFI; p-
BLNK) in global B cells after crosslinking with F(ab’)2 anti-IgG/IgA/IgM for 30 s (anti-BCR; n=8). Error bars indicate 
mean ± SEM; *, P < 0.05; **; p-values determined by Kruskal-Wallis test with a Dunn’s post hoc test for pairwise 
multiple comparisons (c) and Wilcoxon signed-rank test (d). 
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We next endeavoured to look at pathways upstream of Ca2+ mobilisation by examining the 
phosphorylation status of B-cell linker protein (BLNK), an adaptor molecule important in co-
ordinating B cell receptor signalling. Following BCR ligation, BLNK is phosphorylated by Syk and 
transduces signals that activate PLC-g2 and Ca2+ mobilisation (Ishiai et al., 1999; Kurosaki and 
Tsukada, 2000; Tan et al., 2001). Levels of phosphorylated-BLNK (p-BLNK) were decreased in 
atMBCs compared to cMBC upon BCR triggering (Figure 4.15D). Together, these data provide 
evidence to suggest that atMBCs may have attenuated B cell receptor signalling in response to 
antigen stimulation. This defect may impair activation of atMBCs, thus impacting on downstream 
antiviral function. However, more in-depth analysis of downstream messenger proteins is required 
to elucidate how BCR signalling may be impaired in atMBCs. 
 
4.3.8 atMBCs demonstrate impaired antiviral function 
Due to the impaired signalling and inhibitory profile of atMBCs, we next investigated their antiviral 
function by examining their capacity to secrete key antiviral cytokines in response to both T cell 
dependent and T cell independent stimulation. It is increasingly recognised that B cells can be an 
important source of cytokines in a number of settings, including viral infection (Das et al., 2012; 
Lin et al., 2002; Rosser and Mauri, 2015). In antiviral immune responses, B cell-derived cytokines 
promote the organisation of lymphoid structures and differentiation of effector and memory T cells 
(Section 1.4.7.1). However, they can also have direct acting effects on HBV itself (Shen and 
Fillatreau, 2015); both TNFa  and Interleukin-6 (IL-6) have been shown to have potent non-
cytolytic antiviral activity in HBV infection (Bouezzedine et al., 2015; Guidotti et al., 1996; Hösel et 
al., 2009; Palumbo et al., 2015; Xia et al., 2016). The production of these key antiviral cytokines by 
B cells has, to our knowledge, not yet been determined. 
To test this, PBMCs were stimulated using T-cell dependent or independent stimuli in the presence 
of Brefeldin-A to block egress of cytokines from the endoplasmic reticulum. Cells were then 
stained for the presence of intracellular cytokines, in combination with B cell phenotypic markers 
to permit subset identification. Stimulation was limited to 16 hours to avoid sizeable changes to B 
cell phenotype throughout the duration of the culture period. Crosslinking of the B cell receptor in 
association with CD40 stimulation demonstrated that CD27-CD21low/- cells secrete significantly less 
TNFa and IL-6 compared to CD27+CD21+ cMBCs (Figure 4.16A, B), indicative of impaired 
antiviral function.  
Previous reports have described atMBCs that do not respond to BCR signalling, but remain 
receptive to triggering through Toll-like receptors (TLR) (Portugal et al., 2017). Thus, we next 
assessed the ability of these cells to respond to TLR signals, independently of BCR signalling. 
TLR-7 is highly expressed on memory B cell subsets (Bernasconi et al., 2003), where it can bind 
viral single stranded RNA (Sepehri et al., 2016) and induce the secretion of cytokines, including 
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IL-6, IL-8 and IL-10 (Barr et al., 2007; Glaum et al., 2009; Hanten et al., 2008). atMBCs stimulated 
with R848 (TLR-7/8 agonist) were again significantly impaired compared to cMBCs in their ability 
to produce both cytokines (Figure 4.16A, B). Both atMBCs and cMBCs showed reduced cytokine 
production in response to BCR triggering relative to TLR stimulation; however, this was more 
marked on atMBCs, in line with their attenuated BCR signalling. Overal, these data suggest that 
atMBCs are impaired in their ability to secrete important antiviral cytokines, in line with previous 
reports (Portugal et al., 2015), and are hypo-responsive to typical B cell stimuli. Efficient activation 
of atMBCs may therefore require a combination of multiple stimuli.  
 
 
 
Figure 4-16 Antiviral cytokine production by memory B cell subsets 
Intracellular cytokine staining for A. IL-6 and B. TNFα in atMBC and cMBC after stimulation with F(ab’)2 
anti-IgG/IgA/IgM and CD40-ligand (anti-BCR; sCD40-L; n=10 patients with CHB) and R848 (Resiquimod; TLR7/8 
agonist; 1ug/ml; n=35 patients with CHB) for 16-18hrs. Frequencies are presented minus a paired unstimulated control. 
Frequency is presented minus a paired unstimulated control. Error bars indicate mean ± SEM; **, P < 0.01; ***, P < 
0.001; ****, P < 0.0001; p-values were determined by Wilcoxon signed-rank test (a and b).  
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4.3.9 atMBCs show impaired differentiation into antibody secreting cells 
The differentiation of memory B cells into antibody-secreting plasma cells is a key arm of B cell 
immunity in viral infections. Data discussed in the previous chapter showed that B cells from 
patients with CHB had impaired capacity to differentiate to anti-HBs secreting cells, detectable by 
ELISPOT (compared to healthy HBV-vaccinated controls), and did not produce protective levels 
of anti-HBs IgG in vitro. To understand whether this can be attributed to an expansion of atMBCs 
in patients with CHB, we next isolated matched numbers of atMBCs and cMBCs and compared 
their capacity to differentiate into ASCs. FACs-sorted cells were first activated using a TLR-9 
agonist (CpG-B), before being cultured with cytokines that promote plasma cell formation (IL-2, 
IL-15, IL-21, IL-6 and IFNa), as in Figure 3.4. Differentiation was determined post-culture by flow 
cytometry, with ASCs defined as IgD-CD38hiCD20lowCD27+CD138hi/int (Figure 4.17A). Due to 
limitations related to FACS-sorting of category two hazard material, the majority of this analysis 
was performed on healthy control samples. For comparison, a matched number of cMBCs were 
activated and cultured in complete RPMI only (Figure 4.17A bottom panel), which showed 
markedly impaired differentiation, as expected. 
Despite starting with the same number of cells, fewer atMBCs survived and acquired an ASC 
phenotype, compared to cMBCs from the same donor (Figure 4.17A, B). Staining for live cells 
using a fixable live/dead stain revealed that the viability of cultured atMBCs was significantly 
decreased relative to cMBCs (representative example in Figure 4.17C). Therefore, not only did 
atMBCs have a decreased ability to differentiate into ASCs, but they also demonstrated an increased 
propensity towards apoptosis, as was initially indicated by decreased survival of HBsAg-specific 
B cells isolated from patients with CHB, shown in Figure 3.9. Interestingly, those atMBCs that were 
able to survive and differentiate produced robust levels of total IgG, as measured by cytometric 
bead array, suggesting that a proportion of atMCBs within healthy individuals retain the ability to 
form functional ASCs (Figure 4.17D). Of note, atMBCs isolated from a patient with CHB (shown 
in black) showed markedly impaired differentiation to ASCs compared to counterpart cMBCs, in 
accordance with substantially reduced production of IgG (Figure 4.17B, D).  
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Figure 4-17 ASC differentiation of FACS-sorted memory B cell subsets  
A-B. Representative staining and cumulative data: atMBC were FACS sorted from healthy control blood (n=7; white) and 
one patient with CHB (black) and differentiated into plasma cells alongside a matched number of cMBCs. For 
comparison, a matched number of cMBCs were cultured in cRPMI without cytokines (bottom panel). B. Cumulative data 
shows the proportion of cells that acquire a plasma cell phenotype. Cells were analysed by flow cytometry, with plasma 
cells defined as CD45+CD19+CD3-IgD-CD38hiCD20-CD27+CD138+. C. Representative example demonstrating 
impaired survival of atMBCs relative to cMBCs during culture, as assessed using a fixable live/dead dye. D. Production of 
total IgG (ng/ml) measured in culture supernatant by cytometric bead array. Error bars indicate mean ± SEM; *, P < 
0.05; p-values were determined by Wilcoxon signed-rank test (b and d). 
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To further investigate apoptosis within atMCBs, we first stained PBMCs directly ex vivo for 
Annexin-V. Annexin-V binds phosphatidylserine which, when expressed on the cell surface, is used 
as a marker of cells in early stages of apoptosis (Mourdjeva et al., 2005). Positive staining was 
determined through comparison to an FMO and CD8 T cells (where positive staining was more 
defined) (Figure 4.18A).  
 
 
 
Figure 4-18 Ex vivo expression of apoptotic markers on B cell subsets 
A. Representative ex vivo staining for Annexin-V on B cells on atMBCs, compared to FMO and CD8 T cells.  
B. Percentage of cells expressing Annexin-V, stratified by cMBC and atMBC phenotype (n=10 patients with CHB).  
C. Expression of Bcl-2 (MFI) on cMBC and atMBCs (n=10 patients with CHB). D. Expression of Annexin-V stratified 
by PD-1 expression on total B cells (n=10 patients with CHB). Error bars indicate mean ± SEM; **, P < 0.01; p-values 
were determined by Wilcoxon signed-rank test (b-d). 
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Ex vivo atMBCs expressed higher levels of Annexin-V compared to counterpart cMBCs, suggestive 
of an increased propensity towards apoptosis (Figure 4.18B). In line with this, atMBCs had 
decreased expression of B cell lymphoma-2 (Bcl-2), an anti-apoptotic protein that protects cells 
from premature apoptosis (Chipuk et al., 2010; Merino et al., 1994) (Figure 4.18C). Interestingly, 
Annexin-V expression was also shown to be higher on PD-1+ B cells (Figure 4.18D), agreeing with 
previous reports associating PD-1 with cell death in B cells (Nicholas et al., 2013) and 
T lymphocytes (Freeman et al., 2006). 
The proportion of cells expressing Annexin-V ex vivo was low due to the relative viability of 
immediately thawed PBMCs. To test the predisposition of memory B cells towards apoptosis in 
culture, we next analysed Annexin-V expression in PBMCs following BCR simulation and 
CD40-ligation for 96 h. Cells were analysed according to memory B cell subset with Annexin-V 
gates set according to FMO on counterpart stimulated cells (Figure 4.19A). Following culture for 
this extended period of time, the proportion of cells with a CD27-CD21low/- phenotype had 
increased; however, in line with ex vivo data, CD27-CD21low/- B cells demonstrated an increased 
proportion of apoptotic cells compared to their counterpart cMBCs, indicative of increased 
susceptibility to cell death (Figure 4.19B). Again, Annexin-V expression was increased on PD-1+ 
B cells (Figure 4.19B), suggesting that PD-1 expression may associated with a propensity towards 
apoptosis. To further investigate this effect of PD-1 expression on apoptosis, we tested the effect 
of in vitro blockade of PD-1 following BCR stimulation and CD40-ligation using a monoclonal 
antibody. PD-1 blockade significantly decreased the proportion of atMBCs staining positive for 
Annexin-V, whilst a matched isotype control demonstrated no difference in Annexin-V expression 
on atMBCs following stimulation (Figure 4.19C). Combined, these data suggest that 
PD-1hi atMBCs exhibit increased propensity towards apoptosis, along with impaired differentiation 
to critical effector cells. This impaired survival and differentiation capacity of atMBCs may 
underscore the diminished production of anti-HBs in patients with CHB.  
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Figure 4-19 Expression of Annexin-V on atMBCs following in vitro stimulation 
A. Representative staining of Annexin-V on atMBCs after stimulation with F(ab’)2 anti-IgG and -IgM (1ug/ml) and 
CD40-L (0.5ug/ml) for 4 d. B. Percentage of cells expressing Annexin-V stratified by cMBC and atMBC phenotype 
(n=15) and by PD-1 expression on total B cells (n=7 patients with CHB), following BCR stimulation and CD40-ligation. 
C. Annexin-V expression on atMBCs stimulated ± anti-PD-1 mAb or matched isotype (clone EH12.2H7; 10ug/ml) for 
4 d (n=17). Error bars indicate mean ± SEM; *, P < 0.05; ***, P < 0.001; ****, P < 0.000; p-values were determined by 
Wilcoxon signed-rank test (b-c).  
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4.3.10 Antiviral function of atMBCs is partially rescued by in vitro PD-1 blockade 
Data collected thus far suggests that antigen-experienced atMBCs have upregulated expression of 
inhibitory receptors, which may in turn be responsible for repressing their function and/or 
promoting premature apoptosis. To further elucidate mechanisms of suppression at play, and to 
test putative immunotherapeutic targets for rescue of antiviral potential, we examined the effect of 
in vitro blockade of inhibitory receptors and assessed recovery of function by cytokine production.  
Blockade of PD-1 ligands, PD-L1 and PD-L2, has previously been shown by our group and others 
to rescue cytokine production in HBV-specific T cells in CHB (Boni et al., 2007; Schurich et al., 
2013). Initial evidence showed that PD-L1/2 blockade had minimal restorative effects on cytokine 
production by atMBCs stimulated overnight (data not shown). However, this could have been due 
to partially stimulatory effect of the PD-L1 mAb on B cells expressing this ligand. Therefore, we 
next tried blocking PD-1 receptor directly, as in previous reports. PD-1 blockade of B cells from 
patients with HIV improved responses to viral antigen associated with in increased expression of 
activation markers on treated cells (Nicholas et al., 2013). Similarly, in vivo PD-1 blockade in 
SIV-infected macaques enhanced antibody responses to non-SIV and SIV antigens, providing 
evidence for PD-1 mediated repression of humoral responses (Titanji et al., 2010).  
In vitro PD-1 blockade resulted in modest increases in the proportion of atMBC able to produce 
IL-6 after short-term BCR cross-linking, greater than that observed by the addition of an isotype 
control. Consistent with their lower expression of PD-1, cMBC did not increase IL-6 production 
upon PD-1 blockade (Figure 4.20). Combined, these data suggest that PD-1 may be partially 
responsible for restraining the antiviral function of atMBCs, and hint at the capacity for inhibitory 
receptor blockade to restore atMBC function.  
  
   
 
 
139 
 
 
Figure 4-20 IL-6 production by atMBCs following PD-1 blockade 
Intracellular staining for IL-6 on atMBCs and cMBCs, stimulated with F(ab’)2 anti-IgG and -IgM (1ug/ml) and CD40-L 
(0.5ug/ml) ± anti-PD-1 or matched isotype mAb for 16-18hrs (n=18). Frequency is presented minus a paired 
unstimulated control. Error bars indicate mean ± SEM; ****, P < 0.0001; p-values were determined by Wilcoxon signed-
rank test (a-c). 
 
4.3.11 Preliminary evidence showing partial rescue of antibody production in HBsAg-specific B 
cells by PD-1 blockade 
Accordingly, we were next interested in examining the effect of PD-1 blockade on the capacity of 
B cells to differentiate to anti-HBs secreting plasma cells, since reduced in vitro production of 
anti-HBs was demonstrated in B cells from patients with CHB (Chapter Three). Global B cells were 
magnetically enriched from PBMCs isolated from patients with CHB and stimulated as before in 
the presence of anti-PD-1 blocking mAb. Again, comparison to IgG-secretion, as measured by 
ELISPOT, confirmed that viable cells capable of producing antibodies were formed and seeded. 
PD-1 blockade increased the frequency of anti-HBs secreting cells in 4/7 patients tested; however, 
responses still remained minimal (Figure 4.21A).  
Hence, we hypothesised that additional signals may be required to rescue antibody production by 
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expressing CHO cell line as a surrogate for T cell help. This was performed in seven patients with 
CHB with data shown for the four patients who demonstrated anti-HBs production in any 
condition. Three patients failed to produce detectable anti-HBs responses in either condition, 
despite showing positive total IgG responses, and are not shown. Comparison to cells cultured in 
the presence of CD40-negative cells (performed where there were sufficient numbers of cells) 
showed that co-stimulation via CD40-ligand marginally increased anti-HBs responses in 2/5 
patients, irrespective of PD-1 blockade (patients three and four; Figure 4.21B, C).  
 
 
Figure 4-21 Effect of CD40 co-stimulation and PD-1 blockade on anti-HBs production 
A. Frequency of anti-HBs producing cells following polyclonal stimulation of purified global B cells ± PD-1 blockade, 
determined by ELISPOT. B-C. Representative ELISPOT-well images (B) and cumulative data (C) showing anti-HBs 
producing cells in B cells stimulated ± CD40-L-expressing feeder layer and ± PD-1 blockade. Experiment was performed 
in 7 patients with CHB; only those that had detectable results in any condition are shown. SFC; Spot Forming Cells. All 
ELISPOTS were performed using purified global B cells. Each assay was performed in triplicate and normalised 
according to the number of cells seeded (denoted in bold). 
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CD40 stimulation in the presence of in vitro PD-1 blockade had variable effects; some patients (e.g. 
patient two) showed a minimal decline in anti-HBs secretion following PD-1 blockade, whilst 
patient five showed a significant increase in the number of spot forming cells, suggestive of a partial 
recovery of anti-HBs production (Figure 4.21B, C). Overall, the effects of PD-1 blockade showed 
inconsistent responses; much more work on a larger cohort of patients is required to determine its 
efficacy. It is likely that additional mechanisms also contribute to restraining HBsAg-specific 
B cells. 
 
4.3.12 Preliminary evidence for a role of immune complexes in regulating atMBC/B cell 
responses 
The identification of inhibitory Fc receptors on atMBCs and HBsAg-specific B cells may also have 
important roles in the regulation of B cell responses in CHB. Recent work has demonstrated that 
FcRL5 binds intact IgG (Franco et al., 2013; Wilson et al., 2012), suppressing B cell activation in a 
similar way to the inhibitory Fc receptor, FcgRIIB (Karnell et al., 2014; Smith and Clatworthy, 
2010; Szili et al., 2014). Physiologically, these mechanisms likely have a role in tuning down 
antibody production by activated B cells once sufficient levels of immunoglobulin are detected. 
However, high expression of these inhibitory receptors in atMBCs raises the possibility that 
circulating immune complexes may crosslink Fc receptors and the BCR, resulting in suppression of 
BCR signalling. Moreover, expression of FcRL5 is thought to be induced upon sustained antigenic 
stimulation of the BCR (Damdinsuren et al., 2016). In this way, crosslinking of FcRL5, in 
combination with co-stimulation of BCR and TLR-9, results in a transient increase in FcRL5 
expression, and can drive the differentiation of naïve B cells to antigen-primed, switched B cells 
(Dement-Brown et al., 2012). Therefore, we were next interested in examining whether circulating 
HBsAg:anti-HBs immune complexes, a well-recognised feature of CHB, further contribute to the 
suppression of B cells in HBV (Gerlich, 2007).  
To begin to investigate this, we first isolated and cloned two anti-HBs antibodies – referred to as 
E6 and C7 - from a vaccinated healthy control, and generated immune complexes through 
incubation with recombinant HBsAg for two hours at 37°C (cloning was performed by Dr. Laura 
McCoy, Division of Infection and Immunity, UCL). Synthesised immune complexes underwent 
initial confirmation using size-exclusion chromatography to determine their relative size to 
individual, un-complexed components, with inconclusive results (collaboration with Prof. Mark 
Cragg and Dr. Richard Stopforth, University of Southampton). Supposed complexes made using 
C7 IgG (“C7 complex”) eluted at a similar point to HBsAg alone, possibly indicative of a failure to 
incorporate IgG or formation of smaller antibody-antigen complexes (Zhang et al., 2015). E6 
complexes were of a size more typical of immune complexes, as shown by comparison to a 
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reference immune complex. Both E6 and C7 IgG alone eluted later, indicative of their smaller size; 
however, they appeared much smaller than expected for unknown reasons (Figure 4.22A).  
Preliminary testing for a possible inhibitory effect on BCR signalling, was examined by the 
phosphorylation of BLNK (p-BLNK) after short stimulation with F(ab’)2 anti-IgM/IgG/IgA-
specific antibodies in the presence or absence of immune complexes. Cells stimulated in the 
presence of “C7 complex” showed suppressed phosphorylation in both total B cells (Figure 4.22B) 
and atMBCs (Figure 4.22C), shown by a shift in MFI compared to anti-IgM/G/A stimulation 
alone. Further analysis showed that stimulation in the presence of both C7 and E6 IgG alone 
suppressed B cells to a similar extent (Figure 4.22D, E), and at comparable levels to the C7 
complexes. However, the size-exclusion chromatography data indicated that C7 complexes did not 
represent IgG alone, suggesting that there may be some aggregation of anti-HBs IgG to HBsAg, 
that is able to exert an inhibitory effect on B cell activation. Alternatively, decreased 
phosphorylation in the presence of C7 complexes may be simply explained by sequestration of 
HBsAg by IgG, thereby prohibiting stimulation of B cells via HBsAg. Complexes consisting of E6 
IgG had a stimulatory effect compared to anti-IgM/G/A stimulation alone, comparable to the 
effect observed with HBsAg alone (Figure 4.22E). One interpretation may be that E6 complexes 
consist only of HBsAg, thus explaining the similarity to HBsAg alone, whereas C7 complexes 
represent true aggregates.  
Immune complexes were also tested using a luciferase assay for the detection of IC-mediated SHP-
1 recruitment to FcgRIIB (Stopforth et al., 2018) (Figure 4.22F). C7 “immune complexes” 
consisting of various ratios of C7 IgG to HBsAg were tested in comparison to PBS alone and a 
control immune complex. A 1 : 1 ratio of HBsAg to C7 IgG increased fluorescence above that of 
PBS alone and monomeric IgG, indicative of low-level binding to FcgRIIB (data courtesy of Dr. 
Richard Stopforth) (Figure 4.22F). However, this was significantly lower than that demonstrated by 
the control immune complex and not sufficient to confirm immune complex formation; further 
optimisation is thus required create definitive anti-HBs:HBsAg and test their effect on atMBCs. 
Finally, the suppressive effects observed using supposed immune complexes may be reflective of 
sequestration of HBsAg by IgG, therefore negating its stimulatory effect. Future studies should aim 
to test the effect of patient-isolated complexes on Ca2+ mobilisation and phosphorylation of BCR 
signalling components, and the subsequent impact of immune complex-mediated suppression on 
antiviral effector function. A recent paper lends support to this hypothesis, showing a role for IgG3 
in dampening BCR responses via FcgRIIB (Kardava et al., 2018). Moreover, secreted IgG3 was 
found bound to IgM-expressing B cells in vivo in HIV-infected, chronically viraemic individuals, 
revealing a new way in which antibodies are able to regulate humoral responses.  
One important consideration is that HBsAg incubated at this concentration alone may form 
multimers and exert some inhibitory effect itself (Siegler and Bruss, 2013). Therefore, we compared 
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HBsAg incubated for two hours at 37ºC with untouched HBsAg. When considering the percentage 
of cells expressing p-BLNK, “complexed” HBsAg was more suppressive than “uncomplexed”, in 
line with this prediction (Figure 4.22D, E).  
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Figure 4-22 Preliminary data investigating a role for immune complexes in suppressing atMBC function 
A. HBsAg-specific B cells were isolated via single-cell FACS-sorting and the k and heavy chains sequenced (experiments 
performed by Dr. Laura McCoy). 293T cells were transfected and cultured for five days at 37°C. Antibody-containing 
supernatant was collected and total IgG isolated using Protein G beads. Purified antibody was concentrated and immune 
complexes (IC) were made through incubation of 100 µg/ml of C7 or E6 anti-HBs IgG with 100 µg of HBsAg for 2 h at 
37ºC. Formation was assessed using size-exclusion chromatography and compared to C7 and E6 IgG alone and HBsAg 
alone (data courtesy of Dr. Richard Stopforth, University of Southampton). B-C. Representative example and summary 
data: phosphorylation of BLNK (p-BLNK; MFI) after stimulation with F(ab’)2 anti-IgM/A/G (20 µg/ml) in the presence 
or absence of IC in total B cells (B) and atMBCs (C) in patients with CHB (n=7). D-E. Phosphorylation of BLNK on 
total B cells (MFI and %) after stimulation with F(ab’)2 anti-IgM/A/G (20 µg/ml) in the presence or absence of IC, 
monomeric IgG alone or HBsAg alone (C7, D; E6, E). Untouched HBsAg was used for comparison. Solid lines connect 
paired samples from within the same individual (n=3). F. Comparison of IC binding to FcgRIIB determined by a 
luciferase assay, with and without a control IC, for scale (data courtesy of Dr. Richard Stopforth, University of 
Southampton). Error bars show mean ± S.E.M; *, P < 0.05; p-values were determined via Wilcoxon signed-rank test (b 
and c).  
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4.4 Discussion 
Ours is the first study to phenotypically analyse antigen-specific B cells in patients with CHB. Data 
in previous chapters revealed that HBsAg-specific B cells are present in the circulation of patients 
with CHB but show impaired ability to secrete anti-HBs. Here, we compared the phenotype of 
antiviral B cells in patients with CHB to those induced by HBV-vaccination. We show that HBsAg-
specific classical CD27+ memory B cells are depleted in the context of CHB infection relative to 
vaccine-induced immunity. In contrast, HBsAg-specific B cells in CHB, and to a lesser extent the 
global B cell compartment, are enriched for B cells with a T-bethi atypical phenotype, characterised 
by low or negative expression of CD27 and CD21. Through characterising global atypical memory 
B cells (atMBCs), we show that these cells have upregulated expression of a number of inhibitory 
receptors, particularly PD-1 and FcR-like receptor 5 (FcRL5). Accordingly, atMBCs demonstrated 
compromised antiviral function, characterised by attenuated Ca2+ mobilisation and impaired 
cytokine production in response to BCR triggering, and a diminished ability to differentiate into 
antibody-producing plasma cells. In vitro blockade of PD-1 suggested that dysfunction may be 
partially attributable to the increased levels of inhibitory receptors described in atMBCs, offering a 
potential target for enhancing B cell immunity in patients with CHB. However, further analysis is 
required to ascertain the mechanisms by which these cells are functionally restrained. Overall, we 
postulate that an expansion of PD-1hi global and HBsAg-specific atMBCs may result in impaired 
B cell-mediated antiviral immunity in patients with CHB. These findings are summarised in 
Figure 4.23.  
 
CD27-CD21low/- B cells have been described in various settings, providing clues to their roles in 
human disease. Accumulating evidence suggests that these cells arise following persistent microbial 
challenge, but also accrue as a result of ageing and in patients with autoimmunity. Combined, these 
data point to an expansion of atMBCs driven by persistent antigenic stimulation, whether by 
pathogenic- or self-antigen. In line with these reports, the accumulation of these cells in CHB 
appears to be, at least in part, driven by chronic exposure to HBV-viral proteins, as evidenced by 
the higher frequency of atMBCs in patients with ongoing infection, compared to healthy controls. 
Due to the high circulating levels of HBsAg in patients with CHB, it follows that atMBCs were 
enriched within the HBsAg-specific fraction during acute and chronic infection, and decreased 
following resolution of disease.  
We propose that the expansion of CD21low B cells may interfere with the formation of functional 
humoral immune responses in patients with CHB, whereby the normal development of memory 
B cells is subverted towards a dysfunctional phenotype. In contrast to autoimmune conditions, 
which describe them as a naïve-like, non-memory population, CD27-CD21low/- atMBCs cells have 
been carefully delineated as memory B cells in models of chronic infection and ageing 
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(Thorarinsdottir et al., 2016). Deep sequencing of VH regions suggested that atMBCs differentiate 
from cMBCs as a result of continued antigen exposure (Portugal et al., 2015). In these studies, 
atMBCs and cMBCs displayed comparable rates of somatic hypermutation and clonal expansion; 
analysis of cell divisions, via measurements of κ-deletion recombination excision circles, further 
confirmed that both cell types had undergone a similar number of cell divisions. These data were in 
agreement with studies of age-associated B cells, which showed a stochastic representation of 
variable light and heavy immunoglobulin genes, suggesting that they arise from within the full BCR 
repertoire (Knode et al., 2017). Clonality analysis of demonstrated evidence of a close clonal 
relationship between CD27+ and CD27- memory B cells (Wu et al., 2011). Combined, these data 
imply that atMBCs and cMBCs share a common ancestry and undergo similar antigen-driven 
expansion in the germinal centre.  
Activated, CD27+CD21low/- memory B cells also represent a population of antigen-experienced 
B cells, but are supposedly intermediate of cMBCs and atMBCs in terms of the extent to which 
they have undergone affinity maturation (Moir et al., 2008; Obeng-Adjei et al., 2017). Therefore, the 
expansion of these cells, within the global and antigen-specific B cell response, may equally detract 
from the generation of long-lived, specific and protective humoral responses. Based on these 
reports, we propose that chronic exposure to HBsAg perturbs formation of memory B cells, 
leading to an accumulation of dysfunctional atMBCs. However, further investigation of the BCR 
repertoire and immunoglobulin gene usage in memory B cell subsets and HBsAg-specific B cells in 
CHB, would reveal the extent to which these cells are shaped by chronic HBsAg stimulation, and 
the pathways by which they arise.  
 
Antiviral effector functions of memory B cells, such as antibody and cytokine production, are 
induced upon secondary encounter of antigen by the BCR. Binding of antigen triggers complex 
signalling events that not only control the proliferation of the cell, but also determine downstream 
differentiation and function. In this regard, CD27-CD21low/- B cells have been described as hypo-
responsive to BCR stimulation, demonstrated by diminished proliferation and immunoglobulin 
secretion following BCR crosslinking (Charles et al., 2008; Isnardi et al., 2010; Portugal et al., 2015; 
Rakhmanov et al., 2009). We showed that in vitro stimulation of the BCR resulted in poor Ca2+ 
mobilisation in atMBCs relative to CD27+ memory B cells, and an impaired ability to secrete 
antiviral cytokines.  
The observed defect in BCR signalling and Ca2+ flux may have important implications in the 
resulting effector function of atMBCs. Ca2+ mobilisation is involved in the regulation of 
transcription factor expression, including NFAT and NFkB, that in turn control cell activation and 
differentiation (Hogan et al., 2003; Scharenberg et al., 2007). The reduced Ca2+ mobilisation 
demonstrated by atMBCs may be the reflective of differences in immunoglobulin isotype 
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expression, as IgG+ B cells have been shown to have amplified responses to BCR triggering relative 
to naïve or IgM+ memory B cells (Davey and Pierce, 2012). However, ex vivo analysis suggested that 
a higher proportion of atMBCs were class-switched relative to naïve B cells, yet both subsets 
displayed comparable levels of Ca2+ mobilisation following BCR stimulation.  
Further analysis of signalling pathways downstream of the BCR could help pinpoint defects in 
atMBC responses in patients with CHB. Analysis of activation levels of Syk may be particularly 
informative, as Syk has been shown to be the key signal transducer required for coupling the BCR 
to downstream signalling pathways in mature B cells. Ackermann et al., showed that the presence 
of Syk is required for the activation and class-switching of B cells in response to BCR stimulation 
and CD40-ligand stimulation respectively. They demonstrated that Syk-deficient B cells fail to 
differentiate into germinal centre or plasma B cells, and have defective antibody responses 
following T-dependent stimulation (Ackermann et al., 2015). Thus, defects in the activation of Syk 
in atMBCs may account for many of the failings in antiviral function observed. 
Decreased Ca2+ flux was mirrored by an impaired ability to secrete cytokines following BCR 
crosslinking, indicative of impaired antiviral function of atMBCs in patients with CHB following 
antigen stimulation. This defect may have important consequences for the antiviral control of 
HBV. TNFa, together with IFNg, plays a central role in the non-cytolytic control of HBV, through 
the inhibition of virus replication and degradation of cccDNA in infected cells (Guidotti et al., 
1996; Xia et al., 2016). IL-6 has also been linked to cytokine-mediated inhibition of HBV, through 
modes of action such as the downregulation of the entry receptor on host cells (Bouezzedine et al., 
2015), and the disruption of viral transcription and cccDNA acetylation (Hösel et al., 2009; 
Palumbo et al., 2015). The maturation of B cells into immunoglobulin producing cells is also IL-6 
dependent (Muraguchi et al., 1988), with IL-6 shown to promote the generation of TFH cells and 
assist viral control in latter stages of infection (Harker et al., 2011). Our documentation of the 
aberrant production of IL-6 and TNFa by atMBC in CHB, therefore strongly implicates atMBCs 
in limiting antiviral responses.  
Of note, previous reports have described that whilst hypo-responsive to BCR stimulation, atMBCs 
can maintain responses to TLR stimuli. Our data indicated that both plasma cell differentiation and 
cytokine stimulation were significantly decreased in atMBCs relative to cMBCs, even when 
stimulated through TLR-ligands. It is possible that this is reflective of the nature of chronic 
stimulation occurring in CHB. Circulating antigen-specific B cells are exposed to high levels of TLR 
stimuli in the liver, in the form of microbial products draining from the gut (Henao-Mejia et al., 
2013). Moreover, CPG motifs have been identified in HBV viral particles, with HBsAg also shown 
to trigger TLR-9 (Tout et al., 2018). Therefore, in a similar manner to chronic antigen stimulation 
impairing responses to BCR signalling, persistent stimulation through TLR may result in a 
tolerisation of atMBCs to TLR triggering in patients with CHB. Overall, we postulate that atMBCs 
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require a higher threshold of activation than cMBCs, and may necessitate multiple stimuli prior to 
activation and differentiation. 
 
Decreased expression of CD21 may be partly responsible for both attenuating BCR signalling and 
effector function, as CD21, in the context of the BCR co-receptor, contributes to decreasing the 
threshold of stimulation required for B cell activation. However, additional defects are likely 
imparted by inhibitory receptors expressed by atMBCs and HBsAg-specific B cells. We postulate 
that this attenuation of BCR signalling, in combination with a loss of adaptive immune cell 
function, may be reflective of the upregulated expression of inhibitory receptors, including FcRL5 
and PD-1, as both are able to modulate B cell receptor signalling and downstream function. In 
mice, gain of FcRL5 expression is associated with a switch from adaptive to innate-like function (Li 
et al., 2014), with FcRL5 shown to exert binary, compartment-specific effects on BCR function in 
innate-like marginal zone B cells (Zhu et al., 2013). Comparatively, in human memory B cells, 
FcRL5 inhibits B cell activation by recruiting phosphatases SHP-1/2 to ITIM motifs in the B cell 
receptor, thereby inhibiting Ca2+ mobilisation and downstream signalling (Haga et al., 2007). Of 
note, FcRL5 demonstrates heterogeneous expression on atMBCs in CHB and on dysfunctional 
B cells from other chronic infections. Previous studies have shown that FcRL5+ cells have 
significantly deficient function compared to FcRL5- B cells (Li et al., 2016; Sullivan et al., 2015). 
These studies showed that FcRL5+ B cells had a decreased capacity to differentiate into ASCs and 
were more prone to apoptosis when cultured. Moreover, studies demonstrating defective 
phosphorylation of BCR signalling components, Syk, Plc-g2 and BLNK, in CD27-CD21low/- relative 
to CD27+ memory B cells, demonstrated attenuated signalling associated with increased expression 
of FcRL5 (Portugal et al., 2015).Therefore, it is likely that the FcRL5+ atypical memory B cells 
represent the most dysfunctional population.  
B cell expression of PD-1 is also associated with aberrant activation of B cells and resultant loss of 
function in the context of HIV and SIV infection (Nicholas et al., 2013; Titanji et al., 2010). Co-
ligation of PD-1 and the BCR inhibited Ca2+ mobilisation and tyrosine phosphorylation of BCR 
signalling molecules, including Syk and Plc-g2, in a manner similar to FcRL5 (Okazaki et al., 2001). 
Altering expression of these inhibitory receptors could therefore regulate the B cell response to 
antigen. A paper from Kardava et al., used siRNA knockdown to downregulate expression of nine 
inhibitory receptors preferentially expressed on CD27-CD21low/- B cells, including PD-1 and FcRL4 
– a closely related molecule to FcRL5 shown to be highly expressed on CD27-CD21low/- B cells in 
HIV. Downregulation of these molecules significantly increased BCR-induced proliferation and 
cytokine secretion (Kardava et al., 2011), suggesting that it may be possible to rescue the function 
of HBsAg-specific B cells in CHB through the repression of inhibitory receptors.  
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Consistent with this, we were able to modestly enhance the capacity of atMCBs from patients with 
CHB to secrete IL-6 via PD-1 blockade following BCR stimulation. In vivo PD-1 blockade in 
macaques infected with simian immunodeficiency virus (SIV) demonstrated enhanced proliferation 
of memory B cells and production of SIV-envelope specific antibodies, concurrent with expansion 
of virus-specific T cells (Velu et al., 2009). This may have had indirect effects via boosting of TFH in 
vivo; however, previous work in mice has demonstrated a PD-1 blockade dependent inhibition of 
TFH interactions in germinal centres (Good-Jacobson et al., 2010). The direct effects of PD-1 on B 
cells has been further demonstrated, again in SIV-infected macaques, showing preferential 
depletion of PD-1 expressing memory B cells in vivo, and an increased susceptibility to PD-L1-
dependent apoptosis in PD-1hiCD21- actMBCs in vitro (Titanji et al., 2010). This latter finding in 
particular supports our data showing a 3-fold decrease in apoptosis upon PD-1 blockade.  
In contrast, we were not able to detect significant recovery of anti-HBs responses upon PD-1 
blockade and CD40 co-stimulation, despite a back-to-back publication showing rescue of anti-HBs 
production in four patients with CHB (Salimzadeh et al., 2018). PD-1 blockade has shown marked 
variation in success between individuals, with in vitro assays reporting increased effector function of 
HBV-specific T cells in ~30-50% of patients sampled (Schurich et al., 2013). Therefore, it is 
possible that improved responses may be observed once expanded to a wider cohort of individuals. 
It is also possible that rescue of B cell effector function is counter-balanced by inhibition through 
Fc receptors, induced by binding of the Fc portion of monoclonal antibodies to inhibitory 
receptors on the B cell. Therefore, it is likely that additional signals, for example boosting of co-
stimulatory TFH function or blockade of synergistic inhibitory receptors, are required to optimise B 
cell recovery.  
Our data showed close association of PD-1 with the expression of the transcription factor T-bet, as 
also demonstrated in malaria, HCV and HIV (Chang et al., 2017; Knox et al., 2017; Obeng-Adjei et 
al., 2017; Portugal et al., 2015). T-bet expression was elevated in atMBCs compared to cMBCs, and 
as such, was significantly enriched in HBsAg-specific B cells from patients with CHB relative to 
vaccinated healthy controls. This finding is in stark contrast to data suggesting that induction of 
T-bet in virus-specific CD8 T cells represses PD-1 expression, and thus correlated with the 
functional recovery of exhausted T cells (Kao et al., 2011; Kurktschiev et al., 2014; Schurich et al., 
2013). Contrary to our findings, evidence emerging from murine models postulates that T-bet 
expression in B cells has a positive role in promoting viral clearance (Barnett et al., 2016), as 
outlined earlier. Moreover, findings from acute yellow fever and vaccinia vaccination demonstrated 
infection-induced activation of T-bethiCD27-CD21low/- B cells, suggesting that they actively 
participate in antiviral immunity (Knox et al., 2017). One interpretation may be that T-bet+ B cells 
may contribute to acute antiviral response, yet become dysfunctional when they are maintained for 
extended periods of time, such as in CHB. Alternatively, T-bethi B cells may represent functional, 
antigen-experienced B cells, however, function is restrained when expression coincides with 
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exhaustion-induced inhibitory receptor expression. This concept is supported by a recent study 
which showed that T-bet expression was associated with expression of the co-inhibitory molecule, 
FcgRIIB and inversely correlated with the efficiency of BCR signalling (Obeng-Adjei et al., 2017). 
These paradoxical findings are reminiscent of the complex role of PD-1 on T cells, associated with 
both activation and inhibition, limiting T cell function whilst also promoting long-term 
maintenance of immune-surveillance in the setting of chronic antigenic stimulation (Pallett et al., 
2017; Wherry and Kurachi, 2015; Zehn et al., 2016). As a result, T-bethiPD-1hiHBsAg-specific B 
cells may represent a favourable target to release from inhibition since they should be 
transcriptionally wired for antiviral efficacy. Further analysis of BCR signalling and antiviral 
function of PD-1-expressing B cells isolated ex vivo, as well as extension of data using anti-PD-1 
blockade, would provide definitive evidence on the role of PD-1 in B cells. 
 
The expansion of atMBCs and HBsAg-specific B cells expressing high levels of inhibitory receptors 
appears to be driven by chronic antigen stimulation. Analyses presented here indicated that the 
expression of inhibitory receptors on global atMBCs increases in accordance with active disease; 
PD-1hi atMBCS were highest in the patients with viral loads above 2000IU/ml, compared to those 
with low levels of HBV DNA and healthy controls. This finding is similar to data showing that 
virus-specific T cells have high levels of PD-1 expression occurring as a result of chronic antigenic-
stimulation (Boni et al., 2007). This interpretation is further supported by evidence that B cells 
expressing FcRL5, often co-expressed with PD-1, exhibit higher rates of somatic hypermutation 
and a more switched immunoglobulin profile than FcRL5- B cells, despite showing reduced 
function (Li et al., 2016). 
Building on this concept, our data suggested that FcRL5+ atMBCs may consist of two distinct 
subsets: one that has encountered antigen and undergone class-switching, and a second subset that 
has features of a more naïve cell type, characterised by expression of IgM. This theory is supported 
by data from a recent study which purported to the existence of naïve-like age-associated B cells in 
addition to antigen-induced age-associated B cells (Swain et al., 2017). The naïve-like B cells 
described expressed high levels of soluble IgM and were negative for expression of CD11c and 
CD80, in agreement with our data. In contrast, antigen-experienced age-associated B cells that 
increased during the course of murine influenza A infection, were mainly class-switched, and 
expressed higher levels of CD80/86, CD11c and CD38. Our data revealed a concentration of PD-1 
expression on CD24-CD38-IgM-IgD- B cells, pointing to a population of antigen-experienced cells. 
Additional populations of FcRL5-negative CD24-CD38+ and CD24+CD38- B cells, described as 
having similar functions to atMBCs, were also identified (Thorarinsdottir et al., 2016); however, 
their contribution to the CD27-CD21low/- pool was minimal, constituting ~15% of the atMBC 
population.  
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Thus, it is increasingly thought that atMBCs may represent a heterogeneous pool of B cells, which 
have divergent and specialised functions. This heterogeneity is apparent not only within individuals, 
but seems also to exist between disease settings. Our observations, demonstrating the functional 
impairment of atMBCs to differentiate into ASCs, are in line with findings from Plasmodium 
falciparum infection, which showed that FACs-sorted atMBCs could not be stimulated to produce 
antibodies in conditions that otherwise promoted cMBCs to readily differentiate into ASCs 
(Portugal et al., 2015). This defect may be partially attributable to the expression of FcRL5, which 
was shown to suppress immunoglobulin production in FcRL5+ atMBCs and cMBCs (Sullivan et al., 
2015). A contradictory report suggested that atMBCs are capable of producing neutralising 
antibodies to blood stage Pf. parasites, at a similar level to cMBCs. However, this study utilised 
measurements of immunoglobulin transcripts and therefore did not directly pertain to antibody 
production by B cells themselves (Muellenbeck et al., 2013). In HIV, analysis of affinity maturation 
revealed that rates of somatic hypermutation were significantly reduced in CD27-CD21low/- B cells, 
relative to CD27+CD21+ B cells, despite having undergone similar frequencies of cell divisions. 
Decreased levels of affinity maturation directly correlated with reduced HIV-neutralising capacity 
of the resultant antibodies, suggesting that the expansion of CD27-CD21low/- B cells in HIV may 
contribute to impaired neutralisation of the virus (Meffre et al.; Moir et al., 2008).  
In contrast, in settings of autoimmunity, immunoglobulin synthesis is enhanced in CD21low B cells 
relative to CD21+ B cells, suggestive of preferential differentiation into antibody secreting cells 
(Rakhmanov et al., 2009). Notably, despite showing decreased levels of differentiation to ASCs, 
atMBCs from vaccinated healthy controls did not show reduced production of total IgG relative to 
cMBCs. This observation may be reflective of lower levels of inhibitory receptor expression 
identified on atMBCs from vaccinated healthy controls compared to patients with CHB. However, 
it could also be indicative of IgG production by CD21low naïve-like B cells within the atMBC 
population alluded to previously. PD-1low naïve-like atMBCs, described in this study, showed 
marked similarities to CD21low B cells described in CVID that are thought to represent an anergic 
population responsible for the production of polyreactive antibodies (Isnardi et al., 2010). 
Therefore, it is possible that analysis of IgG production by atMBCs in healthy individuals is not 
representative of IgG production by atMBCs that are induced and impaired as a result of chronic 
exposure to HBsAg. Indeed, analysis of atMBCs isolated from one patient with CHB showed a 
marked reduction in IgG by atMBCs, compared to a matched number cMBCs; however, further 
analysis, currently limited by access to category three hazard sorting facilities, is needed to confirm 
these results. Future studies should now focus on assessing the quality of antibody produced by 
atMBCs in HBV, to examine whether this expansion of atMBCs within HBsAg-specific B cells 
directly contributes to the failure of patients with CHB to produce neutralising anti-HBs. Arguably 
the most definitive way to ascertain the relative contributions of these different subsets to HBsAg-
specific immunity would be to analyse gene expression at the single cell level.  
 
 
152 
atMBCs also appeared to be more prone to apoptosis compared to cMBCs, as demonstrated by the 
increased levels of Annexin-V staining following BCR and CD40 stimulation, and the decreased 
survival and differentiation of atMBCs to ASCs. These data were supported by others showing that 
markers of apoptosis were enriched in CD21low B cells (Charles et al., 2008; Rakhmanov et al., 
2009). Apoptosis of lymphocytes is central to the shaping the immune repertoire and terminating 
immune responses. However, the data presented here suggests that premature apoptosis may be 
responsible for curtailing the development of functional humoral immune responses in CHB. It is 
likely that reduced expression of CD21 plays a role in the survival of atMBCs, with CD21 shown to 
be necessary for the maintenance of B cells within the lymphoid compartment (Fischer et al., 1998). 
However, environmental signals may also play an important role in promoting premature apoptosis 
of atMBCs in patients with CHB. For example, persistent TLR-4 signalling triggered by microbial 
gut products in cirrhotic liver may predispose memory B cells towards FAS-mediated apoptosis 
(Chang et al., 2016). The susceptibility of atMBCs towards premature cell death is likely also a 
consequence of their dysfunctional phenotype. Upregulated expression of CD95 on CD21low B 
cells isolated from HIV-viraemic patients correlated with an increased propensity towards FAS-
mediated apoptosis (Moir et al., 2004). CD21low B cells have also been reported to have decreased 
expression of IL-4R (Charles et al., 2008; Isnardi et al., 2010), which might otherwise confer 
resistance to IL-4-mediated protection against Bim-mediated apoptosis (Granato et al., 2014). 
Data presented here may point to a role for PD-1 blockade in rescuing atMBCs from premature 
apoptosis. Although this may be beneficial in terms of preventing cell death of HBsAg-specific 
B cells, it raises the possibility that PD-1 blockade may actually potentiate the accumulation of 
dysfunctional cells within the memory B cell compartment. Pertinent to this concept, melanoma 
patients treated with combination CTLA-4 and PD-1 blockade showed an increased risk of 
developing immune-related adverse events, associated with the rapid appearance of circulating 
CD21low B cells expressing a non-lymphoid tissue-homing profile (Das et al., 2018). As a result, 
therapeutic blockade of inhibitory receptors may preferentially expand CD21-CD27low/- B cells, in 
turn leading to adverse impacts on the generation of humoral immune responses and 
manifestations of autoimmunity (Naradikian et al., 2016b). This also highlights the importance of 
investigating bystander impacts to B cells of checkpoint blockade strategies aimed at rescuing T cell 
responses. 
 
Clearly, the concentration of atMBCs with high inhibitory receptor expression within the HBsAg-
specific compartment cannot wholly explain their defective anti-HBs production, since there 
remains a population of supposedly functional HBsAg-specific CD27+CD21+ cMBCs. Although 
diminished, it is possible that these cells do produce low levels of anti-HBs, accumulating to high 
enough levels for detection in some patients with comparatively high levels of HBsAg-specific 
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cMBCs. Interestingly, transcriptional analysis of naïve B cells and memory B cell subsets in patients 
with CHB compared to healthy controls, suggested that HBV-infection may also have significant 
impacts on supposedly functional B cell responses (Salimzadeh et al., 2018). 
However, there are likely more generalised impacts of HBV infection on B cells that affect their 
ability to form protective humoral immune responses. One consideration is the profile of receptors 
that direct their localisation. Both atMBCs and the total HBsAg-specific B cell population 
expressed high levels of CD11c and CXCR3, alongside decreased expression of CXCR5. 
Expression of CXCR3 and CD11c may promote the migration of atMBCs and HBsAg-specific B 
cells to inflamed tissue sites (Xie et al., 2003). In autoimmunity, CD11c+CXCR3+CD27-CD21low/- 
B cells have been shown to preferentially home to the bronchoalveolar space and synovial fluid in 
patients with CVID and rheumatoid arthritis, respectively (Rakhmanov et al., 2009). In opposition, 
CXCR5 expression facilitates migration of memory B cells to the B cell follicle, along a gradient of 
CXCL13 secreted by follicular dendritic cells resident in the lymphoid tissue. Taken together, we 
propose that altered expression of chemokine receptors may promote the migration of atMBCs and 
HBsAg-specific B cells to inflamed tissues and away from non-lymphoid sites, thereby reducing the 
opportunities for productive interactions with CD4 T helper cells and antigen-driven affinity 
maturation. Due to the centrality of CD4 T cell – B cell interactions to the development of high-
affinity antibody, we postulate that impaired CD4 T cell help may contribute to the suboptimal 
antibody production observed in CHB. Furthermore, high levels of BCR stimulation in the absence 
of appropriate T cell help can lead to the induction of functional anergy and apoptosis in B cells; a 
fundamental mechanism underpinning the development of B cell tolerance. 
In further evidence of this concept, we also observed decreased expression of CD40 on atMBCs 
relative to cMBCs, and on HBsAg-specific B cells from patients with CHB, compared to antigen-
specific B cells isolated from vaccinated healthy controls. The interaction between CD40, expressed 
on B cells, with CD40-ligand on TFH is central to the activation of B cells and the induction of 
class-switch recombination. Therefore, decreased expression of CD40 supports the concept that 
atMBCs and HBsAg-specific B cells experience impaired interactions with T helper cells, leading to 
diminished activation of B cells and decreased affinity antibody responses. This hypothesis may 
contribute to explaining the decreased proportion of class-switched B cells identified in global 
atMBCs. In addition, in models of ageing, an accumulation of CD27-CD21low/- age-associated 
B cells was associated with expansion of ‘aged’ CD4 T cells that lead to decreased formation of 
germinal centres and long-lived plasma cell responses (Swain et al., 2017). The impact of this defect 
was an expansion of age-associated B cells that developed independently of T cell help, but 
required higher dose of PAMP-activation to produce antibodies. This finding illustrates how 
defective T cell help can result in hypo-responsiveness of memory B cells to stimulation, in line 
with our findings. Manipulation of the CD40 – CD40-L axis may therefore represent a promising 
therapeutic angle for rescuing both B cell – and T cell – mediated immunity in CHB.  
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In summary, atMBCs appear to represent a heterogeneous population of naïve-like and antigen-
experienced B cells, the latter characterised by elevated expression of PD-1. These cells accumulate 
in the presence of HBsAg, showing increased frequency within the HBsAg-specific B cell fraction 
in patients with acute or chronic HBV, compared to HBV-vaccinated controls or HBV-resolved 
individuals. More work is required to ascertain whether the increase in atMBCs is a reflection of 
naïve or classical memory B cells becoming dysregulated, or a proliferation of naturally occurring 
atMBCs.  
Investigation of global atMBCs revealed attenuated responses to BCR stimulation, demonstrated by 
decreased Ca2+ mobilisation, impaired cytokine production and susceptibility to cell death. 
Furthermore, atMBCs showed significant defects in their ability to differentiate into plasma cells, 
suggesting that their accumulation within HBsAg-specific responses may play a role in impairing 
humoral immunity in CHB. As a result of their decreased activation status, high expression of 
inhibitory receptors and impaired in vitro function, we propose that PD-1+ atMBCs represent a 
functionally exhausted B cell subset, similar to exhausted T cells that accrue in chronic infection 
and cancer. Data presented here also supports a tentative role of PD-1 blockade in improving 
antiviral function and rescuing atMBCs from premature apoptosis. Further studies are necessary to 
test additional stimuli that bypass attenuated BCR signalling, and/or blocking synergistic inhibitory 
receptors, in order to optimise B cell recovery in CHB. The clinical application of such approaches 
will require caution to protect against the expansion of dysfunctional B cells with the potential to 
drive autoimmunity. 
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Figure 4-23 Summary of chapter findings 
Summary of the phenotypic and functional changes described in HBsAg-specific B cells and atMBCs in patients with 
CHB 
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Chapter 5 HBsAg-specific B cells and atypical memory B cells 
in the liver 
 
Chapter summary 
It is increasingly appreciated that the phenotype, differentiation and function of immune cells is 
significantly impacted by the anatomical location in which they reside. Whilst many studies have 
identified important components of HBV disease pathogenesis through sampling the blood, it is 
now apparent that both the composition and function of lymphocytes is significantly altered in the 
liver (Gill et al., 2018) As an exclusively hepatotropic infection, it is therefore critical to understand 
how both the cellular composition of the liver and its microenvironment may regulate antiviral 
responses to infection. In this chapter, I examine the proportion of intrahepatic B cells with an 
atMBC phenotype and the persistence of HBsAg-specific B cells within the liver 
microenvironment. 
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5.1 Introduction 
5.1.1 Immunology of the liver 
Among very many roles (reviewed in (Michalopoulos, 2007)), the liver stands as the primary organ 
in the body responsible for the metabolism and detoxification of gut-derived products. These are 
delivered to the liver in the form of antigen-rich portal venous blood, which passes through a 
system of capillary-like vessels, referred to as sinusoids, before being metabolised by hepatocytes. 
As part of this, the liver also plays a key role in immune surveillance, whereby liver-specialised 
antigen-presenting cells scan the blood for invading pathogens. To do so, the liver must be 
uniquely tolerised to avoid immune responses against innocuous antigens that could lead to liver 
damage, whilst maintaining the ability to prime and elicit immune responses to blood-borne 
pathogens, where necessary (Crispe, 2009).  
The ability of the liver to carry out immune surveillance is a function of both its anatomy and the 
diverse network of cells resident therein. Structurally, the liver is divided into hepatic lobules, which 
consist of a roughly hexagonal arrangement of hepatocytes that radiate out from the central vein 
(Figure 5.1). Blood enters the liver from the portal vein and flows through the sinusoids out into 
the systemic circulation via the central vein (Ishibashi et al., 2009). Hepatic sinusoids are lined by 
liver sinusoidal endothelial cells (LSECs), that can be distinguished by their large fenestrations that 
permit solute access to hepatocytes and accommodate membrane protrusions from both 
hepatocytes and infiltrating lymphocytes (Warren et al., 2006). Anatomically, LSECs separate 
hepatocytes from the blood flowing through the sinusoidal lumen, establishing formation of the 
Space of Disse between the endothelial lining and the underlying hepatocytes (Figure 5.1). The 
extensive narrow-lumen sinusoidal structure, combined with the low pressure of portal venous 
blood, results in a sluggish blood flow, and facilitates maximal interactions between circulating 
antigen and/or leukocytes and liver-resident antigen-presenting cells (Jenne and Kubes, 2013).  
The tolerogenic nature of the liver was first alluded to following tolerance of fully MHC-
mismatched pig liver transplants (Calne et al., 1969). This observation was later supported by the 
demonstration that co-transplantation of livers, alongside organs normally rejected alone, could 
promote tolerance of the donor organ (Benseler et al., 2007). Accordingly, liver transplant 
recipients have an increased propensity towards tolerance of the donor organ, and are able to 
tolerate withdrawal of immunosuppressive drugs with fewer consequences, in stark contrast to all 
other solid organ transplants (Benítez et al., 2013; Levitsky, 2013). Lastly, the liver is a common site 
for tumour metastases, again reflective of its tolerised nature. 
Antigen-presentation in the liver is carried out by specialised liver resident cells, namely LSECs, 
Kupffer cells and hepatocytes. LSECs comprise ~50% of the non-parenchymal cells in the liver 
and play a critical role in the scavenging of pathogens and antigen presentation to T cells. This 
ability is conferred by the expression of a number of key cell-surface molecules, including pattern-
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recognition receptors (TLR-3, TLR-4, TLR-7 and TLR-9), and the constitutive expression of MHC 
and co-stimulatory molecules (Jenne and Kubes, 2013). Through the expression of both MHC 
Class-I and MHC Class-II, LSECs can cross-present antigen to both CD4 and CD8 T cells 
(Schurich et al., 2009). Moreover, LSECs also express intracellular adhesion molecules 1 (ICAM-1), 
thereby facilitating their interaction with circulating leukocytes. Upon antigen presentation, LSECs 
upregulate expression of programmed death ligand 1 (PD-L1). In this way, LSECs also have a role 
in regulating lymphocyte responses; persistent engagement of PD-L1 with its receptor PD-1 on 
activated T cells culminates in the tolerisation of T cell responses (Berg et al., 2006).  
 
 
Figure 5-1 Schematic of the human liver microenvironment  
Schematic of the human liver architecture and blood supply. A. A portion of a liver lobule. Blood flows from the portal 
vein and into the sinusoid, whereupon it is surveyed by liver-infiltrating and liver-resident lymphocyte populations. B. 
Detailed representation of the liver sinusoid. Hepatocytes are separated from the blood by non-parenchyma LSECs. The 
Space of Disse is defined as the space between the LSECs and the underlying hepatocytes, perforated by numerous 
fenestrate. Liver resident macrophages, Kupffer cells, adhere to the LSECs and rapidly clear pathogens from the blood. 
Adapted from (Maini and Pallett, 2018) and utilising Servier medical art (part A).  
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Kupffer cells (KCs) are a tissue-resident macrophage population that localise in the vasculature of 
the liver and express an array of scavenger receptors. These include TLRs, complement receptors, 
and Fc-receptors, that detect, bind and internalise pathogens. At rest, KCs predispose the liver 
towards tolerance through the secretion of immunosuppressive cytokines, IL-10 and TGFb, and 
the expression of molecules, including Fas-ligand and PD-L1 (Boltjes et al., 2014). However, upon 
activation, KCs become potent antigen-presenting cells and produce a number of cytokines – 
namely, IL-12, IL-6 and TGFb - that act to alert lymphocytes and amplify the immune response.  
Hepatocytes represent the majority parenchymal cell type of the liver and have primary roles in the 
nutrient metabolism, protein production and toxin neutralisation. However, they also have 
additional roles in the adaptive immune response through the expression of MHC molecules: 
hepatocytes express high levels of MHC Class-I, with MHC Class-II shown to be expressed under 
inflammatory conditions (Franco et al., 1988). Through this, hepatocytes have been shown to be 
able to activate naïve T cells (Bertolino et al., 2002; Warren et al., 2006). 
 
5.1.2 Adaptive immune responses in HBV-infected liver 
Several clinically important pathogens have evolved to target the liver and exploit this tolerogenic 
environment to establish persistent infection, including HBV and HCV. In opposition to the blood, 
the liver is selectively enriched for CD8 rather than CD4 T cells. Intrahepatic CD8 T cells are 
dominated by memory subsets, with significantly fewer naïve T cells infiltrating the liver, compared 
to the blood.  
The liver is also enriched for non-conventional T cells, including mucosal associated invariant 
T cells (MAIT cells). MAIT cells are identified by their high expression of the C-type lectin, 
CD161, in association with a semi-invariant TCR restricted by MHC Class-Ib molecule, MR1 
(Ussher et al., 2018). These cells represent a transcriptionally distinct lineage, characterised by the 
expression of RORgT (Billerbeck et al., 2010), and preferentially accumulate in the liver, compared 
to the blood or gut. MAIT cells are activated via their T cell receptor, which recognises bacterial 
riboflavin derivatives, or independently via viral infection or TLR-8 agonists. Other non-
conventional T cells enriched within the liver include γδ-T cells, which share features of innate and 
adaptive lymphocytes (Hammerich and Tacke, 2014). 
Intrahepatic CD8 T cells constitute the major cell type involved in protecting the liver against 
pathogens. Recruitment of CD8 T cells to the liver is mediated via the expression of chemokine 
receptors, including the liver homing chemokine CXCR6 that binds CXCL16 constitutively 
expressed by liver sinusoidal endothelial cells (Sato et al., 2015). Once within the liver vasculature, 
HBV-specific T cells adhere to the liver parenchyma through binding to activated platelets via 
interactions with CD44 on activated CD8 T cells (Guidotti et al., 2015b; Iannacone et al., 2005). In 
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doing so, their transit through the vasculature is slowed down, allowing CD8 T cells to patrol the 
sinusoidal vasculature and probe hepatocytes through the extension of cytoplasmic protrusions for 
the presence of pathogens, elegantly demonstrated by intra-vital imaging (Guidotti et al., 2015b). 
Patients controlling acute HBV infection are able to mount an effective virus-specific T cell 
response; in contrast, HBV-specific responses are markedly depleted and impaired in the presence 
of chronic HBV-infection. Intrahepatic HBV-specific T cells were shown to have high expression 
of Bim (Lopes et al., 2008) - a pro-apoptotic factor induced when T cells are primed in the liver as 
opposed to the lymph node, and that mediates their premature death (Holz et al., 2008). 
Intrahepatic CD8 T cells can be further depleted through interactions with liver-infiltrating and 
liver-resident NK cells, which upregulate the death ligand TNF-related apoptosis-inducing ligand 
(TRAIL), enabling them to kill HBV-specific T cells expressing high levels of the death receptor, 
TRAIL-R2 (Peppa et al., 2013; Stegmann et al., 2016). Moreover, liver-infiltrating CD4 T cells, in 
the context of HBV infection, upregulate the expression of stress-ligands, which bind to the 
NKG2D receptor on NK cells and further promote their activation and cytotoxicity (Huang et al., 
2017). 
Intrahepatic HBV-specific T cells that persist are profoundly dysfunctional and express high levels 
of co-inhibitory receptors, in particular PD-1 (Boni et al., 2007; Fisicaro et al., 2010), associated 
with reduced expression of IFNγ (Schurich et al., 2013). Hepatocytes, KCs and LSECs highly 
express PD-1 ligands, which are upregulated further in settings of disease (Kassel et al., 2009). 
Through this interaction, liver-resident cells are able to suppress the function of infiltrating T cells. 
Additional mechanisms of intrahepatic T cell suppression include the accumulation of specialised 
inhibitory cells, termed granulocytic myeloid-derived suppressor cells (MDSCs). These are 
expanded in the livers of patients with HBV infection and produce high concentrations of the 
enzyme, arginase-1. This enzyme catabolises L-arginine, an essential amino acid required for T cell 
proliferation, resulting in the local deprivation of essential nutrients and the suppression of antiviral 
T cell function (Pallett et al., 2015). Despite this, recent work has identified a population of tissue-
resident T cells that are specialised to overcome local constraints and preferentially expand in 
patients with HBV immune control to mediate immunity (Pallett et al., 2017). 
 
5.1.3 Intrahepatic B cells 
Comparatively, very little is known regarding intrahepatic B cells. B cells are estimated to constitute 
approximately 5-10% of intrahepatic lymphocytes in the human liver, contrasting with up to 50% 
of murine intrahepatic lymphocytes (Racanelli and Rehermann, 2006). However, estimations of 
B cell frequency within the human liver may be underestimated as a result of relative difficulties in 
isolating intrahepatic lymphocytes. Work by Steinert et al., identified that isolation methods fail to 
uniformly isolate the majority of intrahepatic cells, with significant discrepancies demonstrated 
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between immunofluorescent approaches and flow cytometric quantitation (Steinert et al., 2015). 
Cell isolation efficiency was markedly affected by tissue type and lymphocyte localisation, 
suggesting that it may be more difficult to isolate cells that localise deep within liver parenchyma. 
Thus, challenges associated with the isolation of lymphocytes may account for reduced frequencies 
of intrahepatic B cells estimated in human livers.  
In mice, IgM+ hepatic B cells are able to efficiently phagocytose fluorescently-labelled E. coli, and 
display bactericidal properties comparable to KCs (Nakashima et al., 2012). Murine hepatic B cells 
appear also to be potent producers of pro-inflammatory cytokines. Zhang et al., showed that 
following in vivo LPS stimulation, intrahepatic B cells produce significantly more inflammatory 
cytokines (IL-6, IFNg and TNFa) compared to splenic B cells, yet displayed reduced secretion of 
the immunosuppressive cytokine, IL-10 (Zhang et al., 2013). In this system, intrahepatic B cells also 
promoted the maturation and function of liver myeloid dendritic cells; accordingly, intrahepatic 
dendritic cells from mice devoid of B cells were less responsive to LPS and showed a decreased 
ability to produce IL-6, IL-12 and IFNg. This was in contrast to splenic B cells, which were able to 
suppress the function of myeloid dendritic cells (Zhang et al., 2013). Combined, these studies from 
murine models suggest that B cells may have a role in promoting inflammatory responses in the 
liver. 
In contrast, very few studies have explicitly investigated B cells in the human liver due to limitations 
in access to tissue. B cells have indirectly been shown to have a role in the improvement of primary 
biliary cirrhosis following B cell depletion via Rituximab (Tajiri et al., 2013). In line with this, an 
infiltration of B cells and plasma cells, particularly around biliary structures, has been demonstrated 
in both primary biliary cirrhosis and primary sclerosing cholangitis, purportedly playing a role in the 
destruction of intrahepatic bile ducts (Fischer et al., 2014; Jin et al., 2012; Zhang et al., 2010).  
Intrahepatic B cells may also play an important role in the control of hepatic infections through 
their capacities to produce antibody, secrete cytokines and present antigen. A recent report 
identified IgA+ B cells within the liver that robustly produced antibodies against intestinal antigens 
(Moro-Sibilot et al., 2016). In chronic viral infections, monoclonal B cells have been shown to 
infiltrate the liver (Fan et al., 2009), where they can be identified within the portal tracts of patients 
with HCV (Ward et al., 2007). Due to their localisation and capacity as antigen-presenting cells, 
intrahepatic B cells are also able to activate liver-infiltrating MAIT cells, which co-localise with B 
cells within the portal tract. Following exposure to E. coli, intrahepatic B cells were demonstrated to 
activate liver-infiltrating MAIT cells, inducing their degranulation and expression of IFNγ, TNFα, 
and CD40-L (Jeffery et al., 2016). Thus, in their ability to secrete antibodies and cytokines, 
alongside their capacity for antigen presentation, B cells are likely important influencers of local 
inflammatory responses within the liver.  
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In agreement with murine studies above, accumulating evidence suggests that an influx of B cells to 
the liver may be associated with increased inflammation and associated damage. CD20+ B cells 
have previously been identified in the liver of HBV-infected liver, where they were increased in 
patients displaying a higher degree of liver fibrosis (Mohamadkhani et al., 2012, 2014). Moreover, 
gene array data comparing HBV-acute liver failure (ALF) to HBV-negative livers showed an 
upregulation of B cell associated transcripts in ALF. This was associated with an influx of plasma 
cells to the liver, resulting in overwhelming production of IgM and IgG targeted against HBcAg 
(Farci et al., 2010). To our knowledge, this example is the only evidence of antigen-specific B cell 
responses within the liver, thus far. 
 
5.1.4 Evidence for atMBCs in tissue 
The tissue localisation of atMBCs, and their role in disease, is undefined at present and warrants 
investigation. The first description of FcRL4+CD21low/- B cells in the tonsils implicated a potential 
role for CD27-CD21low/- as a tissue-biased B cell population (Ehrhardt et al., 2005). In line with 
this, FcRL4 expressing cells have been identified in the intraepithelial and sub-epithelial regions of 
mucosal-associated lymphoid tissue (Falini et al., 2003). It could therefore be postulated that 
atMBCs represent a tissue-adapted cell type with specialised function in barrier organs.  
Phenotypic analysis presented in Chapter Four identified an array of markers specific to atMBCs 
that might support their identification in the liver. CD11c+CXCR3+ B cells have previously been 
shown to localise within the bronchoalveolar space and synovial fluid in patients with rheumatoid 
arthritis, demonstrating a predisposition of atMBCs towards inflammatory environments 
(Rakhmanov et al., 2009). CXCR3 has also been demonstrated to direct lymphocyte migration to 
inflamed liver: CXCR3 ligands are upregulated on hepatic endothelium and facilitate the migration 
and adhesion of CXCR3hi liver-infiltrating T cells (Curbishley et al., 2005). Similarly, liver-
specialised tissue-resident CD8 T cells express comparatively high levels of CXCR3 compared to 
intrahepatic and peripheral lymphocytes, suggestive of a role for its expression in their 
homing/retention in the liver (Pallett et al., 2017). Thus, elevated expression of CD11c and CXCR3 
on atMBCs and HBsAg-specific B cells may support their homing to inflamed tissue sites. 
In addition, we previously showed that atMBCs could be identified by high expression of T-bet. 
Recent work has begun to identify factors that promote the expression of T-bet in B cells. A 
combination of TLR-stimulation, in association with Th-1 cytokines (IFNγ and Il-21), was 
demonstrated to play an important role in the induction of T-bet (Naradikian et al., 2016a; Obeng-
Adjei et al., 2017; Sindhava et al., 2017); all key features of HBV-infected liver. Due to the apparent 
overlap in phenotype between T-bet+ B cells and atMBCS, it is likely that TLR stimulation, in 
combination with pro-inflammatory cytokine stimulation, may modulate the transcription of T-bet, 
leading to the induction of T-bet- and atMBC- associated characteristics. Thus, not only might 
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atMBCs preferentially migrate to the liver, but the local microenvironment of the liver may induce a 
dysfunctional phenotype in liver-infiltrating B cells. Therefore, the unique receptor profile of 
atMBCs, in combination with the complex microenvironment of the HBV-infected liver, may 
promote an accumulation of HBsAg-specific atMBCs at the site of viral infection. 
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5.2 Hypothesis and aims: 
In this chapter, I aim to examine how the liver microenvironment, in combination with 
HBV-infection, may influence the frequency and phenotype of liver-infiltrating B cells. Phenotypic 
analysis presented in the previous chapter indicated that atMBCs and HBsAg-specific B cells in 
patients with CHB express receptors that would support their homing to inflamed tissues sites, 
namely CXCR3 and CD11c. We hypothesised that liver-infiltrating B cells may exhibit an atMBC 
phenotype as a result of their chronic exposure to antigen, in combination with TLR-stimulation 
and the local cytokine milieu of HBV-infected liver. Finally, using our HBsAg-bait system, we 
aimed to investigate whether HBsAg-specific B cells are able to persist in HBV-infected liver 
samples. These data would have important implications in understanding the role of antigen-
specific B cells at the site of viral replication and disease pathology. 
 
Using our unique access to liver tissue, we set out to: 
1. Examine the frequency and phenotype of atMBCs in paired blood and liver samples, 
comparing healthy and HBV-infected samples; 
2. Assess whether HBsAg-specific B cells are able to persist at the site of viral infection; 
3. Dissect the phenotype of HBsAg-specific B cells using parameters presented in Chapter 
Four. 
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5.3 Results 
5.3.1 B cells with an atMBC phenotype are enriched in HBV-infected and uninfected liver 
We postulated that the microenvironment of HBV-infected liver may support an accumulation of 
exhausted atMBCs at this site. Through unique access to human liver tissue, we were able to assess 
the effect of both the liver microenvironment and HBV-infection on intrahepatic B cell 
populations. To do so, we compared lymphocytes extracted from liver biopsy tissue from 
HBV-infected patients (deemed surplus to diagnostic requirements) to healthy margins of 
metastatic cancer (referred to as cancer margins). These margins are histologically normal and distal 
to the tumour, but have the caveat that they are taken from patients with underlying disease and 
differing treatment regimes. In addition, previous comparison of lymphocytes extracted from these 
and truly healthy tissue (obtained through biopsy of livers prior to transplantation) has 
demonstrated subtle alterations in immune composition, likely resulting from distant influences of 
metastases.  
Our analysis also utilised perfusion liquid of cadaveric liver allografts (referred to as perfusates). 
Analysis of perfusates is arguably biased towards sampling of the lymphocyte populations situated 
within the liver sinusoids; however, careful characterisation of these samples, and comparison to 
biopsy tissue, has demonstrated that perfusates are able to reliably sample tissue resident 
populations, including tissue resident T and NK cells (Pallett et al., 2017; Gill and Pallett., 2018). 
To begin, we first analysed the frequency of total B cells (CD3-CD20+CD19+) as a proportion of 
intrahepatic lymphocytes (defined by expression of CD45). B cells were decreased in HBV-infected 
liver, relative to healthy perfusates or cancer margins (Figure 5.2A). This is likely reflective of a 
significant influx of infiltrating NK cells and T cells into the HBV-infected liver, decreasing the 
relative frequency of intrahepatic B cells as a percentage of total intrahepatic lymphocytes. Similar 
findings were also reported using a separate cohort of liver biopsies (Gill and Pallett., 2018). 
We next assessed the proportion of intrahepatic B cells with an atMBC phenotype, to investigate 
whether atMBCs are preferentially enriched within the B cell pool in the liver environment. Paired 
ex vivo analysis of 27 paired blood and liver samples from patients with CHB or HBV-unexposed 
patients (healthy margins of metastatic cancer), revealed that the atMBC phenotype observed in the 
global B cell compartment in the periphery was exaggerated in the liver, compared to the periphery 
(Figure 5.2B). Comparison of B cells extracted from HBV-infected livers and healthy perfusates 
showed that atMBCs were further increased in the instance of HBV infection (Figure 5.2C), with 
healthy margins demonstrating intermediate frequencies of atMBCs. These data pointed to a 
combined effect of the liver milieu and the virus in the expansion of this subset. Patients with 
HBV-associated end-stage liver failure (shown in red) had markedly higher levels of atMBCs, 
suggesting that an accumulation of atMBCs could be associated with worse disease; however, many 
more patients are required to investigate this concept in full. Interestingly, comparison to a small 
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subset of HBV-naïve liver biopsies taken from patients with non-viral hepatitis (serum ALT levels 
ranging from 53-508) did not show as high frequencies as the HBV-infected cohort, suggesting that 
liver inflammation per se was not the sole driver of intrahepatic atMBCs (Figure 5.2C).  
 
 
 
Figure 5-2 atMBCs are increased within the intrahepatic B cell pool compared to the periphery 
A. Frequencies of total B cells as a % of live CD45+ lymphocytes. B. Representative staining and summary plot: 
frequencies of atMBC in paired intrahepatic leukocytes (IHL) and blood samples (PBMC) from patients with CHB (black 
dots; 10 HBV+ liver biopsies; 5 HBV+ liver resections) and uninfected controls (blue dots; 12 margins from HBV- 
colorectal metastases; CRC; control IHL). C. Frequencies of atMBC in control liver samples (22 CRC margins; 12 pre-
transplant perfusates; 6 biopsies from livers with non-viral hepatitis) HBV-infected liver (11 HBV+ liver biopsies; 1 
perfusate from HBsAg+ liver; 2 perfusates from HBV-resolved livers) including 4 HBV+ explants from HBV-associated 
end stage failure (shown in red); and 6 biopsies from non-viral hepatitis. Error bars indicate mean ± SEM; *, P < 0.05; **, 
P < 0.01; ***, P < 0.001; p-values were determined by determined by Kruskal-Wallis test with a Dunn’s post hoc test for 
pairwise multiple comparisons (a and c); and Wilcoxon signed-rank test (b). 
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5.3.2 Intrahepatic atMBCs are PD-1hi 
The expansion of CD27-CD21low/- B cells in HBV-infected liver led to the hypothesis that 
exhausted B cells may accrue in the diseased liver as a result of persistent antigenic exposure. 
Therefore, we next examined the phenotype of intrahepatic atMBCs, to determine whether these 
cells have comparable attributes to those described in the periphery. 
Similar to the circulating atMBCs, intrahepatic atMBCs expressed high levels of the transcription 
factor T-bet compared to cMBCs, and accordingly accounted for a high proportion of T-bethi 
intrahepatic B cells (Figure 5.3A). Intrahepatic atMBCs also expressed higher levels of FcRL5 and 
PD-1 compared to their counterpart cMBCs (Figure 5.3B), reflecting their dysfunctional phenotype 
observed in the periphery.  
 
 
Figure 5-3 Intrahepatic atMBCs phenotypically resemble those in the periphery 
A. Percentage of intrahepatic B cells with atMBC or cMBC phenotype within global T-bethi, T-betint or T-betlo 
populations (n=2 CRC; 3 HBV+ tissue; 1 healthy perfusate). B. Expression of FcRL5 (n=4 HBV+ infected liver; 12 CRC 
margins) and PD-1 (n=12 HBV+ liver; 13 CRC margins) on intrahepatic atMBC and cMBC. C. Comparison of FcRL5 
expression on atMBCs between the peripheral blood mononuclear cells (PBMC) and intrahepatic lymphocytes (IHL) in 
HBV-infected tissue (n=4) and cancer margins (n=6). D. Comparison of PD-1 expression on atMBCs between PBMC 
and IHL in HBV-infected tissue (n=9) and cancer margins (n=7). E. Comparison of PD-1+ atMBC in uninfected liver 
(%; n=15 CRC margins) and HBV+ liver (n=13). Error bars indicate mean ± SEM; **, P < 0.01; ***, P < 0.001; p-values 
were determined by determined by Wilcoxon signed-rank test (b, c and d); and Mann-Whitney U test for unpaired data 
(e). 
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Limited comparison of the levels of FcRL5 on peripheral and intrahepatic atMBCs showed that 
FcRL5 expression was decreased on intrahepatic B cells, compared to those isolated from the 
periphery (Figure 5.3C). In contrast, PD-1 levels between intrahepatic and peripheral atMBCs 
showed that PD-1 expression was comparable within HBV-infected patients, but showed a 
decrease on intrahepatic B cells in patients with metastatic cancer relative to the periphery (Figure 
5.3D). Of note, PD-1 expression was especially high on atMBCs in HBV-infected liver: a maximum 
of 62% (mean of 28%) of atMBCs expressed PD-1, contrasting to a mean of 3% in uninfected 
livers (Figure 5.3E). This suggests that the high expression of PD-L1/L2 by liver-resident cell types 
may contribute to impairing antiviral B cell responses at the site of viral replication. Combined, 
these data suggested HBV infection, in combination with the unique microenvironment of the 
liver, may drive an accumulation of atMBCs with similar phenotype features to those identified in 
the blood.  
 
5.3.3 HBsAg-specific can localise in HBV-infected liver  
Since HBsAg is secreted in high quantities by infected hepatocytes, we were next interested to 
investigate whether HBsAg-specific B cells are able to persist at the site of infection. Expression of 
CXCR3 and CD11c on HBsAg-specific B cells in the periphery suggested that HBsAg-specific B 
cells may possess the capacity to home to the liver. To investigate whether HBsAg-specific B cells 
can infiltrate and persist at the site of viral replication, we stained HBsAg-specific B cells, in a 
subset of liver samples with sufficient numbers of cells, using the aforementioned HBsAg-bait 
protocol. As in the periphery, a threshold level (mean plus standard deviation of uninfected 
controls) was set to determine detectable populations of HBsAg-specific B cells (0.10%). 
HBsAg-specific B cells were detectable in 12/14 HBV-infected livers sampled, above that seen in 
HBV-unexposed livers (Figure 5.4A). HBsAg-specific B cells were not at a higher percentage of 
total B cells in the liver compared to the blood, apart from in one patient who had HBV-associated 
hepatocellular carcinoma (Figure 5.4B). As seen in the periphery, HBsAg-specific B cells were also 
enriched for an atMBC phenotype (Figure 5.4C), suggesting that the high levels of circulating 
HBsAg in the liver may drive an expansion of exhausted B cells within the HBsAg-specific pool. 
Collectively, these data show that virus-specific B cells can localise at the site of infection, allowing 
their phenotype and function to be shaped by both the local microenvironment and viral 
replication.  
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Figure 5-4 HBsAg-specific B cells can persist in HBV-infected liver 
A. Representative staining and frequency of HBsAg-specific B cells (% of CD19+CD20+) in HBV+ liver samples (n=14) 
compared to uninfected controls (n=4 CRC margins). B. Frequency of HBsAg-specific B cells in paired PBMC and liver 
samples. C. Representative staining and frequencies of HBsAg-specific memory B cell subsets in 7 individual HBV+ liver 
samples (pt1-pt7). Error bars indicate mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; p-values 
were determined by Mann-Whitney U test for unpaired data (a); and Wilcoxon signed-rank test (b). 
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5.3.4 Activated HBsAg-specific B cells can be identified in liver-draining lymph node 
Our data thus far has identified HBsAg-specific B cells in the blood and liver of patients with CHB. 
However, by limiting our analyses to these samples, we are potentially underestimating the true 
frequency of HBsAg-specific B cells that may additionally be concentrated (or compartmentalised) 
within lymphoid tissue. Through our close collaboration with the Royal Free surgical and 
histopathological teams, we were able to obtain matched samples of blood, liver and a liver-
draining lymph node from a patient with end-stage HBV infection, facilitating limited analysis of 
HBsAg-specific B cells in liver-associated lymphoid tissue.  
HBsAg-specific B cells (HBsAg-bait+CD20+CD19+) were detected ex vivo at similar frequencies in 
the blood, liver and lymph node (Figure 5.5A). When phenotyped in more detail, preliminary 
analysis in the lymph node revealed a population of HBsAg-specific Ki67+CD38hi B cells, indicative 
of highly activated and cycling B cells that were present in the lymph nodes and absent in the liver 
and PBMCs (Figure 5.5B). These cells may putatively represent germinal centre B cells; however, 
additional makers - including expression of the master regulator of germinal centre B cells, Bcl-6 
(Basso and Dalla-Favera, 2010) - are required to confirm this phenotype. Notably, Ki67+CD38hi B 
cells were identifiable in the liver, however were not specific for HBsAg.  
We next analysed whether any HBsAg-specific plasma cells/blasts (HBsAg-bait+CD20-CD19+) 
were present in each sample. HBsAg-specific plasma cells/blasts were noticeably present in the 
liver and lymph node, but absent in PBMCs. Strikingly, up to 97.7% of plasma cells/blasts in the 
lymph node were specific for HBsAg, compared to 37.7% in the liver (Figure 5.6A). These cells 
expressed high levels of plasmablast markers, including Blimp-1, CD80, CD86 and Ki67, and were 
negative for expression of CD20 (Figure 5.6B) (Fink, 2012). Combined, these data point to the 
presence of HBsAg-specific germinal centres in liver-adjacent lymph nodes, and to a lesser extent 
in liver tissue itself, resulting in the formation of HBsAg-specific plasmablasts. However, without 
the addition of the plasma cell marker, CD138, we are unable to conclude whether these cells 
represent longer-lived plasma cells; further analysis would be required to dissect whether any of 
these cells have the capacity to form long-lived plasma cells, or whether the cells identified 
represent short-lived plasmablasts. However, this analysis sets a precedent for analysing 
HBsAg-specific plasma cells/blasts in future HBV-infected liver samples.  
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Figure 5-5 Cycling HBsAg-specific B cells detected in the draining lymph node in HBV-infected livers 
A. Frequency of HBsAg-specific B cells (CD20+CD19+) in the blood, liver and draining lymph node of a HBV-infected 
liver. B. Sequential flow cytometric plots of HBsAg-specific B cells with features of germinal centre B cells in the draining 
lymph node (absent in the blood and liver). Cycling B cells were identified by expression of Ki67 and CD19. Cycling 
plasmablasts were excluded through expression of CD20. Putative HBsAg-specific germinal centre B cells were identified 
by their expression of CD38 and binding to HBsAg-bait. Numbers in plots represent the gated population as a % of the 
parent population. 
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Figure 5-6 Evidence of HBsAg-specific plasmablasts in the draining lymph node in HBV-infected liver 
A. Frequency of HBsAg-specific plasmablasts (CD20-CD19+) in the blood, liver and draining lymph node of a HBV-
infected liver. B. Flow cytometric plots demonstrating the expression of plasmablast markers on HBsAg-specific 
plasmablasts in the lymph node (identified as HBsAg-bait+CD20-CD19+; purple) compared to B cells (CD20+CD19+; 
grey). Numbers in plots represent the gated population as a % of the parent population (a) or corresponding MFI (b). 
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5.4 Discussion 
In this chapter, we describe an increased proportion of intrahepatic B cells with an atMBC 
phenotype, relative to paired blood samples. These cells phenotypically resemble those seen in the 
periphery, but in particular, demonstrate elevated expression of PD-1 and T-bet. Through 
comparison of HBV-infected livers to uninfected livers, we demonstrate that HBsAg-specific 
B cells are able to persist at the site of infection, yet acquire an atMBC phenotype similar to the 
periphery. In particular, we show preliminary data indicating that HBsAg-specific B cells can also 
be identified in liver-adjacent lymph nodes, where they represent antigen-experienced populations 
akin to germinal centre B cells and plasmablasts. 
In contrast to HBV-specific T cells, that are enriched within the intrahepatic compared to 
peripheral T cell compartment (Fisicaro et al., 2010; Maini et al., 2000), HBsAg-specific B cells were 
not increased in the liver relative to the blood in terms of their proportion within the total B cell 
compartment. However, it is difficult to interpret this frequency in relation to their absolute 
number, due to overarching alterations in the composition of the lymphocyte compartment in the 
liver compared to the blood. In addition, the frequency of B cells may be underestimated 
depending on their localisation within the liver, as demonstrated by variations in the proportion of 
cells isolated compared to those quantified in tissue sections (Steinert et al., 2015). Moreover, while 
their relative abundance is important, there may also be interesting differences in the fine 
specificities of the antibodies and isotypes produced by intrahepatic B cells, compared to their 
peripheral counterparts. Hence, it is important to study antigen-specific B cells in both the liver and 
periphery in more detail.  
To our knowledge, this is the first demonstration that human pathogen-specific memory B cells can 
localise within an infected organ. These data were supported by the finding that HBsAg-specific 
cells resembling plasmablasts were identifiable in the liver and adjacent lymph node in a patient 
with HBV-associated end-stage liver failure. The identification of intrahepatic HBsAg-specific B 
cells has important implications for their roles at the site of viral replication and disease pathology. 
Firstly, it implies that it may be possible to boost intrahepatic plasma cells capable of producing 
anti-HBs antibodies with neutralising or other antiviral capacity. Local production of anti-HBs 
antibodies would facilitate their binding to intrahepatic virions to block infection of new 
hepatocytes, or to HBsAg on the hepatocyte membrane to promote elimination through antibody-
dependent cell-mediated cytotoxicity (ADCC). Immunohistological staining of HBV-infected liver 
biopsies has demonstrated both cytoplasmic and membranous HBsAg staining, depending on the 
target epitope of the anti-HBs antibody used, revealing the potential for ADCC-mediated depletion 
of infected hepatocytes (Eren et al., 1998; Ray et al., 1976). Expression of HBsAg on the plasma 
membrane is postulated to vary according to disease state, with membranous localisation closely 
related to active viral replication (Chu and Liaw, 1987). These reports lend strength to the idea that 
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local production of anti-HBs may facilitate eradication of HBV-infected hepatocytes through 
ADCC. Moreover, work using a hepatoma cell line has suggested hepatocytes may also be able to 
internalise anti-HBs antibodies through FcR receptors that could then directly exert intracellular 
antiviral effects (Schilling et al., 2003).  
Analysis of liver-adjacent lymphoid tissue showed that HBsAg-specific plasmablasts, and to a lesser 
extent, germinal centre B cells, may develop and persist in liver-adjacent lymphoid structures, in line 
with observations of enlarged hepatic lymph nodes in patients with CHB (Choi et al., 2001; Kuo et 
al., 2006). This observation is perhaps counter-intuitive, since we have previously hypothesised that 
patients with CHB have a diminished ability to produce anti-HBs. However, interpretation of this 
data has some important caveats. Firstly, the lack of additional samples limits the context with 
which we have to interpret the data; for instance, we are not able to determine the relative 
abundance of these cells compared to other samples and disease states. In addition, simple 
phenotyping of these cells is too reductionist. The limited assessment of phenotypic markers 
cannot conclude whether these cells represent short-lived plasmablasts or longer-lived, high-affinity 
plasma cells. Finally, we were not able to assess the quality of antibody produced by these cells. 
Thus, future studies should aim to clone the antibody produced by these cells and assess its 
neutralising capacity. Overall, these cells may represent a functional population of anti-
HBs-producing cells that could be harnessed to promote virus neutralisation at the site of 
replication. 
 
The detection of HBsAg-specific plasmacytes within the liver tissue itself may also have important 
inferences for the formation of HBsAg-specific humoral immunity at the site of infection. It has 
long been described that ectopic lymphoid structures resembling germinal centres can arise in non-
lymphoid tissues and assist in the activation, proliferation and differentiation of B cell responses. 
One such description is the formation of bronchus-associated lymphoid tissue (BALT), identified 
in infectious settings of the airways and characterised by a defined B cell follicle containing blasting, 
Ki67hi B cells (Randall, 2010). BALT is postulated to assist in the promoting of local antiviral 
responses: for example, influenza infection rapidly induces the formation of BALT, capable of 
priming antigen-specific T and B cell responses independently of primary lymphoid organs 
(Moyron-Quiroz et al., 2004). Emerging evidence suggests that persistence of germinal centre 
responses may have a role in boosting protection from highly mutating viruses, such as influenza. 
Lung germinal centres support B cell proliferation and the generation of neutralising antibodies, 
and facilitate fine-tuning of B cell responses by antigen and TFH cells (Adachi et al., 2015). The 
identification of these structures in the lung has overturned the dogma that antigen-specific 
responses are solely initiated in lymphoid tissue and suggests that tissue localisation of B cells may 
provide an important mechanism for antiviral control. 
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Thus, the identification of cycling plasmacytes within liver tissue could arguably elude to the 
formation of ectopic germinal centres in the form of intrahepatic lymphoid follicles (ILFs). ILFs 
have been described in the livers of patients with autoimmune hepatitis, primary biliary cirrhosis 
and CHB, yet are most highly reported in HCV infection (Lefkowitch et al., 1993). Here, ILFs with 
features of ectopic germinal centres (including Bcl-6 and Ki67) are postulated to facilitate 
expansion of both HCV-specific and autoreactive clones (Murakami et al., 1999; Tucci et al., 2014). 
Thus, the existence of these structures may have unique importance to HCV, due to the occurrence 
of B cell-associated lymphoproliferative disorders, including mixed cryoglobulinemia and B cell 
non-hodgkin lymphomas that arise in a subgroup of HCV-infected patients.  
In contrast, a role for ILFs in CHB has largely been ignored. In comparison to HCV, patients 
infected with HBV show little signs of autoimmunity. It also seems unlikely that HBsAg-specific B 
cells undergo clonal expansion in the liver as ILFs in CHB have been shown to lack a well-formed 
germinal centre (Murakami et al., 1999), in line with the absence of HBsAg-specific germinal centre 
B cells in our sample. Due to their apparent role in amplifying tissue-based responses, a lack of 
intrahepatic germinal centre formation in the livers of patients with CHB may offer a mechanism 
by which local humoral immunity is impaired. A recent paper testing the immunotherapeutic effects 
of TLR-7 agonists in HBV-infected chimpanzees demonstrated transient induction of B and T cell 
aggregates in portal regions following treatment, coinciding with prolonged suppression of serum 
viral DNA and antigens. Preliminary investigation suggested that these structures did not contain 
germinal centre reactions; however, the association between the formation of these structures and 
the antiviral response to treatment, suggested that they may play a role in promoting an effective 
response against HBV (Li et al., 2018). Further in-depth analysis is required to investigate whether 
memory B cells can become activated and differentiate within the liver, or traffic to the liver post 
activation, and how this affects the development and maintenance of local humoral responses.  
 
These data demonstrated a significant expansion of global and antigen-specific atMBCs as a 
proportion of mature B cells in HBV-infected liver compared to paired blood samples, suggesting 
that liver-infiltrating B cells are skewed towards an atMBC phenotype at the site of disease 
pathology. This accumulation of atMBCs may have important consequences for immune 
pathology. As discussed in detail in previous chapters, a subset of atMBCs express high levels of 
IgM. This finding raises the possibility that liver-infiltrating B cells, with a naïve-like phenotype, 
contribute to the immunopathogenesis of CHB. In particular, it will be important to investigate 
whether the IgM-expressing fraction of atMBC in CHB can synthesise antibodies with pathogenic 
potential, as previously ascribed to intrahepatic IgM+anti-HBc antibodies in HBV-associated acute 
liver failure (Farci et al., 2010).  
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On the other hand, this expansion of atMBCs within the intrahepatic B cell pool, may represent 
adaptations of liver-infiltrating B cells, in line with the tolerogenic environment of the liver. While 
there were significantly more atMBCs in HBV+ liver, CD27-CD21lo/- B cells also represented a 
substantial component of the global B cell pool in healthy perfusate samples and margins taken 
from cancer resections. The liver is exposed to significant amounts of harmless and pathogenic 
antigen due to its role in the detoxification of products in the portal vein blood, draining directly 
from the gastrointestinal tract. It could therefore be proposed that intrahepatic B cells of global 
antigen-specificity acquire this phenotype as a result of excessive antigen exposure in the liver, 
possibly as a tolerogenic mechanism contributing to the preservation of organ integrity. This is 
particularly relevant in the context of cytokine secretion, where a reduced capacity to secrete IL-6 
and TNFa (demonstrated in Chapter Four) may be helpful in containing a pro-inflammatory 
response and limiting excessive tissue damage.  
In line with this, preliminary data from patients with end-stage liver failure showed high levels of 
atMBCs cells within the intrahepatic B cell pool. These patients are well-described as having high 
levels of bacterial infection and endotoxemia in the liver due to worsening of intestinal defence 
mechanisms (Thalheimer et al., 2005). This is likely to increase both the inflammatory state of the 
liver and the antigenic burden, and thus may explain the enrichment of atMBCs seen. However, 
patients with non-viral hepatitis, but high levels of ALT, demonstrated levels of atMBCs similar to 
that of healthy samples, suggesting that inflammation alone has a limited effect on the expansion of 
atMBCs in the human liver. Therefore, it could be postulated that increased exposure to antigen is a 
primary driver of atMBCs in the liver. Although atMBC could be identified in non-HBV infected 
livers, they were more frequent in those infected with HBV and expressed more PD-1 in the latter 
group. These findings, from ex vivo examination of B cells freshly isolated from a large number of 
human liver samples, therefore support a combined effect of the tolerogenic liver milieu and HBV 
viral antigen in driving the atypical and PD-1hi phenotype. 
 
Overall, these data point to a previously unappreciated potential for a role of antigen-specific 
B cells in HBV-immune control at the site of viral replication. Intrahepatic HBsAg-specific memory 
B cells were enriched for an atMBC phenotype, similar to findings of peripheral HBsAg-specific 
B cells, and in line with high levels of antigen and inflammation in HBV-infected liver. Thus, 
immunotherapeutic approaches to boost B cell responses in CHB should consider direct targeting 
of therapies to intrahepatic B cell populations to maximise efficacy and harness B cell effector 
functions at the site of viral replication. Finally, the identification of HBsAg-specific B cells in 
liver-adjacent lymph node suggests that there may be alternative populations of HBsAg-specific B 
cells whose functional contribution to intrahepatic immune responses should now be considered in 
detail. 
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Chapter 6 Discussion and future directions 
 
6.1 Thesis conclusions 
Ongoing work in the field of HBV aims to understand the multi-faceted failure of the immune 
response in the control of HBV and develop new immunotherapeutic strategies to induce 
functional cure in patients with CHB. The rationale for this approach is supported by the 
observation that most adults infected with HBV resolve the infection naturally, and are able to 
maintain the virus under lifelong immune control. It has long been recognised that patients with 
CHB fail to produce sufficient levels of protective anti-HBs antibodies to overcome the significant 
quantities of circulating HBsAg released by infected hepatocytes. However, investigation of B cell 
and humoral responses in CHB has been significantly neglected. In this study, I have for the first 
time analysed the phenotype and function of HBsAg-specific B cells in both the blood and the liver 
of patients with CHB. I demonstrate an accumulation of B cells with defective antiviral function 
within the global and antigen-specific population, in both the circulation and liver of patients with 
CHB. I postulate that this phenomenon may contribute to impaired antiviral responses observed in 
CHB, and provide new targets for immunotherapeutic therapies aimed at achieving functional cure 
in HBV.  
One of the key strengths of this study is the utilisation of well-characterised clinical samples, 
permitting careful description of antigen-specific responses, both in chronic infection and 
longitudinally throughout acute-resolving HBV. In studying these samples, I have been able to 
compare the frequency and phenotype of HBsAg-specific B cells according to the disease status of 
the individual, revealing a number of key findings. Firstly, I showed that HBsAg-specific B cells 
persist in the circulation of patients with chronic infections at similar frequencies to those with 
resolving infection and approximating levels reached by protective HBV-vaccination. However, 
HBsAg-specific B cells demonstrated defective production of anti-HBs antibodies, relative to 
HBV-vaccinated healthy controls. This allowed me to hypothesise that there is not a defect in the 
numerical differentiation or formation of HBsAg-specific B cells, but instead that these cells are 
dysfunctional and incapable of producing sufficient levels of protective anti-HBs antibody.   
Secondly, comparison of HBsAg-specific B cells between vaccinated healthy controls and patients 
with CHB revealed a number of ways in which HBsAg-specific B cells may be impacted by chronic 
HBV infection. Ex vivo staining showed that HBsAg-specific B cells from patients with CHB had 
elevated expression of inhibitory receptors, PD-1 and FcRL5, alongside a number of phenotypic 
markers reflective of an accumulation of “dysfunctional” atMBCs. Patients with CHB also had 
increased frequencies of global atMBCs, relative to vaccinated healthy controls. Further 
characterisation of these cells suggested that these cells have impaired antiviral function following 
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triggering of the BCR and CD40 co-stimulation; thus, their accumulation within the HBsAg-
specific pool may contribute to decreased antiviral activity against circulating antigen and sub-viral 
particles. This expansion of supposedly dysfunctional atMBCs within the global as well as antigen-
specific B cell population is interesting and mirrors that seen within CD8 T cells, whereby global 
T cell dysfunction is thought to arise due to chronic inflammatory events and exposure to the 
inflamed microenvironment of HBV-infected liver (Das et al., 2008; Park et al., 2016; Walker et al., 
2013). Preliminary investigation suggested that B cell function could be partially restored through 
PD-1 blockade in combination with CD40-L stimulation.  
Cross-sectional analysis did not reveal a clear correlation of either the frequency of HBsAg-specific 
B cells or their phenotype to clinical parameters of disease. However, these provide only a snapshot 
into the impact of disease on B cells. In comparison, careful characterisation of HBsAg-specific B 
cells throughout acute- and chronic-resolving infection facilitated consideration of the frequency 
and phenotype of HBsAg-specific B cells throughout the time course of infection. This analysis 
revealed a tendency for HBsAg-specific B cells and atMBCs (both global and antigen-specific) to 
decrease towards the resolution of disease. Although I was unable to attribute these variations to a 
particular component of HBV-infection, I suggest that an expansion of HBsAg-specific atMBCs 
can be associated with active infection. Moreover, patients with active disease (viral loads 
>2000IU/ml) showed higher expression of PD-1, suggestive of a role for high levels of HBV DNA 
in impairing B cell responses.  
Finally, access to precious human HBV-infected and HBV-unexposed liver samples has allowed me 
to characterise antigen-specific B cells at the site of infection; one of the few examples where this 
has been possible in human non-lymphoid tissue. In particular, I provide evidence that HBsAg-
specific B cells are able to persist in the liver; however, their function may be regulated by their 
anatomical location. Intrahepatic HBsAg-specific B cells showed a similar accumulation of atMBCs 
to those identified in the periphery, yet HBsAg-specific cells resembling germinal centre B cells and 
plasmablasts could be identified in the liver-draining lymph node of a patient with end-stage HBV. 
Crucially, the identification of antigen-specific B cells at the site of viral replication raises prospects 
for immunotherapeutic targeting of key antiviral effector cells at the site of pathology. 
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6.2 Unanswered questions and future directions 
The work presented within this thesis raises many interesting avenues for future research into the 
impact of HBV infection on antigen-specific B cell responses and their role in long-term viral 
control. Although not exhaustive, the following describes some of the key unanswered questions 
raised by this study, and discusses potential directions for future work investigating B cell responses 
in CHB. 
 
6.2.1 What is the memory potential of CD27-CD21low/- memory B cells? 
CD27-CD21low/- B cells described within this study have been referred to throughout this thesis as 
atMBCs, due to their similarities in phenotype and function to those reported in the litreature, and 
in particular, their well-documented expansion in the context of chronic infections. However, this 
study has not explicitly characterised the memory potential of these cells. Immunological memory is 
defined as the ability of lymphocytes to respond rapidly upon secondary exposure to their cognate 
antigen to produce high-affinity antibodies. Many methodologies can be applied to distinguish B 
cells with memory potential, including: rates of somatic hyper-mutation and cell division (as a proxy 
of clonal expansion within the germinal centre); isotype class-switching; and increased expression of 
costimulatory molecules, CD80, CD86 and CD27.  
My data also revealed that a significant proportion of atMBCs were IgM+CD27-CD21low/-. By 
conventional definitions, these cells arguably do not represent memory cells and instead may be a 
naïve-like cell type, as discussed in Chapter Four. Relying solely on such definitions, however, may 
ignore some important cell types. Recent studies have shown that antigen-specific IgM+ memory 
B cells represent a key effector cell upon secondary exposure to Plasmodium. As a long-lived cell 
type, these cells dominated early secondary responses, and were able to out-compete IgG+ memory 
B cells to produce rapid and plastic humoral responses (Krishnamurty et al., 2016). However, IgM+ 
memory B cells are typically defined by expression of the classical memory marker, CD27, absent 
on IgM+ atMBCs (Seifert and Küppers, 2016). It will now be key to examine the level of somatic 
hyper-mutation occurring within IgM+CD27-CD21low/- B cells, and determine their memory 
potential through their ability and rapidity in differentiating into antibody-secreting cells.  
 
6.2.2 Dynamics of atMBCs and/or HBsAg-specific B cells during treatment for HBV 
Data presented within this thesis suggest that atMBCs decrease in frequency following resolution of 
disease. To further support this finding, it would be interesting to examine how HBsAg-specific 
B cell responses evolve throughout treatment. Studies in HIV infection have shown that the 
expansion of atMCBs is corrected after prolonged anti-retroviral therapy and subsequent reduction 
in viraemia (Amu et al., 2014; Muema et al., 2015). Cross-sectional analysis pre- and post-treatment 
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showed that the proportion of cells with an atMBC phenotype decreased more significantly upon 
early initiation of ART, and coincided with improved responses to HIV- and non-HIV- antigens 
(Moir et al., 2010). This effect was postulated to be the result of reduced B cell hyper-activation as a 
result of lower antigen loads, resulting in lower rates of B cell turnover and apoptosis. Ongoing 
studies within our group are now assessing the kinetics of B cell subsets in patients undergoing 
nucleoside withdrawal therapy, in some cases followed by short term pegylated-IFN treatment. 
Such strategies aim to reactivate immune control and promote HBsAg seroconversion, whilst 
removing dependency on life-long nucleoside treatment.  
However, recent studies in LCMV infection have suggested that type I IFN may have adverse 
effects on the survival and function of antigen-specific B cells. Early onset type I IFN induced 
inflammation was postulated to bias antiviral B cell differentiation of naïve B cells into short-lived 
plasmablasts, mediated by bystander myeloid cells, dendritic cells and T cells (Fallet et al., 2016). 
Similarly, type I IFN suppressed antibody secretion and impaired the survival of antigen-specific 
B cells via the recruitment of inflammatory monocytes (Sammicheli et al., 2016), and promoted 
CD8 T cell deletion of antiviral B cells (Moseman et al., 2016). In all three reports, blockade of IFN 
signalling significantly boosted antigen-specific B cell survival, resulting in robust production of 
neutralising antibodies. Therefore, it will be important to monitor the effects of interferon 
treatment on HBsAg-specific B cell responses. 
 
6.2.3 Additional factors contributing to B cell dysfunction in CHB 
It is clear that substandard antibody production by HBsAg-specific B cells in CHB cannot solely be 
attributed to the atMBC fraction expressing inhibitory receptors. There are likely additional, more 
generalised B cell defects exerted by the presence of the virus and high levels of circulating antigen. 
Emerging evidence has identified new molecular targets of suppression arising in B cells during 
viral infection. One such mechanism, shown to regulate BCR signalling and antibody secretion in 
B cells, is the upregulation of the inositol phosphatase, PTEN (phosphatase and tensin homolog). 
PTEN is a tumour suppressor protein and has both lipid and protein phosphatase abilities. 
Through its negative regulation of the PI3-kinase cascade, PTEN has diverse effects on multiple 
aspects of cellular homeostasis, including cell proliferation and survival, cell migration and self-
renewal of stem cells (Milella et al., 2015). As a result, it has long been known that alterations in 
levels and activity of PTEN result in an increased susceptibility to various forms of cancer, and 
often underpin rapid tumour progression (Alimonti et al., 2010; Lee et al., 2018). In HBV infection, 
HBx protein has been proposed to drive expression of PTEN in an HBV-expressing HepG2 cell 
line via the upregulation of miRNA-21, resulting in increased hepaotcyte proliferation (Damania et 
al., 2014). However, subsequent studies have since suggested that this effect was independent of 
PTEN, instead showing a role for PTEN in promoting HBV replication (Wu et al., 2018). 
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Following on from this, PTEN expression has been demonstrated to regulate antiviral responses in 
acute viral infection, reflective of defective responses demonstrated by atMBCs in this study. 
Infection with gammaherpesvirus-68 upregulated expression of PTEN in murine B cells, which 
inhibited PI3-kinase signalling and resulted in impaired BCR signalling and CXCR4-mediated 
migration. Importantly, overexpression of PTEN significantly suppressed antibody production by 
B cells, demonstrating a previously unidentified pathway of virus-induced immune suppression of 
humoral responses (Getahun et al., 2017). However, how the virus was able induce PTEN 
expression in B cells not containing the virus is not yet known.  
Thus, in addition to the expansion of dysfunctional atMBCs driven by persistent exposure to high 
levels of circulating antigen, HBV may also impart additional defects on the functioning of global 
B cell subsets. A back-to-back study that compared the transcriptome of memory B cell subsets in 
patients with CHB showed differential expression of genes in all subsets compared to healthy 
controls, including genes involved in the regulation of NFkB signalling and in the maintenance of 
TFH - B cell interactions (Salimzadeh et al., 2018). Whilst these were most pronounced within 
atMBCs, differences were also seen in cMBCs, activated memory B cells and naïve B cells. These 
data showed that HBV infection does not only alter the composition of B cells within patients with 
CHB, but can also impart significant differences in gene expression. A recent study has shed light 
on mechanisms by which HBV viral particles can manipulate B cell responses, whereby HBsAg was 
shown suppress phosphorylation of the transcription factor CREB and restrict TLR-9 promoter 
activity. As a result, TLR-9 expression and downstream function was suppressed in B cells from 
patients with CHB, including proliferation and cytokine production (Tout et al., 2018). 
 
6.2.4 Impact of chronic HBV infection on TFH – B cell interactions  
Several lines of evidence within this study lead us to postulate that T follicular (TFH) – B cell 
interactions may be impaired in CHB, which may have direct effects on the ability of 
HBsAg-specific B cells to secrete protective antibody. These include: 
1. Decreased expression of CD40 on atMBCs, which may impair B cell co-stimulation via 
CD40-ligand expression on CD4 T cells 
2. Decreased expression of CXCR5 on atMBCs, possibly resulting in impaired migration of 
atMBCs to B cell follicles in lymphoid tissue 
3. Decreased levels of class-switching, indicative of impaired TFH help and induction of class-
switch recombination/germinal centre responses 
The efficiency of TFH – B cell interactions in viral infections is key to the generation of antibody 
responses. CD4 T cell depletion studies have shown that the induction of a strong antibody 
response is dependent on an intact CD4 compartment (Vieira and Rajewsky, 1990). Through the 
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expression of ICOS and CD40-ligand, and production of helper cytokine IL-21, TFH cells support 
the expansion and differentiation of B cells into long-lived plasma cells or memory cells (Fahey et 
al., 2011; Harker et al., 2011; Lindqvist et al., 2012). An absence TFH at the onset of LCMV 
infection curtails the humoral immune response, preventing clearance of the virus (Fahey et al., 
2011). However, TFH cells are also important in late stages of persisting viral infection: ablation of 
CXCR5+ CD4 T cells after the initial establishment of immunoglobulin responses, showed that TFH 
are critical to the ongoing production of neutralising antibody against the infecting virus and newly 
emerging variants (Greczmiel et al., 2017). These findings suggest that TFH are central to the 
evolution of B cell clonality throughout the course of persistent infection.  
Accumulating data purport to the dysregulation of TFH responses resulting in aberrant protective 
B cell responses in chronic infection. Similar to CD8 T cells, HBV-specific CD4 T cells are 
detected at very low frequency throughout different stages of HBV infection (Penna et al., 1996). 
HBV-specific TFH have been shown to be increased in CHB compared to healthy controls (Hu et 
al., 2014), yet some reports exhibit functional exhaustion associated with high expression of PD-1 
(Raziorrouh et al., 2014). Dysfunction of CD4 T cells has been partially attributed to an expansion 
of IL-10-producing B cells in hepatocellular carcinoma (Xue et al., 2016). Along the same line, 
IL-10-producing B regulatory cells have also been shown to suppress inflammatory responses by 
promoting the differentiation of T regulatory cells (Tregs) (Flores-Borja et al., 2013). An early study 
addressing the inability of B cells from HBsAg carriers to produce anti-HBs, demonstrated that co-
culture of B and T cells from vaccinated healthy controls with T cells from HBsAg carriers 
suppressed anti-HBs production (Dusheiko et al., 1983), implicating a role for regulatory T cells in 
impairing TFH-help and anti-HBs production in CHB. These data are consistent with a recent 
report of Treg-mediated suppression of HBsAg-specific TFH in HBV, resulting in impaired 
production of anti-HBs antibodies in a murine model of HBV. In vivo blockade of CTLA-4 restored 
the ability to clear HBV infection in mice, and significantly increased IL-21 production by TFH in 
patients with CHB, proposing a potential target for the rescue of anti-HBs responses by 
HBsAg-specific B cells (Wang et al., 2018b). CXCR5+CD4+ TFH in HBV had a significant 
expansion of FoxP3+CD25+ Treg-like TFH cells. These were distinct from CD25- TFH and secreted 
lower IFNg but increased levels of TGF-b. Crucially, CD25+ TFH were less capable of inducing 
plasmablast differentiation in B cells and instead promoted the differentiation of regulatory B cells 
(Wang et al., 2018a).  
Thus, future studies should analyse HBsAg-specific B cells, Tregs and TFH in parallel to better 
define the influence of CD4 T cell help on B cell functionality in patients with CHB. During 
infection, B cells and TFH reside predominantly within the B cell follicles in secondary lymphoid 
tissues. This localisation is mediated via expression of CXCR5, responding to high concentrations 
of CXCL13 within the B cell zone. Therefore, investigation of TFH – B cell interactions would be 
most informative within secondary lymphoid organs or in liver tissue, which may have the potential 
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to serve as a secondary lymphoid site. Due to the relative difficulty in obtaining these samples from 
HBV-infected individuals, this would be most likely achieved through immuohistochemical 
analyses in paraffin-embedded slides. This would facilitate assessment of relative numbers of B and 
TFH cells, co-localisation of cells and formation of germinal centres, and phenotypic analysis of TFH 
subsets. Access to fresh tissue, where possible, would permit functional analyses, for example TFH 
production of IL-21 – the key cytokine involved in driving B cell proliferation and germinal centre 
responses (Linterman et al., 2010). Additional analysis of a newly identified population of CXCR5+ 
CD8 T cells, identified in the B cell follicles of mice during acute and chronic LCMV infection, may 
also have an important role in driving protective immunity (He et al., 2016). These have most 
recently been associated with spontaneous HIV controllers and produced high levels of IL-21 
(Perdomo-Celis et al., 2018). 
However, there also appears to be a role for innate cell types in modulating TFH - B cell interactions 
in chronic viral infection. Activated NK cells have been demonstrated to deplete CD4 T cell 
responses in the spleen of mice infected with LCMV, resulting in impaired germinal centre 
formation and LCMV-specific antibody responses (Rydyznski et al., 2015; Waggoner et al., 2011). 
Follow-up work has since demonstrated that NK cells can directly suppress TFH cells and germinal 
centre formation by a perforin-dependent mechanism, resulting in fewer antigen mutations within 
antigen-specific B cells (Rydyznski et al., 2018). Preliminary data from our group, testing the in vivo 
potential of NK cells to regulate vaccine-induced CD8 T cell responses, has shown that NK cell 
depletion in the setting of chronic HBV infection, increases the frequency and effector function of 
CD8 T cell responses following therapeutic vaccination, and can result in induction of anti-HBs. In 
contrast, therapeutic vaccination in the presence of NK cells was insufficient to induce protective 
humoral immunity (Dr. Mariana Diniz, unpublished data). 
 
6.2.5 Understanding the role of B cells in the liver 
The identification of memory B cells in the liver raises the possibility that liver-infiltrating B cells 
acquire a phenotype adapting them to the tolerogenic environment of the liver. Future studies 
should seek to pinpoint factors that promote their accumulation, for example the relative 
contributions of TLR-ligands, inflammatory cytokines and antigenic stimuli. To build on this, it 
would be of significant interest to examine whether any of these cells are in fact resident within the 
liver, where they may be uniquely specialised and could represent an attractive target for 
immunotherapeutic approaches. Recent studies have characterised specialised tissue-resident 
lymphocyte populations that express an array of receptors mediating their recruitment to, and 
retention within, tissues. Preliminary investigations using murine parabiosis models has identified a 
population of resident, influenza-specific memory B cells, that were dependent on germinal centre 
responses (Allie et al., 2017). These data purport to the existence of tissue-specialised B cells in 
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mice; however, to date, there has been no investigation of tissue-resident B cell populations in 
humans, which is currently limited by a lack of residency markers for human B cells.  
In contrast, many studies have revealed that a large proportion of CD8 T cells in non-lymphoid 
tissue are resident (reviewed in Mueller and Mackay, 2016). Our group has recently characterised a 
population of CD69+CD103+ tissue-resident CD8+ T cells (TRM) present in the liver but absent in 
the blood (Pallett et al., 2017). These cells were selectively increased in HBV+ patients that 
controlled infection, and were shown to be specific for all four major HBV proteins. Importantly, 
these cells appeared to be specialised in line with the liver environment: TRM were capable of rapid 
production of IL-2 and IFNg, but showed diminished granzyme production, supporting a role as a 
non-cytolytic subset involved in immune surveillance. Combined, these data suggested that HBV-
specific TRM are located within the liver, where they are uniquely adapted to exert antiviral effector 
function. 
An additional population of liver-resident NK cells, defined as CXCR6+T-betloEomeshi, have also 
been identified with unique features adapting them to the liver (Stegmann et al., 2016). These cells 
produced fewer cytotoxic mediators and pro-inflammatory cytokines, yet upregulated expression of 
TRAIL – a key ligand in promoting HBV pathogenesis through the deletion of HBV-specific 
T cells (Peppa et al., 2013), hepatocytes (Dunn et al., 2007) and stellate cells (Singh et al., 2017). 
Follow-up work, capitalising on HLA-mismatched liver transplants (i.e. where the donors and 
recipients are HLA-mismatched), suggested that these cells are long-lived and likely did not 
recirculate (Cuff et al., 2016). Importantly, Cuff et al., set a premise for using explanted 
HLA-mismatched liver allografts as a method of examining tissue-resident populations. Through 
methods such as these, it may be possible to identify a unique liver-resident B cell population that 
may have important roles against hepatic pathogens. Overall, liver-resident lymphocytes are 
attractive options for therapeutic targets due to their anatomical location and specialised function 
(Bolte and Rehermann, 2017; Pallett et al., 2017); thus, identification of liver-resident B cells may be 
an important arm of developing new therapeutic strategies.  
In addition, the cytokine-producing potential of B cells is interesting and warrants further 
investigation, particularly with regard to their ability to produce antiviral cytokines that may have 
key roles against HBV in the liver. As discussed earlier, effector B cell subsets have been identified 
that secrete IL-12 and IFN, and amplify T cell responses (referred to as Be-1 cells) (Lund, 2008). In 
opposition, IL-10 and TGF-b producing B cells have an active role in suppressing immune 
responses. Data presented in Chapter Four show that peripheral atMBCs have impaired production 
of antiviral IL-6 and TNFa that was increased following checkpoint blockade. However, the 
cytokine-producing potential of intrahepatic B cells has yet to be examined and may have important 
implications in the control of viral replication in the liver. Pro-inflammatory cytokine production is 
also important to consider with regard to its potential for inducing tissue damage. Thus, it may be 
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important to examine the bystander effects of B cell-derived cytokines, particularly following 
checkpoint blockade. Furthermore, previous work from our group has identified an expansion of 
IL-10-producing B cells with a regulatory phenotype in patients undergoing hepatic flares (Das et 
al., 2012). In light of our identification of HBsAg-specific B cells and their ability to localise within 
this liver, it would now be interesting to examine whether antigen-specific cells with regulatory 
potential, have a role in suppressing intrahepatic immune responses and thus contribute to 
impaired antiviral immunity at the site of infection. 
 
6.2.6 Neutralising antibody production by HBsAg-specific B cells  
The principal way in which B cells contribute to immune control is through the production of 
antibodies that are able to neutralise infectivity of viral particles and induce killing of infected cells. 
Despite circulating at comparable levels to HBV-vaccinated or resolved individuals, data from this 
study suggest that HBsAg-specific B cells are impaired in their ability to produce protective anti-
HBs antibody. However, as demonstrated by ELISPOT data showing low-level production of anti-
HBs by B cells isolated from patients with CHB and in line with clinical observations of immune 
complexes in patients with CHB (Gerlich, 2007), patients with CHB are not completely devoid of 
functional HBsAg-specific B cells, raising prospects for immunotherapeutic boosting of these cells 
to promote HBsAg seroconversion. This is underscored by observations of HBV reactivation in 
patients undergoing treatment for B cell lymphoproliferative disorders, showing a role for 
HBsAg-specific B cells in control of CHB (Evens et al., 2011). Rituximab-mediated depletion of 
CD20+ B cells in HBsAg+ patients worsened parameters of disease, including: reduction of 
protective anti-HBs (Tsutsumi et al., 2005); increases in levels of HBV DNA and HBsAg (Viganò 
et al., 2014); and evolution of hepatitis (Skrabs et al., 2002). Investigation of the quality of 
antibodies produced by HBsAg-specific B cells was beyond the current capability of this study; 
however, future studies should now make it a priority to assess ways in which we can recover or 
replace antibody production by HBsAg-specific B cells. Given that ASCs downregulate surface 
expression of immunoglobulin following antibody production, direct probe-binding methods for 
isolating antigen-specific ASCs are of limited used. Instead, the isolation of antigen-specific 
memory B cells is likely to provide a more viable method. Using a bait to FACs sort single antigen-
specific B cells, it is then possible to reconstitute mAbs with corresponding specificity for the BCR 
of the sorted cell and determine the frequency of mAbs that bind the probe used to sort. This 
method is currently being employed by multiple groups to develop neutralising antibodies (nAb) 
for therapeutic use for the treatment of CHB. 
The development of nAb as therapies or targets for vaccination has been well-illustrated in HIV 
infection. Single-cell cloning of memory B cells in HIV-elite controllers facilitated the isolation of 
antibodies with broad and neutralising activity (Scheid et al., 2009). Injection of highly potent HIV-
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specific broadly neutralising antibodies (bnAbs) has demonstrated efficacious protection against 
HIV against genetically diverse strains in models of simian-HIV (Gautam et al., 2016, 2018) and 
suppression of viraemia (Barouch et al., 2013; Nishimura et al., 2017; Shingai et al., 2013). 
Administration of bnAbs together with TLR-7 agonists has since been demonstrated to delay viral 
rebound following discontinuation of anti-retroviral therapy, suggesting that concurrent innate 
immune stimulation may represent a potential strategy to target the viral reservoir (Borducchi et al., 
2018). 
Taking these forward to human trials, monotherapy using an antibody targeting the CD4 binding 
site of HIV demonstrated potent reduction in viraemia (Caskey et al., 2015). However, 
monotherapy by itself was insufficient to maintain long-term viral suppression. Recent follow-up 
work using combinations of bnAbs in the absence of antiretroviral therapy showed that 
combination therapy could maintain viral suppression and reduced the likelihood of developing 
resistance (Bar-On et al., 2018; Mendoza et al., 2018). Notably, two individuals studied remained 
suppressed beyond the presence of the antibody; thus, antibody therapy likely exerts additional 
effects distinct from direct neutralisation activity.  
It is increasingly recognised that antibody-based therapies such as these may have the added 
advantage of generating or re-activating T cell responses. Hydrodynamic injection of novel nAbs in 
HBV-transgenic mice increased the frequency of HBcAg- and HBsAg-specific effector CD8 T 
cells, likely due to the reduction in levels of HBsAg facilitating restoration of exhausted 
HBV-specific T cell responses (Zhang et al., 2015). However, increasing evidence suggests that 
antibodies may also augment T cell responses through the formation of immune complexes. 
Antigen processing and presentation by dendritic cells promotes CD8 T cell activation through a 
process of cross-presentation. Several studies now suggest that antibody engagement of Fc-
receptors on dendritic cells in the form of immune complexes may result in superior priming of 
T cell responses (Wen et al., 2016). Recent work has suggested that the target of activatory Fc 
receptors on splenic dendritic cells in the presence of co-stimulatory signals, promotes CD4 and 
CD8 T cell responses under inflammatory conditions (Lehmann et al., 2017). This enhanced CD4 
T cell activation can in turn lead to superior B cell responses, referred to as the vaccinal effect, and 
represents a key hope for antibody therapy in chronic infection and anti-tumour treatment (DiLillo 
and Ravetch, 2015). 
Overall, through studying the phenotype of B cells producing functional antibodies in patients that 
naturally resolve infection, it may be possible to identify targets by which to promote the natural 
production of nAb in CHB. In HBV, two classes of nAbs have been described that target the viral 
entry receptor, NTCP, and HSPGs (outlined in 1.6.1). The neutralising efficacy of anti-HBV 
antibodies has been well demonstrated in primate models: inoculation of chimpanzees with human 
monoclonal antibodies prior to viral challenge prevented the development of infection (Hong et al., 
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2004; Kim et al., 2008). Of note, the antigen incorporated within our HBsAg-bait reagent did not 
span the Pre-S1 region and therefore may not detect B cells responsible for secreting antibodies 
that block viral binding to the hepatocyte (Sankhyan et al., 2016). Thus, future studies should also 
aim to dissect antibody responses against different HBsAg epitopes. Comparison of the BCR 
repertoire of HBsAg-specific B cells to anti-HBs secreted by HBV-resolved patients could also 
provide valuable insights into the gold-standard antibody or B cell phenotype required for 
neutralisation of HBV. 
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6.3 Outlook: paving the way for B cell-targeted research in HBV 
To date, none of the currently developed antiviral strategies, including therapeutic vaccination, viral 
entry inhibitors or immune modulators, reliably achieve functional cure. Looking forward, it is 
likely that attempts to promote clearance of HBsAg may reduce HBsAg-induced tolerance enough 
for the host to re-establish protective immune responses. Using HBV-infected murine models, with 
contrasting high and low levels of circulating HBsAg, Zhu et al., showed that clearance of HBsAg 
via therapeutic anti-HBs neutralising antibodies effectively restored protective CD4 T cell and 
B cell responses to prophylactic HBV vaccination, ultimately leading to anti-HBs seroconversion 
(Zhu et al., 2016). In this way, immunotherapeutic approaches to enhance cytotoxic potential of 
CD8 T cells to clear infected hepatocytes and reduce the circulating viral/antigen load may have 
knock-on effects on lifting dysfunction of B cells, whilst simultaneously decreasing the occurrence 
of immune complex formation and releasing the effector function of un-complexed antibodies. 
However, the identification of a number of defects within HBsAg-specific B cells themselves 
identifies novel targets for immunotherapeutic approaches aiming to boost the production of 
neutralising antibodies and promote loss of HBsAg – regarded as the hallmark of functional cure. 
These include targeting of inhibitory receptors and the potential for agonistic anti-CD40 
monoclonal antibodies in promoting antibody responses. This study also highlights the need to 
investigate knock-on effects of immunotherapeutic approaches on B cell function in terms of 
promoting pro-inflammatory cytokine production and potentiating dysfunctional B cell subsets. 
This study has been closely supported by a back-to-back paper that also showed defective antibody 
production by HBsAg-specific B cells in patients with CHB, partially rescued through PD-1 
blockade (Burton et al., 2018; Salimzadeh et al., 2018). During the writing of this thesis, a further 
paper has been published that again demonstrates decreased anti-HBs production by B cells from 
patients with CHB, alongside an expansion of B cells with an atMBC phenotype (Poonia et al., 
2018). Notably, the study from Poonia et al. reinforces the link between the accumulation of 
atMBCs and defective antibody production, by demonstrating impaired anti-HBs production by 
atMBCs relative to cMBCs. Finally, the authors show that culture of B cells with HBV viral 
proteins can directly induce an upregulation of inhibitory receptors on B cells, lending support to 
the concept that chronic antigen exposure impairs B cell responses in HBV.  
Overall, this study has identified previously unappreciated roles for B cells in the immune 
dysfunction observed in CHB, including decreased antiviral cytokine production and secretion of 
anti-HBs (reviewed in Neumann-Haefelin and Thimme, 2018). Importantly, these results make a 
strong argument for B cell dysfunction, as opposed to HBsAg-specific B cell depletion, as the main 
reason for the lack of anti-HBs in CHB. The description of the phenotype of both HBsAg-specific 
B cells and atMBCs raises multiple new avenues of research into possible mechanisms 
underpinning B cell dysfunction in chronic viral infections. Indeed, many open questions remain 
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including the cellular and molecular mechanisms leading to HBsAg-specific B cell dysfunction, as 
well as the optimal strategy to restore anti-HBs responses on the way to achieving functional cure. 
Figure 6.1 summarises the key areas of interest highlighted by this study and contextualises these 
within what is already understood surrounding adaptive immune dysfunction in CHB. Overall, this 
study provides a precedent for B cell-targeted research in hepatitis B.  
 
Figure 6-1 Conceptualisation of the role of atMBCs in immune dysfunction in CHB 
Features identified directly within this thesis are highlighted in bold. Questions arising for future research discussed 
within this thesis are demarcated by boxes. A. How does persistent stimulation/the presence of HBV drive B cell 
dysfunction? B. Are B cell – CD4 T cell interactions impaired in HBV, and if so, does this impact the ability to form a 
functional humoral response? C. Can circulating HBsAg:anti-HBs immune complexes further contribute to the 
suppression of atMBC responses? D. Is the homing of atMBCs/HBsAg-specific B cells to lymphoid organs impaired, and 
does this have an effect on the production of high-affinity antibody? E. Can local production of anti-HBs have a role in 
killing infected hepatocytes through ADCC? 
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